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1. Introduction 
1.1 Amyotrophic lateral sclerosis (ALS) 
Neurodegenerative diseases (NDs), such as Alzheimer’s, Parkinson’s, Huntington’s disease, 
Frontotemporal dementia (FTD), and ALS, are among the most common causes for mortality 
worldwide, with increasing tendency. NDs are highly age-dependent, occurring typically but not 
exclusively in the elderly. It becomes progressively important to understand the underlying 
pathomechanisms of these diseases, since the elderly population has increased over the last 
decades (Heemels, 2016). To date, NDs are generally incurable and only limited treatment 
options exist for most of them, partly because the underlying pathophysiology is very diverse. 
Some disorders primarily cause cognitive impairment and/or memory loss as seen in FTD and 
Alzheimer’s disease (Abeliovich and Gitler, 2016; Canter et al., 2016; Wyss-Coray, 2016), while 
others mainly affect the motor system, causing movement, speech, and breathing deficits, as 
seen in ALS (Taylor et al., 2016).  
ALS is the most common ND specifically affecting cortical (upper) motor neurons in the 
primary motor cortex, and spinal (lower) motor neurons in the brainstem and spinal cord. This 
disease was first described by Jean-Martin Charcot and Alix Joffroy in 1869 (Charcot and 
Joffroy, 1869). Various studies report an incidence for ALS ranging from 0.6 to 3.8 per 100 000 
persons/year and a prevalence of between 4.1 and 8.4 per 100 000 persons, with regional 
differences (reviewed by Longinetti and Fang, 2019). Men are at higher risk to develop ALS 
than women, with reported male-to-female ratios between 1.2 and 1.5 (Manjaly et al., 2010). It is 
a progressive disorder with a median age of onset between 51 and 66 years of age throughout 
the world (Longinetti and Fang, 2019), in Germany around 61 years (Dorst et al., 2019), and 
usually leads to death due to respiratory failure about 2-5 years after symptom onset (Naumann 
et al., 2018). ALS commonly manifests as a spinal onset (e.g. weakness in the limbs, up to 
82 % of cases), but patients may also show bulbar onset (e.g. difficulty in speaking or 
swallowing), mixed spinal and bulbar onset, or other forms of onset, including thoracic onset 
(D’Ovidio et al., 2019), dementia or respiratory symptoms (Longinetti et al., 2018; Leighton et 
al., 2019). While all ALS patients suffer from motoric symptoms, only 30 % of patients also 
develop symptoms of FTD (Lomen-Hoerth, 2011), which also include changes in mood and 
behavior (Erkkinen et al., 2018), and those patients were found to face a shorter life expectancy 
(Olney et al., 2005). 
There is no cure for ALS to date and only two approved drugs, Riluzole and Edaravone. 
For a long time, Riluzole, a presumed glutamate antagonist, has been the only authorized drug 
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for the treatment of ALS after its approval in 1995 (Wokke, 1996). It acts anti-excitotoxic, which 
may be related to its ability to inhibit glutamate release, to inactivate voltage-gated sodium 
channels, or to interfere with intracellular signal transmission following transmitter binding at 
excitatory receptors (Jaiswal, 2019). Recently, Edaravone has been approved in some countries 
as an alternative or additional treatment (Bhandari et al., 2018). Edaravone is thought to be a 
scavenger for reactive oxygen species, and reportedly eliminates lipid peroxides and hydroxyl 
radicals. In neurons, it presumably alleviates injuries caused by free oxygen radicals (Jaiswal, 
2019). The exact cellular and molecular targets of Edaravone are however still unknown. Both 
Riluzole and Edaravone are effective only in subpopulations of ALS patients and increase 
survival time or slow down progression of the disease (Bensimon et al., 1994; Abe et al., 2017; 
Jaiswal, 2019). 
On the cellular level, ALS is a non-cell-autonomous disease and characterized by the 
progressive atrophy of cortical and spinal motor neurons, a reduction in size of the remaining 
neurons, hyperexcitability of the motor system (Ferraiuolo et al., 2011), as well as astro- and 
microgliosis (Saberi et al., 2015). The latter implicates an inflammatory component in ALS, 
which has been subject of a variety of studies in the past. ALS-associated mutations in 
superoxide dismutase 1 (SOD1) expressed in astrocytes have been linked to enhanced 
activation of microglia in a mouse model of ALS, which may play a role in disease progression 
due to the enhanced production of nitric oxide and toxic cytokines (Yamanaka et al., 2008). In 
contrast, reactive astrocytes and microglia were found to surround degenerating motor neurons 
in ALS patients and mouse models (McGeer and McGeer, 2002; Boillee et al., 2006), where 
they secreted proinflammatory cytokines (Saberi et al., 2015). This suggests that a 
neuroinflammatory response may exert neuroprotective as well as neurodegenerative effects, 
and provides additional evidence for an involvement of not only neurons, but also astrocytes, 
microglia, and oligodendrocytes in ALS pathology (Scekic-Zahirovic et al., 2017). 
On the molecular level, there is a general consensus that multiple pathogenic processes 
contribute to the neuropathology of ALS, including abnormal RNA processing (Donnelly et al., 
2014), aberrant protein folding and the formation of stress granules (dense aggregates 
containing proteins and RNA forming under stress conditions within the cell, Gutierrez-Beltran et 
al., 2015; Parakh & Atkin, 2016), mitochondrial dysfunction (Smith et al., 2019) and impaired 
axonal transport (Ferraiuolo et al., 2011; Ikenaka et al., 2012; Sama et al., 2014; De Vos and 
Hafezparast, 2017a). The exact type and degree of neuropathology essentially depends on the 
underlying cause for ALS. 
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About 90 % of cases are sporadic, where no specific genetic or environmental cause can 
be identified. Common risk factors for sporadic ALS include older age (largely increasing above 
age 50) and male sex. Other factors, such as physical fitness, repeated head injury, 
occupational and environmental factors, and previous medical conditions (e.g. diabetes) are still 
controversial, although they most likely strongly influence the development of the disease 
(reviewed in Fang et al., 2015; van Rheenen et al., 2016). The remaining ~10 % of cases are 
familial and are caused by specific mutations (Chen et al., 2013; reviewed in Renton et al., 
2014). The most common variations associated with ALS are within the genes of Chromosome 
9 open reading frame 72 (C9orf72, ~30 %, DeJesus-Hernandez et al., 2011), SOD1 (~20 %, 
first ALS gene to be identified in 1993 by Rosen et al.), TAR DNA-Binding Protein 43 (TDP-43, 
5 %, Sreedharan et al., 2008), and fused in sarcoma (FUS, 5 %, (Kwiatkowski et al., 2009; 
Vance et al., 2009; Naumann et al., 2019). 
1.1.1 ALS-associated FUS 
The FUS gene, also called translocated in liposarcoma, is located on chromosome 16 and 
consists of 15 exons that encode a 526-amino-acid protein (Aman et al., 1996) and has first 
been identified as a proto-oncogene causing liposarcoma by chromosomal translocation (Crozat 
et al., 1993). It belongs to the FET protein family (the other members of that family being the 
Ewing Sarcoma protein and TATA binding associated factor15, Svetoni et al., 2016), is 
ubiquitously expressed in most tissues and mainly localizes to the nucleus (Andersson et al., 
2008; Sama et al., 2014). Its N-terminus is involved in transcriptional regulation and DNA 
damage repair via a prion-like domain (rich in glutamine, glycine, serine, and tyrosine (QGSY)), 
an additional glycine-rich region, and an RNA-recognition motif (Figure 1) (Sama et al., 2014). 
The C-terminal region contains multiple arginine-glycine-glycine(RGG)-rich nucleic acid-binding 
domains, a zinc-finger-binding domain, and a non-classical nuclear localization sequence 
(Prasad et al., 1994) and attributes to e.g. RNA transport.  
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Figure 1: Functional domains of FUS.  
The diversity of functional domains within FUS allows for its involvement in a multitude of cellular processes. 
Depicted are known domains of FUS and their annotated functions, as well as the most common mutations 
associated with familial ALS (adapted from Ticozzi et al., 2009; Sama et al., 2014; An et al., 2019). The mutation of 
interest in this study (P525L) is highlighted in red. 
 
Due to this conserved, albeit complex structure, FUS interacts with DNA (Baechtold et al., 
1999) as well as RNA (Crozat et al., 1993; Zinszner et al., 1997) and its role in a variety of 
cellular processes has long been proven. These include cell proliferation and DNA repair 
(Bertrand et al., 1999), transcription regulation, RNA splicing (Yang et al., 1998) and transport 
within the cell (Zinszner et al., 1997). FUS has been reported to bind RNA of more than 5500 
genes in the central nervous system (CNS), primarily via a GUGGU-binding motif (Lagier-
Tourenne et al., 2012). By transporting mRNA to the distal axon or dendrites, e.g. those 
encoding actin-related proteins, it may regulate local translation in response to external stimuli 
(Fujii and Takumi, 2005; Fujii et al., 2005). Due to its diverse functions, it appears reasonable 
that a series of pathological events are observed upon in its absence or malfunction. 
1.1.2 Molecular pathology of ALS-FUS 
Because FUS is involved in a variety of often interconnected processes within the cell, single 
mutations in its genomic sequence can result in the occurrence of ALS (Figure 1), although it is 
not yet clear whether the disease is caused by a loss-of-function or gain-of-function in FUS. 
Mutations in FUS account for 35 % of cases manifesting before 40 years, typically presenting 
classical ALS symptoms, and are responsible for the youngest case described (Conte et al., 
2012; Millecamps et al., 2012). These are autosomal-dominant mutations and primarily occur in 
the C-terminal NLS, such as R521C or P525L, resulting in cytoplasmic mislocalization of FUS 
due to reduced interaction with the nuclear import receptor Transportin-1 (Dormann et al., 2010) 
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and in impaired interaction of FUS with other RNA-binding proteins (RBPs) (Marrone et al., 
2019). Interestingly, there seems to be a direct relationship between the degree to which 
nuclear import of FUS is diminished and the severity of the disease (defined by age of onset 
and time till death) (Dormann et al., 2010; Kino et al., 2011; Niu et al., 2012). 
FUS preferentially localizes to active chromatin (Immanuel et al., 1995), where it binds to 
single-stranded DNA motifs in the promotor region of its target genes. Current evidence points 
towards its function as a general transcriptional regulator, with only modest changes in mRNA 
levels in its absence (Tan and Manley, 2010; Hoell et al., 2011; Lagier-Tourenne et al., 2012; 
Rogelj et al., 2012; Tan et al., 2012; Li et al., 2013; Nakaya et al., 2013). FUS may also directly 
bind to and recruit RNA polymerase II and III by preventing its phosphorylation at specific sites 
(Immanuel et al., 1995; Bertolotti et al., 1996, 1998; Tan and Manley, 2010; Schwartz et al., 
2015). Additionally, FUS regulates transcription via interaction with specific transcription factors 
(e.g. Runx2 or NF-κB, Du et al., 2011; Hallier et al., 1998; Kim et al., 2010; S. Sato et al., 2005; 
Uranishi et al., 2001) and transcription initiation factor TFIID (Bertolotti et al., 1996; Hallier et al., 
1998; Uranishi et al., 2001; Li et al., 2010).  
FUS modulates splicing of pre-mRNA in conjunction with other splicing regulators 
machinery (e.g. SMN, U11, U11, U12, Sm proteins, SFPQ, and others) (Alliegro and Alliegro, 
1996; Hackl and Lührmann, 1996; Zhou et al., 2002; Meissner et al., 2003; Yamazaki et al., 
2012; Gerbino et al., 2013; Tsuiji et al., 2013; Sun et al., 2015; Reber et al., 2016; Ishigaki and 
Sobue, 2018) by binding to long introns within the prespliced RNA (Hoell et al., 2011; Ishigaki et 
al., 2012; Lagier-Tourenne et al., 2012; Rogelj et al., 2012). As such, FUS is involved in the 
splicing of actin pre-mRNA, as has been shown for example in mouse brain extracts (Fujii and 
Takumi, 2005), but also of the microtubule-associated protein (MAP) tau, a neuron specific 
cytoskeleton related protein (Ishigaki et al., 2012; Lagier-Tourenne et al., 2012; Orozco et al., 
2012; Rogelj et al., 2012). Altered splicing by mutant FUS variants hence might affect the 
cytoskeletal architecture of neurons. FUS also regulates its own splicing (Lagier-Tourenne et al., 
2012; Nakaya et al., 2013), specifically by FUS-mediated skipping of exon 7 in FUS pre-mRNA, 
which results in its nonsense-mediated decay (Ishigaki and Sobue, 2018). This process is 
disrupted for mutant FUS variants due to their mislocalization to the cytoplasm. Impaired FUS 
splicing may in turn exacerbate the pathogenic cytoplasmic accumulation of FUS (Zhou et al., 
2013). Further, FUS is involved in alternative splicing of more than 3200 exons, of which many 
are part of mRNAs coding for proteins important in neuronal function or neurodegeneration 
(Ishigaki et al., 2012). 
Mechanisms of Axonal Transport in ALS  Introduction 
Anne Seifert  6 / 157   
There is evidence that the physical binding capability between FUS and its RNAs is not 
altered between wildtype and mutant FUS variants, as 80 % of transcripts binding to mutant 
(R521G and R521H) FUS can also bind to wildtype FUS (Hoell et al., 2011). This supports the 
hypothesis of a gain-of- function phenotype for mislocalized cytoplasmic mutant FUS variants 
with respect to RNA binding and processing. After splicing, FUS subsequently shuttles mRNA 
between the nucleus and the cytoplasm (Fujii et al., 2005). FUS has been attributed to interact 
with several actin- and microtubule-binding motor proteins, including Myosin-Va (Yoshimura et 
al., 2006) as well as Myosin-VI (Takarada et al., 2009), and has been isolated as part of large 
granules that associates with KIF5B (Kanai et al., 2004). This hints towards an involvement of 
FUS in cellular transport of mRNAs to their dedicated locations for local translation. Indeed, 
upon synaptic activation via the metabotropic glutamate receptor mGluR5, FUS translocates 
into dendritic spines (by to date unknown mechanisms) and may facilitate the local translation of 
actin-associated proteins (Fujii and Takumi, 2005). This is in line with the fact that loss of FUS 
consequently results in abnormal spine morphology and attenuated spine density (Fujii et al., 
2005), since spine structure and stability is largely dependent on the actin cytoskeleton (Penzes 
and Rafalovich, 2012; Basu and Lamprecht, 2018). Local translation is however not solely 
regulated by the transport of mRNA, but also by sequestering mRNA together with its RBPs. 
As a protein with primarily nuclear localization under physiological, non-stressed 
conditions, FUS binds single- and double-stranded DNA (Baechtold et al., 1999; Liu et al., 
2013), thereby promoting DNA damage repair via homologous recombination (HR) and 
nonhomologous end joining (NHEJ) (Mastrocola et al., 2013; Wang et al., 2013). For HR, the 
pairing of homologous DNA is an essential step which has been proposed to be a crucial 
function devoted especially to the C-terminal region of FUS (Akhmedov et al., 1995; Baechtold 
et al., 1999; Liu et al., 2013). Phosphorylated FUS (Pezzano et al., 1996) is one of the first 
proteins recruited to sites of DNA damage (Mastrocola et al., 2013; Wang et al., 2013), where it 
interacts with histone deacetylase 1 (HDAC1) and poly-ADP ribose (Deng et al., 2014). A 
subset of ALS-associated mutations impair FUS in its function in DNA damage response 
(Rulten et al., 2014; Naumann et al., 2018). In the absence or in case of malfunction of FUS, 
DNA double-strand repair by HR and NHEJ was decreased between 30-50 % (Mastrocola et al., 
2013; Wang et al., 2013). In primary mouse cortical neurons, the decrease in DNA repair 
efficiency by NHEJ upon FUS depletion was even higher, namely 65 % (Wang et al., 2013). 
Together, these results suggest a role of FUS in DNA damage repair in proliferating as well as 
postmitotic cells. It has further been shown that FUS interacts with HDAC1 at sites of DNA 
double-strand breaks (Miller et al., 2010; Dobbin et al., 2013; Thurn et al., 2013), while it is 
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recruited to single-strand breaks by poly adenosine diphosphate ribose polymerase (PARP), 
which binds to these sites and subsequently polymerizes poly adenosine diphosphate ribose 
(PAR) chains (Schreiber et al., 2006; De Vos et al., 2012). In a transgenic mouse model 
expressing FUS-R521C next to its wildtype form, mutant FUS forms a complex with wildtype 
FUS and alters its interaction with HDAC1 (Qiu et al., 2014), calling for a dominant negative 
effect of this FUS mutation. This is in line with the finding that several mutant FUS variants 
(R244C, R514S, H517Q, and R521C) showed deficiencies in HR--mediated repair relative to 
wildtype FUS in U2OS cells, independent of their nuclear or cytoplasmic localization (Wang et 
al., 2013). As DNA damage accumulates with increasing age (e.g. due to a lifetime exposure to 
DNA-damaging factors and a decay of quality control mechanisms over decades, Gorbunova et 
al., 2007), it seems logical that the pathological consequences, i.e. the phenotype of FUS -ALS, 
becomes apparent only later in the life of patients. It also indicates why mainly neurons are 
affected by the disease, since they lack the ability to replicate and self-renew and are therefore 
more susceptible to accumulate DNA damage. This is in line with the finding of increased levels 
of γH2AX in postmortem brain sections of patients harboring the FUS R521C or P525L mutation 
(Wang et al., 2013). γH2AX is a marker for DNA damage, but also correlates with apoptosis 
(Rogakou et al., 2000; Pasinelli and Brown, 2006). 
The low complexity, prion-like domain of FUS, with its high content of glycine, accounts for 
its tendency to aggregate (Han et al., 2012). Under physiological conditions, RBPs with such a 
domain can accumulate together with mRNA, ribosome translation initiation factors, and other 
proteins into membraneless compartments called stress granules (Dewey et al., 2012; Mateju et 
al., 2017). Stress granules are stalled translational complexes evolving upon metabolic or 
environmental stress involved in the triage of mRNAs, determining whether an mRNA is 
translated, degraded, or suppressed in order to promote the expression of proteins essential to 
reestablish homeostasis (Sama et al., 2014). Wildtype FUS can rapidly and reversibly shuttle to 
the cytoplasm upon induction of cellular stress, where it associates with stress granules. Under 
physiological conditions, it returns to the nucleus once stress is resolved (Dormann et al., 2010). 
ALS-associated, consistently mislocalized FUS variants, however, have long been observed to 
assemble within pathological stress granules upon protein overexpression, heat shock, and ER 
or oxidative stress (Andersson et al., 2008; Bosco et al., 2010; Dormann et al., 2010; Gal et al., 
2011; Kino et al., 2011; Bentmann et al., 2012; Daigle et al., 2013). However, if mutated variants 
of RBPs are incorporated into these structures, they undergo a pathological liquid-to-solid phase 
transition, resulting in solidified SGs (Bowden and Dormann, 2016). Solidified SGs have lost 
their dynamicity and show altered mechanical properties (Nötzel et al., 2018), and hence can no 
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longer fulfill their physiological roles. This results in impaired stress response and mRNA 
transport, changes in local translation, and the formation of pathological aggregates, all of which 
contributes to neuron dysfunction and the progression of neurodegeneration (Bowden and 
Dormann, 2016). The formation of SGs and how severely it affects the cell therefore also largely 
depends on the local concentration of a respective protein. For instance, cytoplasmic 
accumulated mutant FUS colocalizes with these pathological aggregates (Dewey et al., 2012; 
Wolozin, 2014). Hence, while FUS itself is not essential for the formation of SGs, the 
cytoplasmic mislocalization of its mutant variants largely contributes to the transformation of 
SGs. 
Another class of cellular organelles that seems to be substantially influenced by mutant 
FUS variants is mitochondria. Disruptions in various mitochondrial characteristics, such as 
structure, dynamics, bioenergetics, calcium homeostasis, endoplasmatic reticulum (ER)-
mitochondrial contact, mitochondrial quality control, and cellular transport have been reported in 
ALS patients and various model systems (reviewed in Smith et al., 2019). One of the first 
observed changes in ALS patient motor neurons are structurally altered (i.e. swollen and 
vacuolated) and aggregated mitochondria (Atsumi, 1981; Sasaki and Iwata, 2007). 
Overexpression of FUS R521G/H or P525L variants results in mitochondrial shortening 
(Tradewell et al., 2012; Deng et al., 2015; Sharma et al., 2016). The P525L mutation additionally 
results in deformation and loss of mitochondrial cristae in mouse models (Deng et al., 2015; 
Sharma et al., 2016). FUS seems to directly influence mitochondrial function through interaction 
with the mitochondrial chaperone heat shock protein of 60 kDa (HSP60) (Deng et al., 2015) and 
overexpression of FUS leads to reduced mitochondrial ATP production (Stoica et al., 2016) as 
well as augmented levels of reactive oxygen species (ROS), causing oxidative stress (Deng et 
al., 2015). 
Non-functional and damaged mitochondria are subject to clearance by mitophagy under 
physiological conditions and need to be replaced by functional mitochondria (Sterky et al., 2011; 
Hamacher-Brady and Brady, 2016). This process requires a robust transport of mitochondria 
throughout the cell. However, in motor neurons carrying the P525L mutation, generated from 
ALS patient-derived induced pluripotent stem cells (iPSCs), virtual arrest of mitochondrial 
movement in distal, but not proximal axons was observed, accompanied by a loss of membrane 
potential in these mitochondria along with reduced mitochondrial length (Naumann et al., 2018). 
In general, a defect in transport of mitochondrial and other organelles has reportedly been 
observed, often as one of the earliest pathophysiological events in motor neurons affected by 
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ALS, which indicates that deficits in axonal transport might be a primary cause of motor neurons 
loss (De Vos et al., 2008; De Vos and Hafezparast, 2017a). 
1.2 Axonal transport 
Intracellular transport of RNA, proteins, and organelles is essential to cell survival and correct 
function, as well as neurotrophic and injury signaling. It becomes particularly important in 
(motor) neurons, which have to facilitate long-range transport along dendrites and axons, latter 
with lengths up to one meter (Grafstein and Forman, 1980; Fletcher and Theriot, 2004). In 
addition to the large distance that needs to be covered by cellular transport mechanisms, 
cellular homeostasis requires transport in two directions, namely anterograde (i.e. away from 
the cell soma) and retrograde (i.e. towards the cell soma). Two main classes of axonal transport 
can be distinguished based on the average speed of transport movement. Fast axonal transport 
is characterized by a speed of ~50 - 400 mm/day or 0.6 - 5 µm/s. Slow axonal transport is 
further subdivided into two parts, depending on the proteins transported and the speed, namely 
slow component a and b, which cover a distance of 0.2 - 3 mm/day or 0.0002 - 0.03 µm/s and 
2 - 10 mm/day or 0.02 - 0.1 µm/s, respectively (De Vos and Hafezparast, 2017a). Each of these 
transport types delivers a distinct set of cargoes, and the differences in overall speed results 
from prolonged pauses between movement phases in slow axonal transport (Black, 2016). Both 
fast and slow transport is mediated by the same molecular motors moving along tracks of the 
cytoskeletal network, defining motors and the cytoskeleton as the two major components of 
axonal transport. 
1.2.1 Microtubules as part of the neuronal cytoskeleton 
The neuronal cytoskeleton consists of three major components, namely actin filaments, 
neurofilaments, and microtubules. Actin filaments are composed of granular (G-) actin 
monomers, which assemble to form a ~6 nm wide double-helix of filamentous (F-) actin (Boron 
and Boulpaep, 2005) and are most prominent in the axonal growth cone and dendritic spines 
(Schevzov et al., 2012). Neurofilaments are type IV intermediate filaments with an average 
diameter of ~10 nm and are present in the perikarya and dendrites, but particularly in axons, 
where they are vital for the radial growth of axons during development and the further 
maintenance of axon caliber, as well as the transmission of electrical impulses along the axon 
(Friede and Samorajski, 1970; Ohara et al., 1993; Eyer and Peterson, 1994; Zhu et al., 1997; 
Yum et al., 2009; Yuan et al., 2012).  
The major portion of axonal transport occurs along microtubules, which are rigid hollow 
cylinders about 25 nm in diameter (Figure 2). They are dynamic filaments that frequently 
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assemble and disassemble within the cell. Microtubules polymerize from free tubulin, which 
itself is a heterodimer of two closely related 55 kDa polypeptides, α- and β-tubulin. Microtubules 
are formed by 13 linear chains of these heterodimers, so called protofilaments. Both tubulin 
polypeptides bind GTP to regulate polymerization, but only GTP bound to β-tubulin is 
hydrolyzed shortly after polymerization. GTP hydrolysis weakens the binding affinity of β-tubulin 
to adjacent molecules, which favors depolymerization and enables dynamic behavior of 
microtubules (Cooper, 2000a). This behavior is referred to as dynamic instability and describes 
the alternating cycles of growth and shrinkage of microtubules at their individual protofilaments, 
a process determined by the rate of GTP hydrolysis relative to the rate of tubulin dimer addition 
(Mitchison and Kirschner, 1984). Since the sequential addition of tubulin heterodimers results in 
so called head-to-tail arrays (Cooper, 2000b) with alternating α- and β-tubulin units in each 
protofilament, microtubules are polar structures with a fast-growing plus end (protofilament 
ending with a β-tubulin subunit) directed towards the cell cortex, and a slow-growing, more 
stable minus end (protofilament ending with a α-tubulin subunit) directed towards the soma 
(Maday et al., 2014). In axons, microtubules form a unipolar array with the plus end facing 
towards the distal axon, while the microtubule organization in dendrites often consists of arrays 
with mixed polarity (Baas et al., 1988; Kwan et al., 2008; Kleele et al., 2014). Hence, the correct 
polarity and orientation of microtubules majorly contribute to the specific distribution of cargo 
throughout the cell by a variety of motor proteins.  
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Figure 2: The motor protein kinesin-1 transports cargo along microtubules.  
Microtubules are hollow tubes with a diameter of 25 nm, which are composed of 13 individual protofilaments formed 
by the continuous addition of α- and β-tubulin heterodimers. GTP bound to β-tubulin becomes rapidly hydrolyzed after 
polymerization, which weakens the binding affinity of tubulin to adjacent molecules and allows for depolymerization of 
the microtubule, a continuous process referred to as dynamic instability. Microtubule growth occurs if GTP-bound 
tubulin is added more rapidly to the growing microtubule than GTP is hydrolyzed, with the rate of polymerization 
being typically much faster at the plus end of the microtubule, where β-tubulin is exposed, than at the minus end, 
where α-tubulin is exposed. Microtubules are stabilized by microtubule associated proteins such as tau, which on the 
other hand also act as roadblocks for microtubule-associated motors walking along a protofilament, hindering their 
motility. This figure shows the microtubule-associated motor kinesin-1, a heterotetramer consisting of two kinesin 
heavy chains and two kinesin light chains (KLC). One kinesin heavy chain is comprised of a catalytic motor domain, 
which hydrolysis ATP to facilitate movement in 8 nm steps across the microtubule, a neck linker region, an α-helical 
stalk with two hinge regions required for dimerization, and a tail domain interacting with KLCs to mediate cargo 
binding (Cooper, 2000a). 
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1.2.3 Microtubule motor proteins 
There are two major families of motor proteins that associate with microtubules, namely kinesins 
and dyneins. The human kinesin superfamily consists of 45 members, of which 38 are 
expressed in the brain (Miki et al., 2001), and can be subdivided into 15 subfamilies. Most 
kinesins move towards the plus end of microtubules in a straight path along a single 
protofilament (Maday et al., 2014), thereby mainly driving anterograde transport in neuronal 
axons. Members of the kinesin-1 (also referred to as KIF5), kinesin-2 (i.e. KIF3A and B, KIF17), 
and kinesin-3 (i.e. KIF1A, KIF1Bα, and KIF1Bβ) family collectively contribute to this anterograde 
(Maday et al., 2014), with fast axonal transport mainly involving kinesin-1 and members of the 
kinesin-3 family, while slow anterograde axonal transport appears to be mainly mediated by 
kinesin-1 (Xia et al., 2003). Kinesin-1 is to date the best studied motor protein and was first 
discovered in axons of the giant squid in 1985 (Vale et al., 1985). It is a heterotetramer 
consisting of two kinesin heavy chains (KHCs), encoded by the three mammalian genes KIF5A, 
B, and C, and in most cases two kinesin light chains (KLCs), which are substantial for cargo 
binding and in part contribute to the autoinhibition of kinesin in the absence of cargo (Figure 2) 
(Sun et al., 2011a). KHCs are comprised of the catalytic motor domain, which facilitates walking 
along the microtubule by hydrolyzing ATP and conveys processivity and direction of movement 
together with a neck linker region. The motor domain is linked to an α-helical stalk interrupted by 
two hinge regions, which is required for dimerization. Further, a tail domain interacts with cargo 
either on its own or through KLCs and facilitates autoinhibition of the motor domain (Williams et 
al., 2014, reviewed in Nobutaka Hirokawa et al., 2010). Cargo binding often requires a variety of 
adaptor proteins, such as c-Jun N-terminal kinase-interacting protein (JIP), trafficking kinase 
(TRAK), or mitochondrial Rho GTPase (Miro) 1 and 2, which directly or indirectly (i.e. via KLCs) 
link kinesin-1 to specific cargoes (Fu and Holzbaur, 2014). Kinesin-1 walks in a hand-over-hand 
mechanism with a step size of ~8 nm (about the size of a tubulin dimer) for approximately 100 
steps before it detaches, walks at a speed of ~0.5 - 1 µm/s and a stall force of 5 - 6 pN 
(Svoboda and Block, 1994; Hackney, 1995; Hua et al., 1997; Coy et al., 1999; Yildiz et al., 
2004; Asbury, 2005) Cargoes transported by kinesin-1 include organelles such as mitochondria, 
as well as vesicular and non-vesicular cargoes (i.e. lysosomes, signaling endosomes containing 
e.g. brain-derived neurotrophic factor (BDNF), amyloid precursor protein vesicles, AMPA 
vesicles, and mRNA/protein complexes (Hirokawa et al., 2010).  
In contrast, members of the kinesin-2 family can assemble into both homodimeric and 
heterodimeric motors (Scholey, 2013) and transport for example fodrin-positive plasma 
membrane precursors (Takeda et al., 2000), N-cadherin and β-catenin (Teng et al., 2005), 
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choline acetyltransferase (Ray et al., 1999), and Rab7-positive late endo-lysosomes (Hendricks 
et al., 2010; Castle et al., 2014). Members of the kinesin-3 family dimerize upon cargo binding to 
form highly processive motors (Soppina et al., 2014) and drive the motility of dense core 
vesicles and synaptic vesicle precursors (Hall and Hedgecock, 1991; Okada et al., 1995; Lo et 
al., 2011). 
While anterograde transport is driven by a pool of different kinesins, retrograde transport 
is almost exclusively carried out by cytoplasmic dynein (Roberts et al., 2013). Cytoplasmic 
dynein belongs to the family of AAA+ ATPases and can be subdivided into cytoplasmic dynein 1 
and 2. Cytoplasmic dynein 1 (hereafter referred to as dynein) is the main retrograde molecular 
motor in neurons. It is a large, ~1.5 kDa protein complex comprising two homodimeric dynein 
heavy chains (DHCs) dimerizing by their N-terminal tail domain, and multiple dynein 
intermediate chains, dynein light intermediate chains, and light chains (King, 2012). The latter 
three are encoded by several genes giving rise to various isoforms, and therefore contribute to 
cargo-specific recruitment (Kuta et al., 2010). Similar to kinesin-1, multiple adaptor proteins, 
including the dynactin complex, Bicaudal D2, lissencephaly 1, or nuclear distribution protein, 
regulate the correct function, specific cargo binding and localization of dynein (Kardon and Vale, 
2009). Dynein is a fast motor with velocities ranging from 0.5 - 1 µm/s, but unlike kinesin, it 
frequently takes back- and side-steps between microtubule protofilaments (Mallik et al., 2005; 
Ross et al., 2006). The coordinated activity of multiple motor or the binding of activators such as 
Bicaudal D2, however, converts dynein into a unidirectional, highly processive motor (Mallik et 
al., 2005; McKenney et al., 2014; Schlager et al., 2014). With ~1 pN, the stall force of dynein is 
much weaker than those of kinesins (e.g. 5-7 pN for processive kinesin-1 or 1.5-7 pN for weakly 
processive kinesin-5 in vitro, Hesse et al., 2013; Schroeder et al., 2010). 
Most cargoes are not transported by a single type of motor, but by an ensemble of various 
oppositely directed kinesins and dyneins (Hendricks et al., 2010; Encalada et al., 2011), even if 
they are processively transported in a single direction over long distances (Maday et al., 2012). 
A single organelle may be transported by 1-2 kinesins and 6-12 dyneins (Hendricks et al., 2010; 
Schroeder et al., 2012; Rai et al., 2013). Several models have been suggested as to how this 
assembly of motors is organized (Gross, 2004; Welte, 2004; Gross et al., 2007). The simplest 
model postulates an unregulated tug-of-war between opposing kinesins and dyneins, which 
could be successfully modelled for late endo-lysosomes (Müller et al., 2008; Hendricks et al., 
2010). In this scenario, movement-of-directionality of cargoes might be determined by the 
biophysical characteristics of motors themselves. Kinesin-2 for instance shows load 
force-dependent attachment, indicating it may be less likely to win in a tug-of-war situation 
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(Schroeder et al., 2012). In contrast, other cargoes such as autophagosomes exhibit strong 
unidirectional motility (Maday et al., 2012), suggesting a possible down-regulation of kinesin and 
pointing towards two alternative models: i) the coordinated regulation of all motor types on a 
single cargo, so that only one type of motor is active at a given time, or ii) a tight regulation of 
only one type of motor, i.e. kinesin as it is the stronger motor, while the other, i.e. the weaker 
dynein motor, might simply be overpowered if both motors are active simultaneously and only 
becomes active when the stronger motor is downregulated. This is supported by evidence for a 
regulatory role of scaffolding proteins to regulate opposing motors on the same cargo (Fu and 
Holzbaur, 2014; Fu et al., 2014). In addition, the well-studied autoinhibitory mechanisms of 
kinesin-1 provides further evidence for this model: in the absence of cargo, the kinesin-1 tail 
domain binds to the motor domain and thereby blocks motor function (Kaan et al., 2011), which 
is only relieved by binding of specific scaffolding proteins such as JIP1 and JIP3 (Blasius et al., 
2007; Sun et al., 2011a). Apart from kinesin-1, regulatory mechanisms for other kinesins or for 
dynein have not been elucidated in such detail to date.  
The exact regulatory mechanism for each cargo most likely results from combinations of 
these models. Nevertheless, a few general commonalities can be found among the diverse 
patterns of motility: i) during transport, motors remain stably associated with their cargo, even in 
their inactive state; ii) cargo can be effectively transported over large distances (>1 µm) by a 
small ensemble of (usually opposing) motors; iii) regulatory mechanisms to control motor activity 
include specific recruitment by Rab-GTPases, scaffolding proteins, and upstream regulation by 
kinases and phosphatases (Maday et al., 2014). 
As motor proteins are often biased, if not limited, by their preference of walking towards 
one or the other end of a microtubule, they are highly influenced by the assortment of MAPs and 
other posttranslational modifications they encounter along their way. While MAPs often act as 
physical barriers for motors walking on cytoskeletal tracks, they can also alter the stability of 
these tracks and thereby influence motor motility. 
1.2.2 Microtubule-associated protein tau 
Because of their dynamic instability, microtubules frequently disassemble and assemble within 
the cell. Disassembly is mediated either by microtubule severing proteins or by increasing the 
rate of tubulin depolymerization at the microtubule ends. Continuous assembly, i.e. the growth 
of microtubules, requires stabilization of joined tubulin heterodimers, which can be achieved 
through posttranslational modifications of tubulin, such as detyrosination or acetylation, or 
through tightly regulated interactions with MAPs. The best characterized MAPs are MAP-4 in 
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non-neuronal cells, and MAP-1, MAP-2 (which is absent in axons), and tau (which is absent in 
dendrites, but abundant in axons) in neuronal cells (Weingarten et al., 1975; Witman et al., 
1976; Cooper, 2000a). The ability of MAPs to interact with microtubules highly depends on the 
posttranslational modifications of MAPs, specifically phosphorylation in case of tau (Lindwall 
and Cole, 1984; Mandelkow et al., 1995; Drewes et al., 1997; Stoothoff and Johnson, 2005; 
Ramkumar et al., 2018). Hyperphosphorylation of tau is associated with a variety of diseases 
(Ksiezak-Reding et al., 1992; Köpke et al., 1993), but also with fetal development (Matsuo et al., 
1994; Yu et al., 2009) or a state of hibernation (Arendt et al., 2003). Tau is to date the best 
studied MAP, in part because of its implication in a group of neurodegenerative diseases called 
tauopathies (e.g. AD) (Brion et al., 1986). 
The tau gene is located on chromosome 17q21 and is comprised of 16 exons, of which 
exon 2,3, and 10 are alternatively spliced to produce six different isoforms in the human brain 
(Goedert et al., 1989a, 1989b). Exons 2 and 3 encode for two amino-terminal inserts (N), while 
exon 10 encodes for one of a total four microtubule-binding repeats (R), followed by a short C-
terminal tail sequence (Schweers et al., 1994). An isoform hence contains 0N, 1N or 2N as well 
as 3R or 4R and ranges from 352 to 441 amino acids (45-75 kDa) in length (Figure 3) (Bukar 
Maina et al., 2016; Guo et al., 2017a; Pîrşcoveanu et al., 2017). The isoform 0N3R is the 
predominant isoform expressed during fetal development, while all isoforms are expressed in 
the adult brain (Goedert et al., 1989b; Hefti et al., 2018).The C-terminal microtubule-binding 
repeats form the microtubule-binding domain of tau, with their in- or exclusion influencing the 
tau microtubule binding affinity, while the N-terminal domain projects away from the microtubule 
surface, possibly determining the space between microtubules and interacting with other 
cytoskeletal components (Hirokawa et al., 1988; Chen et al., 1992; Lu and Kosik, 2001). Under 
physiological conditions, tubulin is present in 10- to 20-fold molar excess of tau in mature adult 
neurons, with a physiological concentration of tau ~2-4 µM (Butner and Kirschner, 1991; 
Khatoon et al., 1992; Dixit et al., 2008; Avila, 2010) and a ratio of 3R to 4R isoforms of about 1:1 
(Goedert et al., 1989a; Andreadis, 2005; Ishigaki et al., 2017; Pîrşcoveanu et al., 2017). 
Interestingly, recent publications demonstrated an increase in 4R:3R ratio upon knockdown of 
FUS and demonstrate that FUS, in combination with splicing factor proline- and glutamine-rich 
(SFPQ), directly regulates the splicing of tau mRNA (Ishigaki et al., 2017), pointing towards an 
involvement of tau isoform ratio changes in FUS-ALS pathology. 
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Figure 3: Functional domains of tau.  
Six different isoforms of tau are expressed in the adult human brain. Since there is only one gene coding for tau, 
isoforms are created by alternative splicing of exons 2 and 3, coding for one of two N-terminal repeats (N1 or N2), 
and exon 10, coding for the second of four microtubule binding repeats (R2). The projection domain, facing away 
from the microtubule surface, is linked to the microtubule binding domain through a proline-rich region. Depicted are 
known domains of tau and their annotated functions (adapted from Ambadipudi et al., 2017; Bukar Maina et al., 2016; 
T. Guo et al., 2017; Polverino de Laureto et al., 2019; Tepper et al., 2014). 
 
The constant association and disassociation of tau with microtubules, along with the 
different microtubule binding affinities of each tau isoform, provides microtubule stabilization as 
well as flexibility as needed for correct cytoskeletal organization, especially in the distal part of 
the axon (Black et al., 1996; Kempf et al., 1996). Tau localizes to labile, unstable domains of 
microtubules (Black et al., 1996), where it increases its stability, thereby promoting assembly 
while preventing depolymerization (Brandt and Lee, 1993; Panda et al., 1995). On the other 
hand, MAPs bound to microtubules may act as roadblocks for microtubule-associated motor 
proteins walking along individual protofilaments. Especially kinesin-1 has been shown to detach 
at patches of microtubule-bound tau, while dynein tends to reverse direction upon encountering 
lattice bound tau (Dixit et al., 2008). In addition, kinesin-1 has been proposed to compete with 
tau for the same binding site on microtubules (Stamer et al., 2002; Dubey et al., 2008).  
The sensitive interplay between motors, cargoes, microtubules and their posttranslational 
modifications as described above can be disturbed, leading to perturbed axonal transport 
perturbed as observed in for example ALS. 
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1.2.4 Axonal transport in ALS 
First evidence for defects in axonal transport as part of ALS pathology came from post mortem 
studies that reported abnormal accumulations of cytoskeletal filaments and organelles, such as 
mitochondria and lysosomes (Hirano et al., 1984b, 1984a; Rouleau et al., 1996). Since then, 
numerous studies have been carried out on endosome and mitochondrial trafficking or the 
distribution of mRNA-containing granules (reviewed in (De Vos and Hafezparast, 2017a), 
highlighting the importance of axonal transport defects in ALS pathology as a pathological event 
preceding symptoms of ALS in a mouse model (Bilsland et al., 2010). However, most studies 
focused on axonal transport defects associated with mutant SOD1 variants. Only little is known 
about the extent and underlying pathological mechanisms of axonal transport defects caused by 
abnormal FUS variants. The FUS-P525L variant causes severe impairment in axonal transport 
of mitochondria in a Drosophila melanogaster model of ALS and in spinal motor neurons 
differentiated from ALS patient-derived iPSCs (Baldwin et al., 2016; Naumann et al., 2018). 
FUS has been proven to directly bind and regulate expression of mRNAs for several 
motor proteins such as KIF5C and KIF1B (Guo et al., 2020), which are part of the ensemble that 
regulates mitochondrial movement and distribution in neurons (Schwarz, 2013; Campbell et al., 
2014). In addition, stress granules undergoing a pathological liquid-to-solid phase transition 
caused by FUS-NLS mutant variants, as described above (see 1.1.2), sequester RNA and 
proteins in the cytoplasm, including those of the axonal transport machinery (Aulas and Vande 
Velde, 2015). A more indirect influence of FUS on axonal transport has been proposed due to 
the fact that expression levels of histone deacetylase 6 (HDAC6) are decreased when FUS is 
silenced in mammalian cells, leading to cytoskeletal changes due to aberrant acetylation and 
hence ultra-stabilization of microtubules (Hubbert et al., 2002; Kim et al., 2010). Conversely, 
Guo et. al. could show that axonal transport is restored in FUS-ALS patient-specific 
iPSC-derived motor neurons upon HDAC6 inhibition (Guo et al., 2017b), suggesting that the 
role of tubulin acetylation in causing axonal transport defects is more complex and needs further 
investigation. Changes in the underlying cytoskeletal tracks likely influence the motility of motors 
walking on them. Apart from impaired transport itself, improper functioning of mitochondria has 
also been suggested to contribute to ALS pathophysiology. Several FUS variants with a 
mutation in their NLS disrupt mitochondrial ATP production and calcium homeostasis. The latter 
is likely caused by dysfunctional communication between the ER and mitochondria due to a 
reduction of their contact sites (Stoica et al., 2016). A disruption in mitochondrial ATP production 
might indicate that impaired transport is due to a local depletion of ATP, the essential energy 
source for motor motility.  
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Our limited understanding of the pathomechanisms involved in axonal transport defects in 
FUS-ALS highlight the importance for further studies addressing this matter. A number of model 
systems have been established that mimic FUS-ALS pathology and/or axonal transport in 
general. 
1.3 Modelling ALS and axonal transport in vitro 
Age-related NDs are human-specific, as non-human primates or rodents do not readily develop 
comparable neuropathological or clinical phenotypes (Mullane and Williams, 2019). Despite this 
fact, especially mouse and rat models have long been the gold standard to study NDs in general 
(Petrov et al., 2017; Van Damme et al., 2017), and although the results obtained from these 
studies have been fundamental in uncovering disease pathogenesis, potential drugs identified in 
animal trials have failed in clinical tests (Matus et al., 2014). 
1.3.1 FUS-ALS specific phenotypes in iPSC-derived motor neurons 
A more physiological model system for NDs developed with the availability of iPSCs. iPSCs are 
generated by transfecting e.g. the so called Yamanaka transcription factors (Oct3/4, Sox2, Klf4, 
and c-Myc) into human adult somatic cells, which induce the reprogramming and conversion of 
these somatic cells to pluripotent stem cells (Takahashi and Yamanaka, 2006; Takahashi et al., 
2007). This technique allows for the generation of patient-specific iPSCs from e.g. human 
fibroblasts, which are easily obtained by a skin biopsy. After successful regeneration, iPSCs can 
be differentiated into virtually every cell type (Yu et al., 2007; Aasen et al., 2008), including 
neuronal subtypes (Emdad et al., 2012; Japtok et al., 2015; Maury et al., 2015; Douvaras et al., 
2016), and have as such been used to model ALS (Chen et al., 2014; Kiskinis et al., 2014; 
Wainger et al., 2014; Japtok et al., 2015). One of the most important advantages of this model 
system is that neurons, or every other cell type, derived from patient-specific iPSCs exhibit 
endogenous pathomechanisms. Such might be masked in conventional transgenic models due 
to unphysiological overexpression of proteins, species-specific differences in protein expression 
profiles, or the lack of availability of cell types of interest (e.g. human postmitotic neurons). The 
emergence of improved gene-engineering techniques, such as CRISPR/Cas9, further increased 
the capability of iPSC models to study intrinsic and endogenous cellular mechanisms, as it 
allows for the reversion of single mutations to their wildtype state or the introduction of a specific 
mutation into the wildtype genome (Deveau et al., 2010; Deltcheva et al., 2011; Jinek et al., 
2012; Hsu et al., 2013; Ran et al., 2013). Pairs of so called isogenic cell lines can thereby be 
created from a single donor line, which contain either the wildtype or the mutated form of a 
specific gene in an otherwise identical genetic background. Hence, differences observed 
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between those two lines can quite precisely be attributed to the individual and direct influence of 
a genetic mutation. 
Although motor neurons derived directly from iPSCs have been used in the past for drug 
screening purposes (Egawa et al., 2012), the technique required further improvement as the 
cultivation of iPSCs requires expensive growth factors, frequent feeding and splitting at narrow 
ratios and needs significant time for differentiation, while it often results in inefficient 
differentiation. Therefore, protocols were developed that prime iPSCs towards certain cell 
lineages, e.g. neuronal cell types, using only a limited set of small molecules, i.e. growth factors 
or inhibitors influencing WNT and sonic hedgehog signaling (Reinhardt et al., 2013). Using such 
protocols, neuronal precursor cells (NPCs) can be derived from iPSCs, which are much easier 
to propagate and can be efficiently and repeatedly differentiated into e.g. spinal motor neurons 
using a different set of small molecules (Reinhardt et al., 2013; Naumann et al., 2018). Spinal 
motor neurons differentiated from iPSC-derived NPCs of two isogenic cell lines can hence be 
utilized to specifically and reproducibly investigate the direct influence of a single ALS-
associated mutation on cellular (patho-) mechanisms in an endogenous environment.  
1.3.2 Reconstitution of axonal transport in vitro 
In cell culture models, it is difficult to study the contribution of a single protein to pathological 
changes in its endogenous environment. One particular protein is often involved in various 
cellular pathways and in its absence or malfunctioning, it can in some cases be substituted by 
other proteins. The involvement of this protein in a particular cellular mechanism might hence be 
masked in cell culture models. To address this limitation, minimal systems have emerged to 
study the direct interaction of a few much defined components. One of these systems is the so 
called stepping assay, where single fluorescently labelled motors move across 
surface-immobilized microtubules. First experimental setups involved binding of motors to 
micron-sized beads, which can be tracked with nanometer precision (Howard, 2001), and 
subsequent video imaging (Sheetz and Spudich, 1983; Yanagida et al., 1984; Spudich et al., 
1985) or optical trap experiments to measure forces generated by motors (Svoboda et al., 1993; 
Mehta et al., 1999; Rief et al., 2000; Schnitzer et al., 2000). With advances in microscopy 
techniques, e.g. TIRF microscopy, the use of smaller cyanine-based fluorophores, such as Cy3 
(Funatsu et al., 1995; Vale et al., 1996), and GFP (Pierce et al., 1997) coupled to individual 
kinesin molecules became possible. To date, these single molecule experiments have not only 
been used to study the stepping characteristics of motors, but also (de-) polymerizing activities 
and diffusion of motors and various MAPs (Yildiz et al., 2003; Helenius et al., 2006; Varga et al., 
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2006, 2009; Bieling et al., 2007; Brouhard et al., 2008; Fink et al., 2009; Bugiel and Schäffer, 
2018; Mitra et al., 2018). 
Another method to reconstitute cellular transport in vitro has been developed with gliding 
motility assays, where fluorescently labelled microtubules or actin filaments are propelled by 
underlying surface-immobilized molecular motors, using ATP as an energy source. Motors are 
typically immobilized on surfaces either via antibodies or by adsorption (Figure 4), while the 
number of motors can vary and even be reduced to the point where a microtubule is propelled 
by a single motor (Howard et al., 1989). The setup can be easily observed and analyzed using 
conventional widefield fluorescence microscopy (Nitzsche et al., 2010). In the past, actin 
filaments as narrow as 6 nm could observed by dark-field (Nagashima and Asakura, 1980) or 
epifluorescence microscopy (Yanagida et al., 1984).  
 
Figure 4: Principle of a microtubule gliding motility assay. 
Fluorescently labeled microtubules are propelled by truncated kinesin-1 motors that are immobilized on a glass 
surface. As a first step in assays preparation, the assay’s glass surface is blocked with casein to prevent unspecific 
binding (Nitzsche et al., 2010). 
 
By tracking the distance a microtubule filament is propelled by multiple underlying motors within 
a defined time, the integrated motility of the underlying motors can be determined (Ruhnow et 
al., 2011). The best understood and hence most widely used motor in these assays is kinesin-1, 
but other motors can and have also been employed (Braun et al., 2011, 2017; Herold et al., 
2012; Monzon et al., 2019). Microtubules in vivo are characterized by high dynamic instability, 
but often need to be highly stabilized for the use in microtubule gliding assays. This can be 
achieved by growing them in the presence of the slowly hydrolysable GTP analogue guanylyl-
(α, β)-methylene-diphosphonate (GMP-CPP) or by adding microtubule stabilizing drugs such as 
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taxol after polymerization (Schiff et al., 1979; Korten et al., 2010), a drug which has also been 
used for in vivo applications. 
Taxol, or paclitaxel, was first isolated from Taxus brevifolia (pacific yew) in 1971 (Fischer 
and Ganellin, 2006) and has since become one of the most widely used chemotherapeutics to 
treat a variety of common solid tumors (Hagiwara and Sunada, 2004; Speyer et al., 2017). It 
induces mitotic arrest and consequently apoptosis in rapidly dividing cancer cells by binding 
along the length of microtubules, thereby stabilizing them, promoting microtubule assembly, and 
suppressing microtubule dynamics (Schiff et al., 1979; Kumar, 1981; Howard and Timasheff, 
1988; Wang et al., 2016; Zhu et al., 2016) by strengthening the lateral protofilament interactions 
between tubulin dimers (Downing and Nogales, 1998; Nogales et al., 1999). There is also 
evidence that taxol decreases the number of protofilaments and increases filament flexibility 
(Dye et al., 1993; Felgner et al., 1996; Díaz et al., 1998). What is crucial for the elimination of 
malignant tumor cells is, however, detrimental for other, healthy cells within the body that are 
also susceptible to taxol, e.g. in neurons, where it leads to microtubule hyper-stabilization and 
subsequent axonal degeneration (Shichinohe et al., 2015; Tasnim et al., 2016; Gornstein and 
Schwarz, 2017). Although taxol is known to cause an array of sometimes severe side-effects 
(e.g. sensory and painful neuropathy, Kuroi and Shimozuma, 2004; Mielke et al., 2006; 
Scripture et al., 2006; Reyes-Gibby et al., 2009; Li et al., 2015; Gornstein and Schwarz, 2017), it 
has recently been suggested to exploit its microtubule-stabilizing characteristics for the 
treatment of diseases other than cancer (reviewed in Baas and Ahmad, 2013), 
neurodegenerative diseases (Zhang et al., 2005; Michaelis et al., 2006; Ballatore et al., 2012), 
as well as nerve injury (Hellal et al., 2011; Sengottuvel et al., 2011), despite the fact that it has a 
poor blood-brain-barrier permeability (Brunden et al., 2011). The microtubule-stabilizing feature 
of taxol has been exploited for decades to stabilize microtubules assembled from purified tubulin 
dimers in vitro (Nitzsche et al., 2010) 
 Microtubule gliding assays have been used in a wide range of studies for varying 
purposes, including understanding the active self-assembly of the transport machinery (Lam et 
al., 2016), or different nanotechnological applications (Bachand et al., 2014; Hess and Saper, 
2018), such as high-throughput compound screening for modulators of motor activity (Korten et 
al., 2018) or establishing molecular detection devices for e.g. diagnostic purposes (Korten et al., 
2010). A microtubule gliding motility assay thereby provides insights into the biophysical 
properties of molecular motors, but, when additional proteins are introduced, also makes it 
possible to investigate potential direct interactions of these proteins with microtubules and/or 
motors (Howard et al., 1989; Böhm et al., 1997; Korten and Diez, 2008; Scharrel et al., 2014). 
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While many studies previously used gliding assays to investigating the role of MAPs like tau on 
microtubule-dependent motor motility (Peck et al., 2011; Yu et al., 2014), a potential interaction 
of FUS with microtubules or motors has not been evaluated in this setup to date. Microtubule 
gliding assays therefore provide a suitable tool to model the translocation of motors along 
microtubules, and hence to model microtubule-dependent axonal transport. In contrast to in vivo 
model systems, the direct and sole interaction between proteins and microtubules or motors can 
be investigated. This allows for studying the influence of either a single protein of interest (i.e. 
recombinant protein) or complex solutions comprising a mixture of proteins (i.e. cell lysates) on 
microtubule-dependent axonal transport. Thereby, using microtubule gliding assays, 
disturbances in the axonal transport machinery can be investigated which might otherwise be 
masked in in vivo models of axonal transport (e.g. cell culture models).  
 
1.4 Aim of this study 
Although axonal transport defects have long been described as a pathological hallmark of FUS-
ALS, little is known about the cause and exact underlying mechanisms. FUS protein colocalizes 
with kinesin-1 mRNA and was isolated as part of an RNA-transporting granule associating with 
kinesin-1 protein (Kanai et al., 2004; Yasuda et al., 2017), but whether FUS directly interacts 
with kinesin-1 or microtubules remains unknown to date. This thesis hence aims at developing a 
novel and robust assay mimicking axonal transport in vitro in a complex environment such as 
neuronal whole cell lysates. Using this assay, two hypotheses on the pathomechanisms that 
might contribute to axonal transport defects will be tested. 
I) FUS directly interacts with kinesin-1 or microtubules in order to transport e.g. RNA, and its 
mislocalized, mutant form directly alters this interaction and impairs kinesin-1 motility on 
microtubules. This would indicate that disturbances in axonal transport are a direct 
consequence of cytoplasmic mislocalization of FUS. 
II) An increased ratio of 4R:3R tau isoforms, as previously observed in FUS-ALS, is sufficient to 
impair kinesin-1 motility on microtubules, indicating an indirect disturbance of axonal transport 
as a consequence of the nuclear loss-of-function of FUS. 
To address these hypotheses, axonal transport will be modelled utilizing a 
kinesin-1-dependent microtubule gliding assay. The assay will be modified to be compatible with 
and provide robust results in the presence of physiological buffers and complex solutions such 
as whole cell lysates. First, in order to test the direct interference of wildtype FUS-GFP or the 
FUS-P525L-GFP variant with kinesin-1 and/or microtubules, recombinant FUS-GFP variants, as 
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well as cell lysates generated of spinal motor neurons differentiated from isogenic iPSC lines 
expressing the same FUS variants, will be generated and administered to the modified gliding 
assay. Second, to test the influence of increasing 4R:3R tau isoform ratios on the kinesin-1 
motility on microtubules, recombinant human 2N4R tau-mScarlet and 2N3R tau-GFP isoforms 
will be purified from insect cells and administered individually or combined at different ratios to 
the modified kinesin-1-dependent microtubule gliding assay. 
In both scenarios, the relative microtubule gliding velocity in the presence or absence of 
proteins is assessed, which is determined as a measure for kinesin-1 motility. In addition, the 
binding of recombinant proteins is either qualitatively assed by widefield-epifluorescence 
microscopy (in the case of recombinant FUS variants) or quantitatively by total internal reflection 
fluorescence (TIRF) microscopy (in the case of recombinant tau variants).  
This study will hence investigate the direct or indirect interference of ALS-associated FUS 
on kinesin-1-dependent transport. It will thereby provide important contributions to 
understanding the pathomechanisms leading to axonal transport defects in FUS-ALS. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Technical equipment 
Table 1: Technical equipment 
Instrument Company 
70 mL Polycarbonate Bottle Assembly Beckman Coulter GmbH, Krefeld, Germany 
ÄKTA pure protein purification system General Electric Company, Boston, MA, USA 
Analytical Balance - CP225D-0CE  Analytical Balance - CP225D-0CE  
Axio Observer Z1 microscope with a 1. 63x oil 
immersion objective 
Carl Zeiss, Jena, Germany 
Azure c600 Gel Imaging System Azure Biosystems Inc., Dublin, CA, USA 
Balance - SBA 52  Scaltec Instruments GmbH, Heiligenstadt, 
Germany 
BAT-10 Multipurpose Thermometer Physitemp Instruments, LLC, Clifton, NJ, USA 
Biosafety cabinet HERAsafe® HS Heraeus Holding GmbH, Hanau, Germany 
Cell culture Microscope – Axiovert 35  Carl Zeiss, Jena, Germany 
Centrifuge – 5403  Eppendorf, Hamburg, Germany 
Centrifuge - MiniSpinPlus  Eppendorf, Hamburg, Germany 
Centrifuge Heraeus® Biofuge® Pico Thermo Fisher Scientific, Massachusetts, USA  
Centrifuge Heraeus® Biofuge® Primo Thermo Fisher Scientific, Massachusetts, USA  
Centrifuge Heraeus™ Biofuge™ Stratos™ Thermo Fisher Scientific, Massachusetts, USA 
CORIO CP-200F Thermostat JULABO GmbH, Seelbach, Germany 
Elektro Automatik EA-PS 3016-10B Power 
Supply 
Elektro-Automatik GmbH & Co. KG, Viersen, 
Germany 
EmulsiFlex-C5 High Pressure Homogenizer AVESTIN Inc., Ottawa, ON, Canada 
Fluorescence Microscope - Observer.Z1  Carl Zeiss, Jena, Germany 
Fluorescence Microscope – Ti-E Nikon GmbH, Düsseldorf, Germany 
Freezer -80°C HERAfreeze® Thermo Fisher Scientific, Massachusetts, USA  
Hemocytometer - Neubauer improved  Paul Marienfeld GmbH Co. KG, Lauda-
Königshofen, Germany 
Hybridization oven - OV3 Biometra GmbH, Göttingen, Germany 
iBlot® Gel Transfer Device Thermo Fisher Scientific, Massachusetts, USA 
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Imager - LAS3000  Fujifilm, Tokyo, Japan 
Incubator - Heracell 150 Thermo Fisher Scientific, Massachusetts, USA  
iXon EM+ DU-897 BV back-illuminated 
EMCCD camera 
Andor Technology Ltd., Belfast, UK 
iXon Ultra back-illuminated EMCCD camera Andor Technology Ltd., Belfast, UK 
Liquid Nitrogen Tank K Series Worthington Industries, Columbus, Ohio, USA 
Microcentrifuge Heraeus™ Fresco™ 17 Thermo Fisher Scientific, Massachusetts, USA 
Microscope CKX41 Olympus Deutschland GmbH, Hamburg, 
Germany 
MINIPULS 3 Peristaltic Pump Gilson Incorporated, Middleton, WI, USA 
Multi-channel micropipette Transferpette®-8 
electronic 
Brand GmbH & Co. KG, Wertheim, GER  
neoVAQ Maxi Vacuum Pump neoLab Migge GmbH, Heidelberg, Germany 
Nikon Eclipse Ti microscope with a 1.49 
PlanApo 100x oil immersion objective 
Nikon, Tokio, Japan 
OptimaTM LE-80K Ultracentrifuge 
with Type45 Ti Rotor 
Beckman Coulter GmbH, Krefeld, Germany 
pH meter - inoLab ph 720  Wtw GmbH, Weilheim, Germany 
Sunrise™ Absorbance Reader Tecan Trading AG, Switzerland 
Thermomixer – Thermomixer 5436  Eppendorf, Hamburg, Germany 
Thermomixer – Thermomixer Comfort  Eppendorf, Hamburg, Germany 
Water bath Julambo SW22 JULAMBO Labortechnik GmbH, Seelbach, 
Germany 
Water purification system - GenePure  Thermo Fisher Scientific, Massachusetts, USA 
XCell SureLock Mini-Cell Electrophoresis 
System 
Thermo Fisher Scientific, Massachusetts, USA 
 
2.1.2 General equipment 
Table 2: General equipment 
Equipment Company 
15 mL and 50 mL Falcons BD, New Jersey, USA 
96-Well White Clear Flat Bottom Plates Corning Inc., Tewksbury MA, USA 
Amicon® Ultra-4 centrifugal filters Ultracel® 30K Merck Millipore Ltd., Tullagreen, Ireland 
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Axygen® Filter Tips 10-200 µL Corning Inc., Tewksbury MA, USA 
BD Luer-Lok 50 mL syringe Becton Dickinson S.A., Madrid, Spain 
BD MicrolanceTM Canula 27 G 3/4 0.4 x 19 mm Becton Dickinson GmbH, Heidelberg, 
Germany 
Biosphere® Filter Tips 1000µl Sarstedt AG & Co, Nürnberg, Germany 
Bio-Spin® Columns Bio-Rad Laboratories Inc., Hercules, CA, USA 
Cell scraper TPP, Trasadingen, Switzerland 
Costar® 6-well cell culture plates Corning Inc., Tewksbury MA, USA 
Cryotubes Greiner Bio-One, Frickenhausen, Germany 
Disposable Serological Pipettes Corning Inc., Tewksbury MA, USA 
Eppendorf Tubes, 1.5mL, 2mL Eppendorf AG, Hamburg, Germany 
iBlot® Nitrocellulose transfer stack Thermo Fisher Scientific, Massachusetts, USA 
Mikrozid® Liquid Schülke&Mayr, Norderstedt, Germany 
Millex HV low binding PVDV membrane filters 
0.45 μm 
Merck Millipore, Billerica, USA 
Nalgene® Mr. Frosty Freezing Sigma Aldrich, St. Louis, USA 
Omnifix® Syringes, 2-3 mL B. Braun Medical Inc., Bethlehem, PA, USA 
Parafilm® Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
ROTI®Nanoquant Protein Assays Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
SuperdexTM 200 Increase 10/300 GL GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
Surgical mask Paul Hartmann AG, Heidenheim, Germany 
T25 Cell Culture Flasks Thermo Fisher Scientific, Massachusetts, USA 
 
2.1.3 Cell culture ingredients, chemicals and reagents 
Table 3: Cell culture ingredients, chemicals and reagents 
Chemical Company 
Accutase Life Technologies Corporation, Carlsbad, USA 
Activin A Biomol GmbH, Hamburg, Germany 
Amersham ECL Prime Western Blotting 
Detection Reagent 
GE Healthcare Life Sciences, Marlborough, 
MA, USA 
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Ascorbic Acid Sigma-Aldrich, St. Louis, USA 
B-27 Supplement minus Vitamin A Life Technologies Corporation, Carlsbad, USA 
Benzonase(R) Nuclease Sigma-Aldrich, St. Louis, USA 
BSA Fraction V  Thermo Fisher Scientific, Massachusetts, USA  
CHIR99021 Cayman Chemical, Michigan, USA 
Chromatography paper grade 3mm GE Healthcare UK Limited, Buckinghamshire, 
UK 
cOmplete EDTA -free Protease Inhibitor 
Cocktail Tablets 
Roche Holding AG, Basel, Switzerland 
DAPT Cayman chemical company, Ann Arbor, USA 
dbcAMP Sigma-Aldrich, St. Louis, USA 
Dichlorodimethylsilane Sigma-Aldrich, St. Louis, USA 
DMEM/F-12 Life Technologies Corporation, Carlsbad, USA 
DMSO Sigma-Aldrich, St. Louis, USA 
DPBS without Ca2+/Mg2+ Life Technologies Corporation, Carlsbad, USA 
Ethanol VWR International GmbH, Dresden, Germany 
Glycerol MP biomedicals, Santa Ana, USA 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
HaltTM Phosphatase inhibitor Cocktail (100x) Thermo Fisher Scientific, Massachusetts, USA 
HaltTM Protease Inhibitor Cocktail (100x) Thermo Fisher Scientific, Massachusetts, USA 
HisTrap™ HP Columns GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
Hydrofluoric acid ACS reagent, 48 % Sigma-Aldrich, St. Louis, USA 
Imidazole Sigma-Aldrich, St. Louis, USA 
Isopropanol VWR International GmbH, Darmstadt, 
Germany 
Kel-F Hub needle, 30 gauge, 2 inches, point 
style 3 
Hamilton Bonaduz AG, Bonaduz, Switzerland 
KnockoutTM DMEM Thermo Fisher Scientific, Massachusetts, USA 
Laminin from EHS sarcoma (mouse) Sigma-Aldrich, St. Louis, USA 
Laminin from EHS sarcoma (mouse) Roche Holding AG, Basel, Switzerland 
Luer-LokTM syringe Becton, Dickinson and Company, Franklin 
Lakes, NJ, USA 
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Magnesium chloride hexahydrate Merck Millipore, Billerica, USA 
MatrigelTM Basement Membrane Corning Inc., Tewksbury MA, USA 
MenzelTM glass coverslips, 18 x 18 mm, 
22 x 22 mm 
Gerhard Menzel Glasbearbeitungswerk GmbH 
& Co. KG, Braunschweig, Germany 
Mikrozid Schülke&Mayr, Norderstedt, Germany 
Monoclonal Anti-β-Tubulin I antibody, 
clone SAP.4G5 
Sigma-Aldrich, St. Louis, USA 
N2-Supplement Life Technologies Corporation, Carlsbad, USA 
NeurobasalTM Medium Life Technologies Corporation, Carlsbad, USA 
Ni-NTA agarose beads Qiagen, Hilden, Germany 
Non-Silicone Thermal Interface Compound Electrolube, Leicestershire, UK 
Novex™ MagicMark™ XP Western Protein 
Standard 
Thermo Fisher Scientific, Massachusetts, USA 
Novex™ NuPAGE™ LDS-Probenpuffer (4X) Thermo Fisher Scientific, Massachusetts, USA 
Novex™ SeeBlue™ Plus2 Prestained 
Proteinmarker 
Thermo Fisher Scientific, Massachusetts, USA 
Novex™ Sharp Pre-stained Protein Standard Thermo Fisher Scientific, Massachusetts, USA 
NuPAGE™ MOPS SDS Running Buffer Thermo Fisher Scientific, Massachusetts, USA 
NuPAGE™ Novex™ 4-12 % Bis-Tris-
Proteingel 
Thermo Fisher Scientific, Massachusetts, USA 
Parafilm Bemis Company Inc., Neenah, WI, USA 
Penicillin-Streptomycin Life Technologies Corporation, Carlsbad, USA 
Phosphatase Inhibitor (100x)  Thermo Fisher Scientific, Massachusetts, USA 
Phosphate Buffer Saline (PBS) Thermo Fisher Scientific, Massachusetts, USA 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, Massachusetts, USA 
Pluronic F127 Sigma-Aldrich, St. Louis, USA 
Poly-L-Ornithine Sigma-Aldrich, St. Louis, USA 
Potassium chloride Merck Millipore, Billerica, USA 
PreScission (HRV 3C + GST) Protein Expression Facility, MPI-CBG, 
Dresden Germany 
Purmorphamine Cayman Chemical, Michigan, USA 
Retinoic Acid Sigma-Aldrich, St. Louis, USA 
rhBDNF Promega GmbH, Mannheim, Germany 
rhGDNF Sigma-Aldrich, St. Louis, USA 
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SAG Cayman chemical company, Ann Arbor, USA 
SDS Sigma-Aldrich, St. Louis, USA 
Sf9-ESF Expression Systems, LLC, Davis, CA, USA 
SimpleBlue Safe Stain Invitrogen, Carlsbad, CA, USA 
SuperSignal™ West Femto Maximum 
Sensitivity Substrate 
Thermo Fisher Scientific, Massachusetts, USA 
TGFβ-3 Peprotech, London, UK 
Tris-HCL Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Tween 20 Serva Elektrophoresis GmbH, Heidelberg, 
Germany 
β-Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
2.1.4 Media and buffers 
Table 4: Media and buffers, all amounts given in percent refer to volume/volume 
Medium Composition 
N2B27 medium 48.75 % DMEM/F12, 48.75 % NeurobasalTM Medium, 1 % 
Penicillin/Streptomycin, 1 % B-27 Supplement without 
Vitamin A, 0.5 % N2-Supplement 
Normal culture (expansion) 
medium 
N2B27 medium with 3 µM Chiron99021, 150 µM AA, 
0.5 µM SAG 
Patterning medium N2B27 medium with 1 ng/mL rhBDNF, 0.2 mM AA, 1 µM 
retinoic acid, 1 ng/mL rhGDNF, 0.5 µM SAG 
Maturation medium N2B27 medium with 0.1 mM cAMP, 2 ng/mL rhBDNF, 
0.2 mM AA, 1 ng/mL TGFβ-3, 2 ng/mL rhGDNF, 5 ng/mL 
Activin A (on day 1 of maturation), 5 µM DAPT (on day 4 
of maturation) 
Lysis buffer for whole cell lysates PBS with 1 x protease inhibitor, 10 % glycerol, 10 mM β-
glycerophosphate 
FUS-GFP storage buffer 50 mM Tris-HCL, 500 mM KCL, 1 mM DTT, 5 % glycerol 
in H2O 
BRB80 80 mM PIPES, 1 mM EGTA, 1 mM MgCl2 
Standard motility buffer PBS with 10 µM taxol, 10 % glycerol, 10 mM β-
glycerophosphate, 0.3 % methylcellulose, 1 mM ATP, 
Mechanisms of Axonal Transport in ALS  Materials and Methods 
Anne Seifert  30 / 157   
20 mM D-glucose, 20 μg/mL glucose oxidase, 10 μg/mL 
catalase, 10 mM DTT (and 0.2 mg/mL casein in absence 
of recombinant protein, BSA, or cell lysate) 
VALAP Vaseline, lanolin, and paraffin in a 1:1:1 ratio 
Transfer buffer for western blot 200 mM glycine, 25 mM Tris-HCL, 6.7 % methanol (in 
cathode buffer) or 0.1 % SDS (in anode buffer) in H2O, pH 
8.3 
PBST PBS with 0.05 % Tween20 
Stripping buffer 3 g glycine, 0.1 % SDS, 1 % Tween20, in H2O, pH 2.2 





HisTrap storage buffer with 30 mM imidazole, 10 mM β-
mercaptoethanol in H2O 
Lysis buffer for the purification of 
tau-GFP from Sf9 cells 
50 mL equilibration buffer with one protease inhibitor 
tablet 
High salt buffer Equilibration buffer with 200 mM KCL 
Elution buffer Equilibration buffer with 200 mM imidazole 
2.1.5 Antibodies 
Table 5: Primary antibodies 
Antibody Host Dilution Company Reference Number 
FUS Mouse 1:1000 Sigma-Aldrich, St. Louis, USA AMAB90549-100UL 
3R Tau Mouse 1:2000 Merck KGaA, Darmstadt, 
Germany 
05-803 
4R Tau Mouse 1:2000 Merck KGaA, Darmstadt, 
Germany 
05-804 
β-actin Rabbit 1:8000 Cell Signaling Technology, Inc, 
Beverly, MA, USA 
#4967 
 
Table 6: Secondary antibodies 
Antibody Host & Reactive 
Species 
Dilution Company Reference 
Number 
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2.1.6 Software 
Table 7: Software 
Product Type Company 
FIJI (ImageJ) 1.52p Image analysis Open source (Schindelin et al., 2012) 
Matlab R2017a Data evaluation and graphics The MathWorks, Inc., Natick, MA,USA 
Inkscape 0.91 Figure preparation Open source (www.inkscape.org) 
GraphPad Prism 7 Statistical analysis GraphPad Software Inc., La Jolla, USA 
Microsoft Office 2010 Data analysis and writing Microsoft Corporation, Redmond, 
Washington, USA 
MetaMorph 7.8.4.0 Image analysis Molecular Devices, Sunnyvale, CA, 
USA 
Image StudioTM Lite, 
5.2.5 
Western blot image analysis LI-COR Biosciences, Lincoln, Nebraska 
USA 
OriginLab 2019b Statistical analysis OriginLab Corporation, Northampton, 
MA, USA 
 
2.1.7 Patient-derived isogenic iPS cell lines 
Isogenic cell lines used in this study were generated and characterized previously by members 
of the group of Prof. Andreas Hermann. The specifications for both lines are summarized in 
Table 8. This study was approved by the local ethics committee (EK45022009, EK393122012). 
Table 8: Characteristics for isogenic cell lines used in this study 
Name Genotype Gender 
Year of 
birth 










F 1952 58 (Naumann et al., 2018) 
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2.2 Methods 
2.2.1 Coating of cell culture plates and flasks 
NPCs were maintained and primed for differentiation in T25 flasks. Flasks were coated with 
Matrigel diluted 1:100 in KnockOut™ DMEM and incubated at room temperature (RT) for 
30 min. For maturation, cells were cultured on 6-well plates coated first with 15 % Poly-L-
Ornithine (PLO) in PBS, then with 0.005 mg/ml laminin in PBS at 37 °C overnight, respectively. 
2.2.2 NPC thawing, culture, and cryoconservation 
NPCs were thawed by suspending them in pre-warmed N2B27 medium, centrifuged with 
230 x g for 5 min and subsequent seeded into Matrigel-coated culture flasks in expansion 
medium. Cells were maintained at standard cell culture conditions (37 °C in a humidified 
atmosphere containing 5 % CO2) in N2B27 medium supplemented with 3 µM Chiron99021, 
150 µM ascorbic acid (AA), and 0.5 µM smoothened agonist (SAG). Medium was changed three 
times a week, while cells were split at 85 % confluency, on average once per week. For splitting, 
cells were detached from the surface via incubation with accutase at 37 °C for 5 min. Detached 
cells were taken up in pre-warmed N2B27 medium and either reseeded at an appropriate 
density or cryopreserved at -80°C. For this, cells were resuspended in N2B27 medium 
containing 10 % DMSO as a cryoprotectant. Cells were frozen over night at a cooling rate of 
~1 °C per hour, and subsequently transferred to liquid nitrogen (-180 °C) for long-term storage. 
2.2.3 Differentiation and maturation of NPCs towards spinal motor neurons 
The generation of spinal motor neurons out of NPCs requires the addition of different small 
molecules to the culture medium at specified time points (Figure 5). After splitting, NPCs were 
reseeded in N2B27 medium supplemented with 1 ng/mL recombinant human brain-derived 
neurotrophic factor (rhBDNF), 0.2 mM AA, 1 µM retinoic acid, 1 ng/mL recombinant human 
glial-derived neurotrophic factor (rhGDNF), and 0.5 µM SAG in order to prime their 
differentiation into spinal motor neurons. Medium was exchanged every two days until day six 
post induction, where the maturation phase was started by the addition of N2B27 medium 
supplemented with 0.1 mM cAMP, 2 ng/mL rhBDNF, 0.2 mM AA, 1 ng/mL Transforming growth 
factor β-3 (TGFβ-3), and 2 ng/mL rhGDNF, which marked day 0 of maturation. On this day only, 
5 ng/mL Activin A was additionally supplemented to the maturation medium. Primed NPCs were 
split one more time between days 2-4 of maturation and reseeded in maturation medium into a 
6-well plate coated with PLO and laminin, at a concentration of 1 x 106 cells/well (determined 
using a Neubauer counting chamber). On day 4 of maturation only, 5 µM N-[N-(3,5-
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Difluorphenacetyl)-L-alanyl]-S-phenylglycin-tert-butylester (DAPT) was added to the maturation 
medium. DAPT is a γ-secretase inhibitor that inactivates Notch signaling and thereby results in 
fewer cells in culture with progenitor morphology while increasing cells with a neuronal 
morphology (Nelson et al., 2007). Maturing spinal motor neurons were kept in maturation 
medium without any additional supplements, with medium changes twice a week, until they 
were lysed on day 21 of maturation. 
 
Figure 5: Timeline for the differentiation and maturation of NPCs towards spinal motor neurons 
Different sets of small molecules are added to N2B27 medium during the differentiation and maturation of NPCs 
towards spinal motor neurons. 
2.2.4 Generation of cell lysates – isolation techniques 
At day 21 of maturation, spinal motor neurons were gently washed with PBS once, scrapped off 
the dish surface and resuspended in fresh PBS. Cells were then lysed by following methods: 
A | Chemical lysis using the Active Motif® Nuclear Extraction Kit according to the 
manufacturer’s instructions for the generation of whole cell lysates. For the exchange of buffers 
after chemical lysis, PD Minitrap™ G-10 desalting columns or Vivaspin® 500 centrifugal 
concentrators were used according to the manufacturer’s instructions. Protein in PD Minitrap 
columns was eluted in PBS. Centrifugation speed and time for Vivaspin columns was 13.000 x g 
and 30 min, respectively. 
B | Lysis by grinding in liquid nitrogen: Cells were pelleted at 14.000 x g for 5 min at 4°C 
and the cell pellet was resuspended in 1 ml fresh PBS supplemented with 1 x protease inhibitor 
cocktail (containing 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, aprotinin, bestatin, 
E-64, leupeptin and pepstatin A), dropwise frozen in liquid nitrogen and ground to a fine powder 
using a pre-chilled mortar. 
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C | Mechanical lysis with glass beads: Cells were pelleted at 14.000 x g for 5 min and the 
cell pellet resuspended in 1 ml fresh PBS supplemented with 1 x protease inhibitor. Sterile glass 
beads were added to each Eppendorf tube to an approximate volume of 400 µL, and the tube 
was vortexed for 5 min. Glass beads were allowed to sediment on ice for 5 min and the 
supernatant was aspirated. 
D | Mechanical lysis using a dounce homogenizer: Cells were pelleted at 14.000 x g for 
5 min and the cell pellet was resuspended in 1 ml fresh PBS supplemented with 1 x protease 
inhibitor. Resuspended cell were sheared in a dounce homogenizer on ice using ten strokes. 
E | Mechanical lysis using a syringe: Cells were pelleted at 14.000 x g for 5 min. The cell 
pellet was resuspended in 1 ml fresh PBS supplemented with 1 x protease inhibitor and cells 
were sheared by pulling them ten times through a thin needle (0.4 x 19 mm; 27G ¾) using a 
2 ml syringe while on ice.  
Lysates prepared by methods B through E were subsequently centrifuged at 4 °C and 
70.000 x g for 5 min. The supernatant was then transferred to a new tube, supplemented with 
1 x protease inhibitor, 10 mM β-glycerophosphate, and 10 % glycerol, and snap-frozen in liquid 
nitrogen for long term storage at -80 °C. 
2.2.5 Determining protein concentration 
Protein concentrations were determined using the Pierce™ bicinchoninic acid (BCA) protein 
assay kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Briefly, 
standards were prepared with BSA diluted in lysis buffer to concentrations ranging from 
25 µg / ml to 1 mg / m and measured in duplicates in a white 96-well transparent flat bottom 
plate. Lysates were measured in triplicates. All probes were mixed with the kit’s working reagent 
within the plate and subsequently incubated at 37 °C for 30 min. After incubation, the plate was 
allowed to cool down to RT, the absorbance of samples at 562 nm was measured with a 
TECAN plate reader and corrected for the values of blank measurements. A standard curve was 
created in Microsoft Excel 2010, and the sample concentration was calculated from a linear 
regression line. The BCA assay is a highly sensitive, two-step reaction. In the first step, cupric 
ions (Cu2+) are reduced to cuprous ions (Cu+) by proteins under alkaline conditions, a reaction 
referred to as the Biuret reaction (Gornall et al., 1949), while two BCA molecules are chelated in 
the second step by one cuprous ion, resulting in a water-soluble, stable BCA/copper complex 
(Smith et al., 1985). This complex absorbs light at 562 nm, which causes a color change of the 
solution from blue to intense purple, measurable using a spectrophotometer. The measured 
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absorbance is directly proportional to the amount of protein in solution. The assay allows for the 
measurement of protein over a wide range of concentrations (between 0.5 ng/µL and 1.5 µg/µL) 
and is compatible with many detergents and other substances. However, exogenous reducing 
agents, such as DTT or mercaptoethanol, or copper chelating agents in particular greatly 
interfere with the reaction and hence may influence the results. Similarly, the presence of 
certain amino acids (i.e. cysteine, tyrosine, and tryptophan, Wiechelman et al., 1988) influences 
the accuracy of the results. In addition, the assay requires comparably long incubation times of 
30 min up to two hours and incubation at 37°C, as the reaction is temperature sensitive (Lowry 
et al., 1951; Smith et al., 1985; Krohn, 2002; Brady and Macnaughtan, 2015).  
For reasons of comparison, the protein concentration of lysates produced by chemical 
lysis was additionally determined using the ROTI®Nanoquant Bradford assay in a microtiter 
plate according to the manufacturer’s instructions. In brief, standards were prepared with BSA 
diluted in PBS ranging from a concentration of 1 to 100 µg / ml and again prepared in duplicates 
in a white 96-well transparent flat-bottom plate. Lysates were diluted 1:20 and measured in 
triplicates. All probes were then mixed with working reagent diluted 1:5 in H2O and incubated at 
RT for 5 min, after which absorbance was measured three times at 450 nm and 590 nm, each 
and respectively, in a TECAN plate reader. For each well, the measured value at 590 nm was 
divided by the value measured at 490 nm, and the average of three subsequent measurements 
was taken to calculate the final concentration. A standard curve was created in this way, 
through which the sample concentration could be estimated using a linear regression line. The 
Bradford assay is comparably sensitive, but more straightforward as it deploys the ability of the 
dye Coomassie blue to directly bind to proteins and subsequently change its color from red 
(absorbance at 465 nm) to blue (absorbance at 595 nm). The absorbance can be measured at 
both wavelengths, and the change in color is directly related to the amount of protein present in 
the sample. Since this method does not require a series of reactions to indicate protein 
concentration, the incubation time is much faster (5 min) compared to BCA, although the range 
of protein amount that can be detected is limited (between 1 and 20 µg). The reagent is 
however compatible with a large variety of buffers and solvents, as well as reducing and 
chelating agents, which makes it a suitable alternative to BCA if such agents cannot be 
removed from solution. The downside is that the Coomassie reagent precipitates in the 
presence of surfactants and is highly acidic, indicating that proteins with poor acid solubility 
cannot be measured with this dye. Similar to BCA, it is also very sensitive to certain amino acids 
(i.e. aromatic acids such as arginine, histidine or lysine, Compton and Jones, 1985; de Moreno 
et al., 1986; Fountoulakis et al., 1992). In addition, it adsorbs to glassware or quartz cuvettes, 
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which require thorough cleansing after detection in order to be reusable (Bradford, 1976; Zor 
and Selinger, 1996; Krohn, 2002; Georgiou et al., 2008; Brady and Macnaughtan, 2015). 
2.2.6 Acquisition of kinesin-1, tubulin, and recombinant human FUS-GFP variants 
Porcine tubulin was purified from porcine brain (obtained from Vorwerk Podemus, Dresden, 
Germany) using previously established protocols (Castoldi and Popov, 2003) and fluorescently 
labeled using mixed isomers of 5-(and 6-) carboxytetramethylrhodamine, succinimidyl ester 
(5(6)-TAMRA,SE, Invitrogen, C1171), a member of the rhodamine family of dyes (Gessner and 
Mayer, 2000). Drosophila melanogaster kinesin-1 heavy chains were expressed in full length in 
insect cells and purified as previously described (Korten et al., 2016). Recombinant human 
FUS-GFP variants were kindly provided by Dr. Jie Wang, Max Planck Institute of Molecular Cell 
Biology and Genetics, Dresden. The first batch of recombinant human 2N4R tau-GFP protein 
used for the determination of assay sensitivity was kindly provided by Dr. Marcus Braun, 
Institute of Biotechnology CAS, Prague. 
2.2.7 Expression and purification of recombinant human tau variants 
The construct for recombinant human 2N3R tau-GFP was kindly provided by Prof. Eckhard 
Mandelkow, Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Bonn and is 
described in Gustke et al., 1994 and Seitz et al., 2002. The construct for recombinant human 
2N4R tau-GFP was kindly provided by Dr. Amayra Hernandez Vega, Max Planck Institute of 
Molecular Cell Biology and Genetics, Dresden, and is characterized in Hernández-Vega et al., 
2017. In order to express both constructs in insect cells, the gene of interest was amplified by 
PCR and flanked with the restriction sites NotI and AscI using the respective 
5’ (AATAATAACATGCGGCCGCAATGGCTGAGCCCCGCC) and 
3’ (AATAATAACATGGCGCGCCCAAACCCTGCTTGGCCAG) primers. The resulting product 
was inserted into the vector pOCC61, containing a C-terminal monoGFP tag and a 
3C-cleavable 6xHis-tag for affinity purification. Baculovirus for the expression in insect cells was 
generated from these constructs by Régis Lemaitre at the Protein Expression Purification and 
Characterization (PEPC) facility at the Max Planck Institute of Molecular Cell Biology and 
Genetics, Dresden (Lemaitre et al., 2019). Insect cells (Sf9-ESF) were infected with the 
respective virus with a ratio of 1:100 (v/v) and harvested 72 hours post infection by 
centrifugation at 350 x g for 10 min. 
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Purification of recombinant human tau-GFP variants 
Harvested cell pellets were resuspended in 20 mL lysis buffer (50 mL equilibration buffer with 
one protease inhibitor tablet) and the suspension lysed by passing them three times through an 
Emulsiflux French press on ice. All further steps were performed at 4°C or on ice. The lysate 
was collected in cold Beckmann centrifuge bottles, supplemented with benzonase (at least 
1:6000), and cleared of cell debris by centrifugation at 14000 x g at 4°C for 45 min. The cleared 
lysate was then passed through a 0.45 µm filter in order to completely remove cell debris before 
protein purification via nickel-sepharose affinity chromatography. His-trap columns were 
equilibrated with 10 column volumes (CV) of equilibration buffer before the protein was loaded 
onto the column by passing the supernatant through the column at a flow rate of about 
0.75 ml/min with the help of a peristaltic pump. The column was washed once with 10 CV high 
salt buffer or equilibration buffer (50 mM HEPES, 300 mM KCL, 0.2 % Tween20 (v/v), 
10 mM β-mercaptoethanol in H2O) without imidazole. The protein was then eluted by flowing 
elution buffer through the column and collecting 1 ml fractions. Eluted fractions were pooled and 
supplemented with PreScission 3C-6xHis protease (1 mg/ml) for GST(His)-tag removal, shaking 
at 4°C overnight. On the next day, the sample was concentrated and the elution buffer 
exchanged for equilibration buffer by centrifugation through 30K AmiconUltra filters at 7000 rpm 
for 10 min three times. In order to remove the cleaved His-tag from the cleaved protein fraction, 
the concentrated sample was incubated with 1 mL Ni-NTA agarose beads shaking at 4°C for 
one hour. This solution was then passed through a 10 mL gravity flow filter column which 
retained the beads and the flow through was concentrated again by centrifugation as described 
above. 50 µL samples were collected after each step to determine purification efficiency in a 
subsequent sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel (Figure S1). The protein of 
interest was further purified by size exclusion chromatography (SEC) with equilibration buffer 
through a superdex200 column on an ÄKTA pure liquid chromatography system at 4°C. 
Absorbance was measured at 480 nM for eGFP construct and 569 nM for the mScarlet 
construct and the fractions under the peak (0.5 mL per fraction) were collected. These pooled 
fractions were again concentrated by centrifugation as described above, and the concentrated 
protein was flash frozen in liquid nitrogen and stored at -80°C in 5 µL aliquots. 
Protein quantification by SDS-PAGE gel electrophoresis and Coomassie staining 
Purified proteins and samples taken throughout the purification procedure were analyzed by 
SDS-PAGE for purification efficiency and concentration measurement. SDS loading buffer, 
supplemented with 0.1 M DTT, was mixed 1:4 with the respective samples to be analyzed and 
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boiled at 95°C for 5 min. 10 µL of sample was loaded onto a 4-12 % Bis-Tris gel, together with 
an appropriate protein ladder. The gel was assembled into an SDS gel electrophoresis running 
chamber filled with 1 x MOPS buffer and run at 120 V, 85W, and 60 mA until all protein had 
passed to the end of the gel (at least one hour). Gels were then stained with Coomassie 
SimplyBlue SafeStain for at least 45 min up to overnight. Afterwards, gels were destained in 
ddH2O until bands were clearly visible. 
Protein quantification on SDS-PAGE gels 
Purified 6xHis-eGFP protein at a known concentration was run as a standard on SDS-PAGE 
gels, together with different dilutions of the protein of interest and stained with Coomassie blue 
as described above. Gels were scanned with an Azure c600 Gel Imaging System and the 
integrated density of protein bands was quantified using ImageJ. A rectangular area was 
selected enclosing the first lane. The same rectangular shape was the applied onto all lanes on 
the gel. The intensity profiles of all lanes were then plotted using the ‘analyze gel’ function of 
ImageJ and the integrated intensities were recorded by selecting the area under each peak. A 
calibration curve was then obtained from the linear fit to the integrated intensity for different 
concentrations of the 6xHis-eGFP protein. Protein sample concentration were then calculated 
for each dilution and averaged to get the undiluted protein concentration. 
2.2.7 Kinesin-1-dependent microtubule gliding assay 
Flow chamber and imaging assembly 
Kinesin-1-dependent microtubule gliding assays were adapted from previously described 
protocols (Nitzsche et al., 2010). Assays were performed in manually assembled flow chambers 
(Figure 6), which were constructed by cutting out seven stripes of parafilm of about 25 x 1 mm2 
size and sandwiching them in between 18 x 18 mm2 (top) and 22 x 22 mm2 (bottom) glass 
coverslips, forming parallel channels. In addition, two 25 x 3 mm2 parafilm stripes were cut and 
placed orthogonal to the channels on the sides of the top coverslip, just above the entry and exit 
sites of channels, to prevent immersion oil from the objective from flowing into the channels 
during later imaging. Overhanging parafilm was cut off using a razor blade. The sandwich was 
heated until the parafilm got soft and six channels were sealed leak-proof by gently applying 
pressure onto the coverslips. Molecular motor motility is very sensitive to changes in 
temperature (Böhm et al., 2000; Hong et al., 2016). In order to minimize temperature 
fluctuations, and therefore improve reproducibility of motility measurements, an objective heater 
was used at the microscope and flow chambers were mounted onto a custom-build Peltier 
element (Figure 6), and both devices were set to 30 °C. The Peltier element makes use of the 
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Peltier effect, which describes the transfer of heat from one junction to another if a voltage is 
applied across joined conductors, creating an electrical current, with consumption of electrical 
energy. The effect was discovered in 1834 by Jean Charles Athanase Peltier (Peltier, 1834) and 
allows for heating as well as cooling, depending on the direction of the current (Taylor and 
Solbrekken, 2008). A Peltier element therefore has two major advantages: i) it does not 
overheat, but can actively cool down its surface by changing the electrical polarity when 
connected to a conventional power supply, and ii) reaches desired temperatures on a very fast 
time scale (e.g. a temperature change of 8 °C is achieved in about 25 s) (Ionov et al., 2006; 
Nitzsche et al., 2010). The temperature of the herein used Peltier element was constantly 
monitored using a thermometer with analogue readout capability and the current was adjusted if 
needed to maintain a steady temperature of 30 °C within flow chambers with an accuracy of 
0.1 °C. The Peltier element and the flow chambers were coupled by applying, electrolube, a 
silicon-free heat transfer compound, in a thin layer on the surface of the Peltier element. The 
flow chamber was stuck with its bottom coverslip onto the lube and firmly attached by gentle 
pressure on the flow chamber. Because of this setup, flow channels were images upside down 
through the 18 x 18 mm2 top glass slip. To prevent light reflecting from the surface of the Peltier 
element, bottom coverslips of all flow chambers were darkened with a black permanent marker 
before fixation to the Peltier element.  
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Figure 6: Assembly, mounting, and imaging of flow channels. 
Flow chambers are assembled by stacking two coverslips of different sizes on top of each other, with parallel stripes 
of parafilm in between to form individual channels. Two wider stripes of parafilm are mounted orthogonal to flow 
channels on the edges of the top coverslip to prevent immersion oil from flowing into the channels during imaging. By 
heating this assembly, the parafilm melts and tightly seals channels. The backside of the bottom coverslip was 
painted with a black permanent marker to prevent reflection of light after the assembly was mounted on a custom-
built Peltier element, using electrolube as a temperature conducting adhesive. The Peltier element was equipped with 
a temperature sensor at its surface to constantly monitor the temperature. All solutions used in the experiments are 
pipetted onto one side of the flow chamber and aspirated at the other end of the channel using chromatography filter 
paper. Flow chambers in this setup were installed at the microscope upside-down, enabling imaging through the top 
coverslip. 
 
Microtubule assembly and kinesin-1-dependent gliding motility assay 
Microtubules were polymerized at 37 °C for 15 min from 32 μM rhodamine-labeled tubulin in 
BRB80 supplemented with 4 mM MgCl2, 1 mM Mg-GTP, and 5 % DMSO in a total volume of 
6.25 μL. Polymerized microtubules were immediately stabilized with taxol by adding 10 µM taxol 
in BRB80 to a final volume of 100 μL, and further kept at RT in the dark. Directly before use, 
microtubules were diluted 1:10 in standard motility buffer and carefully sheared twice through a 
Kel-F Hub needle (gauge 30, point style 3) using a 1 mL Luer-LokTM syringe. 
For the assay itself, a series of solutions was flushed through each flow channel by 
carefully pipetting 20 μL of each solution on one end of the channel while sucking the previous 
solution out of the channel at the other end using chromatography paper. All solutions were 
applied at RT. In a first step, flow channels were perfused with a casein-containing solution 
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(0.5 mg/mL) in PBS and left to adsorb for 5 min in order to block unspecific protein binding sites 
on the glass surface. Next, a solution containing Drosophila full-length kinesin-1 heavy chains 
(4 μg/mL), casein (0.2 mg/mL), 1 mM ATP, and 10 mM DTT in PBS was flushed through the 
channels and again left to adsorb for 5 min in order for kinesin-1 to attach to the glass surface. 
Following this, diluted and sheared microtubules in standard motility buffer were perfused into 
the channels and allowed to attach to motors for 5 min. Flow channels were then mounted onto 
a Nikon Eclipse Ti microscope equipped with a Perfect Focus System (PFS) and a 1.49 
PlanApo 100 x oil immersion objective heated to 30 °C, the same temperature as the Peltier 
element. During imaging, the Peltier element was continuously monitored and adjusted to 
ensure a constant temperature of 30 °C with a precision of 0.1 °C. Images were acquired using 
widefield-epifluorescence and excited by LED lamp and respective filter sets for excitation at 
550 nm for rhodamine-labeled microtubules, 470 nm for eGFP-labeled proteins, or 640 nm for 
mScarlet- and mCherry-labeled proteins, respectively. Time lapse images were recorded at ten 
different positions within a channel, at a rate of one frame per second and 10 frames at each 
position. Images were recorded with an exposure time of 100 ms using an iXon Ultra back-
illuminated EMCCD camera in conjunction with Nikon NIS-Elements imaging software. 
After imaging rhodamine-labeled microtubules alone, channels were perfused depending 
on the experiment with either recombinant human tau isoforms, recombinant human wildtype 
FUS-GFP or FUS-P525L-GFP, standard motility buffer, BSA, or the respective cell lysate. Each 
of these solutions was supplemented with 0.3 % methylcellulose, 20 mM D-glucose, 20 μg/mL 
glucose oxidase, 10 μg/mL catalase, 10 mM DTT, and 1 mM ATP to ensure optimal conditions 
for efficient kinesin-1 motility. Each channel was then sealed off with VALAP (Vaseline, lanolin, 
and paraffin in a 1:1:1 ratio) to inhibit evaporation. Flow chambers were allowed to equilibrate 
for 5 min before running the imaging workflow as described above. In channels where tau or 
FUS-GFP variants were administered, single frames were captured via excitation with 470 nm 
or 640 nm light and an exposure time of 100 ms at every position immediately before acquiring 
time laps movies of rhodamine-labelled microtubules. For the first batch of 2N4R tau-GFP, 
single frames of the first imaged positions were captured via excitation with 470 nm light and an 
exposure time of 100 ms immediately before acquiring time laps movies of rhodamine-labelled 
microtubules, while single frames of the remaining nine imaging positions were captured via 
excitation with 470 nm light after time lapse acquisition. This workflow takes into consideration 
that analyzing the colocalization of moving microtubules with potentially bound proteins was 
only possible if overlaid images were captured virtually simultaneously in both channels. In case 
of FUS-GFP variants, the buffer control experiments were performed with standard motility 
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buffer to which FUS-protein storage buffer was added in equal dilutions as required for the 
respective protein concentrations tested. When flow chambers were imaged over the course of 
three hours, channels were sealed with VALAP to prevent evaporation. 
2.2.8 Detection of protein binding to microtubules 
Microtubules were polymerized at 37 °C for 30 min from 40 μM Atto647-labeled tubulin in 
BRB80 supplemented with 4 mM MgCl2, 1 mM Mg-GTP, and 5 % DMSO in a total volume of 
6.25 μL. Polymerized microtubules were immediately stabilized with taxol by adding 10 µM taxol 
in BRB80 to a final volume of 100 μL, and further kept at RT in the dark. Microtubules were 
cleared from free tubulin by centrifugation in a table top centrifuge at 13.3 rpm for 30 min at RT, 
the supernatant was removed and the pellet resuspended in 400 μL BRB80 supplemented with 
10 μM Taxol.  
For the assay itself, flow chambers were assembled as described above, except that the 
coverslips used for this assay were silanized with dichlorodimethylsilane (DDS) in order to 
increase the hydrophobicity of the surface.  
The first solution containing α-tubulin antibodies, 1:200 diluted in BRB80, had to be 
sucked through each channel with the help of a vacuum pump due to the strong hydrophobicity 
of the glass surface, and was left to adsorb for 15 min. Next, a solution containing the 1 % of the 
non-ionic detergent F127 was flushed through the channels and again left to adsorb for at least 
one hour in order to reduce non-specific protein binding to the glass surface. Flow chambers 
containing F127 were then either used directly or kept in a sealed humidified container at 4°C 
for up to two days. Channels were washed once with BRB80 directly before use, and then 
perfused with 20 μL undiluted Atto-647-labeled microtubules for 1 min. Unbound microtubules 
were then washed out with standard motility buffer without ATP, before channels were perfused 
with recombinant 2N3R tau-GFP or 2N4R tau-mScarlet or standard motility buffer without ATP. 
Each channel was then sealed off with VALAP to inhibit evaporation. Flow channels were then 
mounted onto an Axio Observer Z1microscope equipped with a Zeiss TIRF slider and a 1.46 
PlanApochromat 63 x oil immersion objective combined with a 1.6x optovar and heated to 
30 °C. Images were acquired by TIRF using a 532 nm laser line for Atto647-labeled 
microtubules, 488 nm for eGFP-labeled proteins, or 642 nm for mScarlet- labeled tau isoforms, 
respectively, with an exposure time of 100 ms. Single images at each wavelength were 
recorded at ten different positions within one channel using an iXon Ultra back-illuminated 
EMCCD camera in conjunction with MetaMorph MicroManager imaging software. 
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2.2.9 Data analysis and statistics 
Kinesin-1-dependent microtubule gliding velocities were derived from time lapse movies using 
an automated MATLAB script based on a microtubule tip-tracking algorithm developed in-house 
(Ruhnow et al., 2011). In detail, the position of a microtubule tip was localized in each frame 
with sub-pixel resolution and compared to its position in the subsequent frame one second later, 
thereby determining the frame-to-frame velocities for this microtubule between two frames. All 
microtubule frame-to-frame velocities determined in each of the ten time lapse movies for one 
experimental condition are combined in a MATLAB cell format for further analysis. The median 
microtubule gliding velocity was determined from this data set, as well as fraction of gliding 
microtubules. The median gliding velocity of microtubules in one channel after perfusion with 
recombinant protein, BSA, cell lysate, or standard motility buffer, respectively, was then 
normalized to the median gliding velocity of microtubules in the same channel in standard 
motility buffer before perfusion. This way of analysis yields the relative speed for microtubule 
gliding in a certain experimental condition, a more robust parameter for comparison among 
experiments than the absolute microtubule gliding velocity. The fraction of non-gliding 
microtubules describes the number of microtubules gliding with a frame-to-frame velocity less 
than 20 % of the gliding velocity in standard motility buffer in that channel. 
The binding affinity of 2N3R tau-GFP and 2N4R tau-mScarlet to microtubules was 
determined by measuring the integrated intensity in the respective image channel along at least 
20 microtubules in each of the ten positions imaged using the line tool of ImageJ, and the 
fluorescence intensity along each microtubule was background corrected locally. Therefore, at 
least 200 microtubules were measured per condition and experiment to obtain the average 
fluorescence intensity for every tested concentration of tau isoforms. Intensities for each tau 
isoform were normalized in every experiment to the respective highest concentration tested in 
order to determine the fraction of bound tau protein to microtubules. The fraction of bound tau 
was plotted against the concentration of tau protein in solution and fit with the Hill model using 
OriginLab 2019. 
Significance was determined using either one-way or two-way ANOVA and Tukey’s 
multiple comparison post-hoc test (see supplementary tables). Kymographs were created using 
the Kymograph plugin for ImageJ created by J. Rietdorf (FMI Basel) and A. Seitz (EMBL 
Heidelberg), while overlay images were generated using MetaMorph. 
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2.2.10 Western blot analysis 
SDS-PAGE gel electrophoresis and blotting 
Probes for Western blot analysis were mixed with NuPage loading buffer in a 3:4 ratio, heated 
to 95 °C for 5 min to denature all proteins and put on ice immediately after. 12 µL of this mixture 
were loaded on a 4-12 % Bis-Tris SDS-PAGE gel, as well as at least one lane with 5 µL of a 1:5 
mixture of two markers, one visible by eye (SeeBlue) and one visible during detection 
(MagicMarker). The gel was assembled into an electrophoresis running chamber filled with 
1 x MOPS buffer and electrophoresis run for at least one hour with the following parameters: 
140 V, 85W, and 60 mA for one and 140 mA for two gels simultaneously. Following 
electrophoresis, gels were kept in transfer buffer supplemented with 0.1 % SDS for 8 min to 
increase protein release from the gel during blotting. In contrast, the PVDF membrane used to 
blot on and the thick filter paper within the iBlot transfer stack were soaked in transfer buffer 
containing 6.7 % methanol prior to blotting in order to activate the membrane and increase 
retention of proteins on the membrane. iBlot transfer stacks were assembled according to the 
manufacturer’s instructions in the iBlot transfer system and blotted for 7 min with 19 V. After 
blotting, membranes were transferred into 50 mL falcons and blocked for one hour at RT with 
PBST containing 5 % milk powder. Membranes were then incubated with primary antibodies 
over night at 4 °C and washed twice with PBST. After incubation with horseradish peroxidase 
(HRP)-coupled secondary antibodies for one hour at RT, membranes were washed again with 
PBST five times before detection. 
As a means to accurately determine whether the expression level of a protein of interest 
differs between two samples, the detected intensity for bands for this protein of interest should 
be normalized to the intensity of a band for a housekeeping protein within the same sample. In 
order to not mask any bands of the protein of interest, membranes were incubated with 
antibodies to detect the protein of interest, as described above, imaged, and subsequently 
stripped. Membranes were stripped at RT by incubating them in fresh stripping buffer twice for 
10 min each, two subsequent washing steps with PBS for 10 min each, and two final washing 
steps with PBST for 5 min each. After this procedure membranes were again blocked and 
incubated with respective primary and secondary antibodies for the detection of the 
housekeeping protein GAPDH. 
Detection, imaging and quantification of protein bands 
Chemiluminescent detection was achieved by applying either Amersham ECL Prime or 
SuperSignalTM West Femto substrate according to the manufacturer’s instructions, depending 
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on the strength of the signal as the latter is more sensitive. Imaging was immediately performed 
after substrate application on an LAS3000 imager with continuous exposure and image 
acquisition every 10 sec. The integrated intensity of protein bands was determined using Image 
StudioTM Lite as follows: a rectangular area was created around the largest band and all other 
bands subsequently selected with the same rectangular area. The background was computed 
as the median pixel intensity within a three pixel area bordering the top and bottom of each 
rectangular area around the corresponding band. The background value was hence calculated 
for every band individually and locally and subtracted from the total intensity in the respective 
rectangular area. To determine the concentration of FUS variants and tau isoforms in whole cell 
lysates, recombinant FUS-WT-GFP, 2N3R tau-GFP or 2N4R tau-mScarlet of known 
concentrations were loaded on SDS-PAGE gels in combination with whole cell lysates. A 
standard curve was created in Microsoft Excel 2010, and the protein concentration in whole cell 
lysates was calculated from a linear regression line. 
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3. Results 
3.1 Modification of a kinesin-1-dependent microtubule gliding assay for the 
application of whole cell lysates 
Defects in axonal transport have long been recognized as part of the pathology in FUS-ALS, but 
only little is known about the causes and mechanisms involved in its development (De Vos and 
Hafezparast, 2017a). This thesis aimed at investigating possible direct engagement of FUS 
variants with the transport machinery, as well as the importance of an altered tau isoform ratio 
caused by FUS variants. For this purpose, a previously established kinesin-1-dependent 
microtubule gliding assay was modified to run reliably in the presence whole cell lysates, so that 
the kinesin-1 motility can be monitored in a minimal system. In this assay, stabilized and 
fluorescently labelled microtubules are propelled by a layer of underlying, surface bound 
kinesin-1 motor proteins (Figure 7A). The collective motility of kinesins, however, depends on a 
variety of external factors such as temperature, ionic strength, the presence of microtubule or 
motor interacting proteins, or whole cell lysates. To study the impact of FUS variants or different 
ratios of tau on this machinery, recombinant FUS-GFP and tau-GFP protein or whole cell 
lysates of isogenic iPSC-derived spinal motor neurons with either wildtype FUS-GFP or 
FUS-P525L-GFP are added to the assay (Figure 7B). 
 
Figure 7: Reconstituting axonal transport in vitro. 
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A) ALS-patient-derived and isogenic control iPSC lines were differentiated towards spinal motor neurons. On day 21 
of maturation, cells were mechanically lysed and centrifuged to obtain the soluble fraction of cell lysates, further 
referred to as whole cell lysates. B) Depending on the experiment, whole cell lysates or recombinant human protein 
(FUS-GFP or tau-GFP) were applied to a kinesin-1-dependent microtubule gliding assay in manually assembled flow 
chambers (see materials and methods for details). 
 
To achieve efficient cell lysis and a high protein yield in the lysates, different lysis methods 
have been tested (Table 9). Chemical lysis using the Active Motif Nuclear Extract Kit and a 
variety of mechanical lysis protocols were assessed for their efficiency in terms of protein yield. 
PBS was used in herein assessed mechanical lysis protocols as a preliminary lysis buffer, since 
microtubule gliding velocity was as efficient in the presence of this physiological buffer as in the 
presence of the most commonly used BRB80 buffer (Figure 8B) (Nitzsche et al., 2010). In 
addition, two methods for determining the total protein concentration were evaluated for their 
accuracy using lysates produced by chemical lysis, one based on the detection of 
BCA/copper-complexes and one modified Bradford assay based on the direct binding of 
Coomassie blue to proteins (Table 9B). In general, higher quantities of total protein were 
detected using the BCA detection kit than with the Bradford detection. Importantly, the average 
relative error for measurements performed with the Bradford assay was much larger 
(0.078 ± 0.035) than for those performed with the BCA assay (0.013 ± 0.005), and hence total 
protein levels in all mechanically prepared lysates were only quantified using the latter.  
Previously established and widely used methods for mechanical lysis, such as glass bead 
shearing, dounce homogenization, and liquid nitrogen grinding (Mackall et al., 1979; Harlow and 
Lane, 2006; Walker, 2009), resulted in low protein yields as determined by BCA or did not 
results in sufficient cell lysis, since the detected amount of the housekeeping protein β-actin was 
very low as determined by western blot (Table 9A). A high yield, together with sufficient 
detection of the housekeeping protein and hence cell lysis, was accomplished by shearing the 
cells via passage through a syringe needle with a diameter of 400 µm or by dounce 
homogenization. Although dounce homogenization yielded similar or even higher protein 
concentrations, a lot of lysate stuck to the walls of the glass tube, so that overall lower volumes 
of lysate were collected. This was not the case for mechanical lysis using a syringe and needle, 
since all lysate could be dispensed with the plunger.  
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Table 9: Comparison of different protein isolation techniques for their cell lysis efficiency, determined by the 
detection of β-actin via western blot, and protein yield, determined by BCA or Bradford assay. 
Representative images and values of single measurements. rel. err. = average relative error of the six depicted 




The highest protein yields in combination with sufficient protein lysis were obtained using 
the chemical lysis kit (Table 9). However, microtubules frequently detached in the presence of 
chemical lysis buffer, even after 10-fold dilution (Figure 8A). To circumvent this problem, the 
buffer was exchanged by passing lysates through a PD MinitrapTM desalting and buffer 
exchange column and eluting protein in PBS through gravity flow. This procedure resulted in a 
severe loss of protein (Table 9B) due to the combination of protein being stuck to the column 
surface and a high dilution of the lysate. In addition, a control experiment, where only chemical 
lysis buffer was passed through the column and one elution step performed with PBS, did not 
eliminate microtubule detachment entirely (Figure 8A), indicating that buffer exchange was not 
sufficient to remove all substances interfering with microtubule-motor interaction. Similarly, while 
buffer exchange lysate concentration using Vivaspin® sample concentrators resulted in very 
high protein yield (Table 9A), the buffer could not be sufficiently exchanged using these columns 
to prevent microtubule detachment (Figure 8A). 
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Therefore, whole cell lysates used in the herein presented study were prepared by 
shearing cells in PBS via passage through a syringe needle, as this presented the most efficient 
mechanical lysis method. Lysates were supplemented with a commercially available protease 
inhibitor cocktail to prevent protein degradation. Using a commercially available phosphatase 
inhibitor cocktail, however, immediately led to diminished microtubule gliding (Figure 8C). 
Therefore, β-glycerophosphate was added to the lysate to steer phosphatase activity towards 
the excess substrate. In addition, 10 % glycerol was added as a cryoprotectant. Glycerol by 
itself did not alter microtubule gliding characteristics, but the addition of 
10 mM β-glycerophosphate caused microtubules to detach from surface-bound motors (Figure 
8D). To prevent this, 0.3 % methylcellulose was added to the assay to allow cross-comparison 
as well to experiments involving recombinant proteins. The addition of methylcellulose did not 
affect microtubule gliding, but effectively eliminated microtubule detachment (Figure 8D). 
Methylcellulose due to its high viscosity acts as a cushion to keep microtubules close to the 
imaging surface. Since microtubules sporadically detach from the surface-bound motors, 
methylcellulose facilitates fast microtubule reattachment to motors (Inoue et al., 2015; Saito et 
al., 2017). Cells were hence lysed in the presence of PBS and lysates supplemented with a 
commercially available protease inhibitor, 10 % glycerol, 10 mM β-glycerophosphate, and 
0.3 % methylcellulose (further referred to as lysis buffer). Similarly, standard motility buffer used 
in subsequent microtubule gliding assays was prepared by addition of 10 µM taxol, 1 mM ATP, 
20 mM D-glucose, 20 μg/mL glucose oxidase, 10 μg/mL catalase, 10 mM DTT, and 
0.2 mg/mL casein to the lysis buffer. 
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Figure 8: Optimal buffer conditions for reproducible kinesin-1-dependent microtubule gliding in the presence 
of whole cell lysates consist of 10 % glycerol, 10 nM β-glycerophosphate and 0.3 % methylcellulose in PBS. 
Top of each panel: rhodamine-labelled microtubules gliding on surface-immobilized kinesin-1 in the presence of 
(A) whole cell lysis buffer obtained from a Nuclear Extraction Kit for whole cell lysates (Active Motif) undiluted or at a 
10-fold dilution, (B) PBS or BRB80 alone, (C) PBS supplemented with a commercially available phosphatase 
inhibitor, (D) PBS supplemented with 10 % glycerol, an additional 10 mM β-glycerophosphate, or moreover with 
0.3 % methylcellulose. Yellow arrows indicate detaching microtubules. Scale bar = 10 µm. Bottom of each panel: 
kymographs showing representative kinesin-1-dependt microtubule movement in the respective conditions. 
Horizontal scale bar = 2 µm, vertical = 5 s. E) Kinesin-1-dependent microtubule gliding velocities of six technical 
replicates in standard motility buffer. Relative velocities were calculated by dividing the microtubule gliding velocity 
after flushing with standard motility buffer by the microtubule velocity in the same channel before flushing. 
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Having optimized the buffer conditions, microtubule gliding assays were set up using 
manually assembled flow chambers with six individual flow channels separated and tightly 
sealed by stripes of parafilm in between two differently sized glass coverslips (Figure 6). Flow 
channels were first perfused with a casein-containing solution to prevent unspecific protein 
adsorption. This was followed by perfusion with a solution containing full-length constitutively-
active Drosophila melanogaster kinesin-1 motors. Both solutions were allowed to settle within 
the channels at RT for 5 min each, before rhodamine-labelled microtubules in standard motility 
buffer were flushed through the channels. Because the microtubule gliding velocity is highly 
sensitive to temperature changes (Böhm et al., 2000), flow chambers were mounted onto a 
custom-built Peltier element to minimize temperature fluctuations during an experiment and 
between single technical replicates. Flow chambers were imaged using 
widefield-epifluorescence microscopy with 10 s time lapse movies (Figure 9A, B) with an 
exposure time of 100 ms and at an acquisition rate of one frame per second. From these time 
lapses, frame-to-frame velocities of gliding microtubules were calculated using a previously 
developed automated filament tracking algorithm (FIESTA, Ruhnow et al., 2011). The median 
microtubule gliding velocity, as well as the 25th and 75th percentile (Figure 9C), were calculated 
for microtubules in a given condition (i.e. presence of standard motility buffer, recombinant 
protein, or whole cell lysates). Normalizing the median velocity to the initial median velocity (i.e. 
before addition of recombinant FUS-GFP variants, recombinant tau isoforms, BSA, or standard 
motility buffer) of microtubule in the same channel allows for cross-comparison of different 
conditions and takes account of small experiment-to-experiment differences in e.g. the motor 
density or motor activity. This normalization procedure further reduces the error arising from 
possible fluctuations in microtubule number between experiments or technical replicates. With 
this multitude of optimization steps, a robust assay to model axonal transport in vitro could be 
established that generated highly reproducible measurements (Figure 9D). 
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Figure 9: Imaging and analysis of kinesin-1-dependent microtubule gliding velocity . 
A) Top panels: microtubule imaging was performed using widefield-epifluorescence microscopy to acquire time 
lapses of 10 s with an exposure time of 100 ms and an acquisition rate of one frame per second. Scale bar = 5 µm. 
Bottom panel: a kymograph representing the kinesin-1-dependent movement of the above microtubule. Horizontal 
scale bar = 2 µm, vertical = 5 s. B) An overlay image illustrating the kinesin-1-dependent microtubule gliding in the 
presence of cell lysate containing wildtype FUS-GFP. Positions of microtubules at time points t = 0 s (cyan) and 
t = 10 s (magenta) are overlaid. White color in the overlay indicates positional overlap at both time points, and hence 
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no microtubule movement. Scale bar = 10 µm. C) A previously developed automated MATLAB script was used to 
calculate frame-to-frame velocities from 10 s time lapse movies. Frame-to-frame velocities of all time lapse movies in 
a given condition (e.g. cell lysate containing wildtype FUS-GFP) of one technical replicate were combined in a single 




 percentile, respectively. 
D) Flow channels containing gliding rhodamine-labelled microtubules in standard motility buffer were flushed with 
buffer to rule out that the process of flushing solutions through a channel changes microtubule gliding velocity. 
Relative speed of gliding microtubules was calculated by dividing the microtubule gliding velocity after flushing with 
standard motility buffer by the velocity of microtubules in the same flow channel before flushing. Six technical 
replicates are shown. 
 
3.2 Determination of assay sensitivity with the microtubule-associated 
protein tau 
In order to estimate the sensitivity of this modified kinesin-1-dependent microtubule gliding 
motility assay for proteins interfering with motor motility on microtubules, human recombinant 
full length (2N4R) tau-GFP was added to the assay at varying concentrations (Figure 10A). Tau 
is a MAP known to inhibit kinesin-1 stepping on microtubules by a simple road-block mechanism 
(Tarhan et al., 2013), thereby significantly reducing kinesin-1 run-length and velocity (Hoeprich 
et al., 2014). To see whether tau shows the same behavior in our modified microtubule gliding 
assay, recombinant 2N4R tau-GFP was added at final concentrations of 2 to 500 nM in 
standard motility buffer, and the gliding velocity as well as microtubule binding were assessed 
by widefield-epifluorescence microscopy. No significant binding of 2N4R tau-GFP to 
microtubules was evident at low tau concentrations, while binding was observed at a 
concentration of 50 nM and above (Figure 10B). The strong background signal of unbound tau-
GFP, however, prevented quantification of the exact amount of microtubule-bound tau, and 
therefore binding was assessed only qualitatively. 
In line with the observed microtubule-binding behavior of tau, kinesin-1-dependent 
microtubule gliding velocity was not altered below a tau-GFP concentration of 24 nM, but 
microtubules considerably slowed down in the presence of 59 nM 2N4R tau-GFP and 
completely ceased movement at concentrations above 118 nM (Figure 10C). Hence, the 
modified kinesin-1-dependent microtubule gliding assay is sensitive enough to detect the 
presence of 60 nM 2N4R tau-GFP, which is equivalent to 2.65 µg/ml. 
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Figure 10: Tau-GFP binds to microtubules and inhibits kinesin-1-dependent microtubule gliding in a 
concentration dependent manner. 
A) Full-length 2N4R recombinant human tau-GFP was introduced to a kinesin-1-dependent microtubule gliding assay 
in standard motility buffer. B) Binding of 2N4R tau-GFP (right panels) at indicated concentrations to rhodamine-
labelled microtubules (left panels). Scale bar = 5 µm. C) Kinesin-1-dependent microtubule gliding velocities in the 
presence of 2N4R tau-GFP at indicated concentrations. Relative speed was calculated by dividing the median 
microtubule gliding velocities after tau-GFP addition by the median gliding velocity of microtubules in the same 
channel in standard motility buffer before tau-GFP addition. Averages of three independent experiments ± standard 
deviation are shown. 
 
3.3 Investigation of a direct interference of recombinant FUS-GFP with 
kinesin-1 motility and microtubule gliding 
Having established and verified the sensitivity of the herein modified kinesin-1-dependent 
microtubule gliding assay for motor-microtubule interfering proteins, it was utilized to address 
the fundamental question whether FUS variants directly interfere with the kinesin-1-mediated 
transport machinery by e.g. binding to microtubules or inhibiting kinesin-1 motility (Figure 11A). 
For this purpose, three increasing concentrations (5 nM, 500 nM, and 5000 nM) of recombinant 
human wildtype FUS-GFP or FUS-P525L-GFP were added to the modified microtubule gliding 
assay, and microtubule gliding as well as FUS-GFP binding to microtubules was again observed 
using widefield-epifluorescence microscopy. Of note, the buffer control in these experiments 
consisted of standard motility buffer supplemented with FUS-GFP protein storage buffer in 
dilutions equal to those required to obtain the tested FUS-GFP concentrations, in order to 
evaluate whether the storage buffer itself influences kinesin-1-dependent microtubule gliding. 
Further, to observe whether kinesin-1 motility on microtubules is impaired in a crowded 
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environment due to the presence of high protein concentrations, as has previously been 
reported (Sozański et al., 2015; VanDelinder et al., 2020), equimolar amounts of BSA were 
tested in the kinesin-1-dependent microtubule gliding assay as an additional control.  
Neither FUS-GFP variant showed any specific microtubule binding (Figure 11B). In line 
with this, kinesin-1-dependent microtubule gliding was also not significantly affected by the 
addition of either FUS-GFP variant in comparison to experiments with equal concentrations of 
BSA as a protein crowding control or to a buffer control (Figure 11C, Table S 1). Since no 
inhibitory effects were found, it can be concluded that neither wildtype FUS-GFP nor 
FUS-P525L-GFP directly binds to microtubules nor inhibits kinesin-1 transport motility over a 
wide range of concentrations. 
 
Figure 11: Recombinant FUS-GFP variants to not inhibit kinesin-1-dependent microtubule gliding. 
A) Recombinant human FUS-GFP variants were introduced to a kinesin-1-dependent microtubule gliding assay in 
standard motility buffer. B) Binding of wildtype FUS-GFP or FUS-P525L-GFP (right panels) at indicated 
concentrations to rhodamine-labelled microtubules (left panels). Scale bar = 5 µm. C) Kinesin-1-dependent 
microtubule gliding velocities in the presence of wildtype FUS-GFP, FUS-P525L-GFP, or BSA in standard motility 
buffer at indicated concentrations. Relative speed was calculated by dividing the median microtubule gliding velocities 
after FUS-GFP or BSA addition by the median gliding velocity of microtubules in the same channel in standard 
motility buffer before FUS or BSA addition, respectively. Averages of three independent experiments ± standard 
deviation are shown. 
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This study focused on the interference of free-in-solution, non-aggregated FUS variants 
with kinesin-1 motility on microtubules. In vivo, cytoplasmic mislocalized mutant FUS variants 
form aggregates (Patel et al., 2015) over the course of hours, developing from liquid 
compartments in the cytoplasm that undergo a liquid-to-solid phase transition (Mateju et al., 
2017; Nötzel et al., 2018). These aggregation events can be reproduced to some extent in vitro, 
where they occur at a time scale of seconds in buffer with high ionic strength (Marrone et al., 
2019). Buffers used in the present study were of low to moderate ionic strength, and hence 
FUS-GFP aggregate formation was, as expected, not observed directly after the addition of 
FUS-GFP variants to the kinesin-1-dependent microtubule gliding assay (Figure 11B). However, 
it cannot be excluded that – similar to the in vivo situation – FUS-GFP variants aggregate over 
time and may further only in this state exhibit direct inhibitory effects on kinesin-1 motility. 
Therefore, kinesin-1-dependent microtubule gliding assays were repeated as above, but the 
microtubule binding and gliding velocity in the presence of wildtype FUS-GFP or 
FUS-P525L-GFP was now observed over the course of three hours. Although the microtubule 
gliding velocities in the presence of either FUS-GFP variant declined linearly over time, this 
effect can be attributed to assay ageing since all control experiments (i.e. presence of standard 
motility buffer or BSA at equivalent concentrations) showed the same age-dependent decline in 
microtubule gliding velocity (Figure 12A, Table S 1). This is again in line with the finding that 
neither FUS-GFP variant bound to microtubules over the course of three hours, and neither 
could aggregate formation be observed in the presence of those FUS-GFP variants during the 
same time course (Figure 12B). From both experiments can hence be concluded that neither 
wildtype FUS-GFP nor the FUS-P525L-GFP variant in its non-aggregated form interferes with 
kinesin-1 motility on or binds to microtubules, even over the course of hours. 
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Figure 12: FUS-GFP variants do not inhibit kinesin-1-dependent microtubule gliding velocity and do not 
aggregate over the course of three hours. 
A) Kinesin-1-dependent microtubule gliding velocities over the course of three hours in the presence of indicated 
concentrations of wildtype FUS-GFP, FUS-P525L-GFP, protein control (BSA), or standard motility buffer. Relative 
speed was calculated by dividing the median microtubule gliding velocities after FUS-GFP addition by the median 
gliding velocity of microtubules in the same channel in standard motility buffer before FUS-GFP addition. Averages of 
three independent experiments ± standard deviation are shown. B) Recombinant human wildtype FUS-GFP and 
FUS-P525L-GFP in standard motility buffer at indicated concentrations and time points. Scale bar = 10 µm. 
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3.4 Kinesin-1-dependent microtubule gliding and assay sensitivity in the 
presence of whole cell lysates expressing GFP-labelled FUS variants 
FUS-GFP variants did not directly interfere with kinesin-1-dependent microtubule gliding (e.g. by 
binding to microtubules or motors). However, kinesin-1 often requires a multitude of adaptor 
proteins in order to efficiently bind its cargo (Hirokawa et al., 2009; Fu and Holzbaur, 2014). 
Using whole cell lysates from spinal motor neurons expressing GFP-labelled FUS variants in the 
modified kinesin-1-dependent microtubule gliding assay, we aimed to investigate whether FUS 
requires endogenous adaptors or whether there are indirect effects (e.g. changes in expression 
levels of other motor or microtubule effector proteins (Fujioka et al., 2013; Akiyama et al., 2019) 
or sequestering of MAPs etc. in aggregates (Yasuda et al., 2017) that may impact the 
kinesin-1-dependent transport on microtubules. Therefore, previously generated and 
characterized ALS-patient-derived and CRISPR/Cas9-engineered isogenic iPSCs (Naumann et 
al., 2018; Pal et al., 2018) were differentiated via NPCs to form spinal motor neurons expressing 
either wildtype FUS-GFP or FUS-P525L-GFP. Whole cell lysates were obtained after 21 days of 
neuron maturation by mechanical lysis through a thin needle. Lysates were cleared by 
centrifugation in order to obtain only soluble parts within the lysate, especially free floating, 
cytoplasmic FUS. For application of whole cell lysates in the kinesin-1-dependent microtubule 
gliding assay (Figure 13A), the total protein concentration in the lysates was determined using 
the BCA assay, and lysates were diluted in cell lysis buffer to a final concentration of 
50, 80, 110, and 140 ng/µL. Due to low yields after protein isolation, higher concentrations could 
not be tested. Imaging and analysis was performed as described above, with respective 
concentrations of BSA in standard motility buffer again serving as a protein crowding control. 
However, neither lysates from wildtype FUS-GFP nor FUS-P5525L-GFP expressing cells had 
any significant effect on microtubule gliding compared to controls (Figure 13B, Table S 3). 
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Figure 13: Cell lysates of spinal motor neurons expressing ALS-associated or wildtype FUS variants do not 
interfere with microtubule gliding on kinesin-1 motors. 
A) Lysates of cells expressing wildtype FUS-GFP or FUS-P525L-GFP were applied to the modified 
kinesin-1-dependent microtubule gliding assay. B) Kinesin-1-dependent microtubule gliding velocities in the presence 
of cell lysates in which wildtype FUS-GFP and FUS-P525L-GFP was expressed, respectively, or BSA in standard 
motility buffer at indicated concentrations. Relative speed was calculated by dividing the median microtubule gliding 
velocities after lysate or BSA addition by the median gliding velocity of microtubules in the same channel in standard 
motility buffer before lysate or BSA addition, respectively. Averages of four independent experiments ± standard 
deviation are shown, with n = 4. C) Kinesin-1-dependent microtubule gliding velocities in the presence of cell lysates 
in which wildtype FUS-GFP and FUS-P525L-GFP was expressed, respectively, or BSA in standard motility buffer at a 
concentration of 80 ng/µL supplemented with indicated concentrations of recombinant human 2N4R tau-GFP. In 
addition, titration of 2N4R tau-GFP from Figure 10C is included for comparison. Relative speed was calculated by 
dividing the median microtubule gliding velocities after lysate, BSA, or tau-GFP addition by the median gliding velocity 
of microtubules in the same channel in standard motility buffer before lysate, BSA, or tau-GFP addition, respectively. 
Averages of three independent experiments ± standard deviation are shown. 
 
In order to estimate the amount of FUS-GFP variants present within cell lysates and 
compare it to the concentrations of recombinant FUS-GFP variants tested above, a western blot 
was performed with four biological replicates of cell lysates expressing wildtype FUS-GFP or 
FUS-P525L-GFP, respectively (Figure 14). The level of endogenous wildtype FUS-GFP and 
FUS-P525L-GFP protein within the herein used cell lysates was much lower (between 2.5 and 
5 nM) than the amount of recombinant human FUS-GFP variants used in the above described 
experiments. Therefore, it is unlikely that potential direct interactions of FUS-GFP variants in cell 
lysates with kinesin-1 or microtubules were missed due to the low concentration of endogenous 
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protein, as recombinant FUS-GFP variants were supplied at a wide range of much higher 
concentrations (5-5000 nM) and did not interfere with kinesin-1-dependent microtubule gliding. 
 
Figure 14: Western blot of FUS-GFP variants expressed in whole cell lysates of spinal motor neurons. 
Representative western blot of recombinant wildtype FUS-GFP at indicated concentrations and four biological 
replicates (n) of whole cell lysates obtained from spinal motor neurons expressing either wildtype FUS-GFP or 
FUS-P525L-GFP. 
 
Due to the protein-rich environment in cell lysates, however, the sensitivity of the 
kinesin-1-dependent microtubule gliding assay might be reduced. Hence, to test assay 
sensitivity, recombinant human 2N4R tau-GFP was titrated at low amounts (2 – 237 nM) into the 
lysates (which were diluted to a total protein concentration of 80 ng/µL). Assay performance was 
re-evaluated to see if a slowdown of microtubule gliding velocity could still be detected below a 
concentration of 118 nM tau-GFP in the presence of whole cell lysates. In contrast to 
experiments with tau-GFP alone, kinesin-1-dependent relative microtubule gliding velocity 
started to decrease already in the presence of 12 nM 2N4R tau-GFP in lysates, but also 
completely ceased at a concentration of 118 nM substituted tau-GFP (Figure 13C), similar to 
what was observed in the absence of cell lysates. This behavior was also independent of the 
FUS variant expressed within the lysate. This implies that, even in a protein-rich environment 
such as in the presence of whole cell lysates, the assay is still sufficiently sensitive to inhibitors 
of kinesin-1 motility. Further, it can be concluded that neither lysates carrying wildtype FUS-GFP 
nor those containing ALS-associated FUS-P525L-GFP negatively affect kinesin-1 motility. 
 
3.5 Arrest in gliding of single microtubules caused by Tau-GFP compared 
to aging of the assay 
Since aging of the assay over the course of three hours and the presence of 2N4R tau-GFP 
both reduced the relative microtubule gliding velocity to a similar extent (Figure 10 and Figure 
12), the mode of action by which this slowdown occurred was further investigated. In the 
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presence of standard motility buffer, microtubules of one technical replicate glide with 
frame-to-frame velocities around 600 nm/s, while microtubule gliding was entirely arrested in the 
presence of 118 nM 2N4R tau-GFP (Figure 15A). When 24 nM 2N4R tau-GFP are 
supplemented to the assay, microtubules display two heterogeneously moving populations, one 
non-gliding fraction indicated by a peak in frame-to-frame velocities around zero, and one 
fraction of microtubules that are gliding with frame-to-frame velocities broadly distributed 
between 200 and 800 nm/s, resulting in a median frame-to-frame velocity of about 250 nm/s 
(Figure 15A). A similar median frame-to-frame velocity of about 300 nm/s could be observed in 
the presence of 5000 nM recombinant FUS-P525L-GFP two hours after protein administration, 
although the peak of frame-to-frame velocities around zero was much smaller. Rather, most 
microtubule frame-to-frame velocities lay between 100 and less than 600 nm/s (Figure 15A). 
This indicates that microtubules collectively glide at a reduced frame-to-frame velocity when the 
assay is aging, possibly due to subsiding motility of the underlying kinesin-1 motors, while the 
presence of small amounts of tau-GFP causes an arrest in gliding of individual microtubules 
while others are still propelled at about similar speed as in standard motility buffer. In order to 
investigate this hypothesis further, the fraction of non-gliding microtubules in the presence of 
2N4R tau-GFP, FUS-GFP variants, cell lysate or BSA, respectively, was calculated as the 
number of microtubules gliding at a velocity less than 20 % of the median microtubule velocity in 
standard motility buffer, and normalized to the total number of microtubules in one time-lapse 
movie (Figure 15B-F). In the presence of standard motility buffer, the fraction of non-gliding 
microtubules consistently appears around 0.1. Corresponding to a decrease in relative 
microtubule gliding velocity upon 2N4R tau-GFP addition (Figure 10C), the fraction of 
non-gliding microtubules begins to increase in the presence of 24 nM 2N4R tau-GFP and 
continues to grow with increasing tau-GFP concentration until virtually all microtubules have 
stopped gliding above 118 nM tau-GFP (Figure 15B). In contrast, the fraction of non-gliding 
microtubules remained around 0.1 in the presence of either FUS-GFP variant at a concentration 
of 5, 500, or 5000 nM, or equal concentrations of BSA (Figure 15C). Even over the course of 
three hours, the fraction of non-gliding microtubules under these conditions only slightly 
increased to a maximum of 0.20 ± 0.04 (i.e. for 5000 nM wildtype FUS-GFP after three hours, 
Figure 15D). Similarly, the presence of cell lysates where either wildtype FUS-GFP or 
FUS-P525L-GFP was expressed resulted in a low fraction of non-gliding microtubules around 
0.1, independent of the total protein concentration (Figure 15E). When varying concentrations of 
2N4R tau-GFP were added to either cell lysates, however, the fraction of non-gliding 
microtubules started to increase already at a concentration of 12 nM supplemented tau-GFP, 
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and again continuously rose until virtually all microtubules have stopped gliding at a 
concentration of 118 nM 2N4R tau-GFP or above (Figure 15F). 
 
Figure 15: 2N4R Tau-GFP binding to microtubules causes an arrest of microtubule gliding. 
A) Representative frame-to-frame velocities of one technical replicate of microtubules gliding in the presence of 
standard motility buffer, 2N4R tau-GFP, or FUS-P525L-GFP at the indicated concentrations and time points. Red 
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 percentile, respectively. B-F) The fraction 
of non-gliding microtubules describes the number of microtubules in one technical replicate gliding with a 
frame-to-frame velocity less than 20 % of the gliding velocity in standard motility buffer, normalized to the total 
number of microtubules in one time lapse movie, before the addition of B) 2N4R tau-GFP at the indicated 
concentrations, C) recombinant human wildtype FUS-GFP, FUS-P525L-GFP, or BSA, at the indicated 
concentrations, D) standard motility buffer, recombinant human wildtype FUS-GFP, FUS-P525L-GFP, or BSA at the 
indicated concentrations over the course of three hours, E) cell lysates expressing wildtype FUS-GFP or the 
FUS-P525L-GFP variant, or BSA, at the indicated concentrations, and F) cell lysates expressing wildtype FUS-GFP 
or the FUS-P525L-GFP variant, or BSA at a concentration of 80 ng/µL supplemented with 2N4R tau-GFP at the 
indicated concentrations. 
 
Of note, while the relative microtubule gliding velocity in the presence of recombinant 
wildtype FUS-GFP decreases over the course of three hours down to 0.65 ± 0.14 (Figure 12A), 
the fraction of non-gliding microtubules in this condition only increases up to 0.20 ± 0.04 within 
the same time frame (Figure 15D). In contrast, the relative microtubule gliding velocity in the 
presence of 35 nM and 59 nM 2N4R tau-GFP decreases from 0.80 ± 0.27 to 0.25 ± 0.35, 
respectively (Figure 10C), accompanied by a drastic increase in the fraction of non-gliding 
microtubules from 0.26 ± 0.14 to 0.72 ± 0.10, accordingly (Figure 15B). Interestingly, the relative 
microtubule gliding velocity tends to decrease stronger when cell lysates supplemented with 
2N4R tau-GFP are administered to gliding microtubules compared to equal concentrations of 
tau-GFP alone (Figure 13C), while the fraction of non-gliding microtubules correspondingly also 
tends to increase at lower concentrations of tau-GFP supplemented to cell lysates (Figure 15F). 
Together, these findings suggest that 2N4R tau-GFP causes an arrest in the gliding of individual 
microtubules, while others seem to be propelled with almost equal velocities as in standard 
motility buffer. Although tau-decoration on microtubules often corresponded to arrest of 
microtubule gliding, some tau-decorated microtubules were still propelled by underlying 
kinesin-1 motors in the presence of low amounts of tau-GFP, e.g. 35 nM (Figure 16), indicating 
that microtubule gliding is only reduced when a threshold amount of tau binds to microtubules 
and further declines the more tau attaches to the filament. 
 
Figure 16: 2N4R Tau-GFP binding to microtubules at low concentrations leads to an arrest in gliding of 
individual microtubules, while others are still motile. 
A) Binding of2N4R tau-GFP at a concentration of 35 nM to rhodamine-labelled microtubule. Scale bar = 5 µm. B) Top 
panels: rhodamine-labelled microtubules gliding (1) or non-gliding (2) in the presence of 35 nM 2N4R tau-GFP. Scale 
bar = 5 µm. Bottom panels: kymographs representing the kinesin-1-dependent movement of the above gliding (1) or 
non-gliding (2) microtubule. Horizontal scale bar = 2 µm, vertical = 5 s. 
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3.6 Differential effects of 2N3R and 2N4R tau individually on 
kinesin-1-dependent microtubule gliding velocity and microtubule binding 
While this work shows that FUS variants have no direct effect on kinesin-1-dependent transport, 
they might indirectly disturb axonal transport by changing the equilibrium of tau isoforms in the 
axon due to nuclear loss-of-function of FUS-P525L (Fujioka et al., 2013; Ishigaki et al., 2017). 
Under physiological conditions, FUS directly binds to tau pre-mRNA in the nucleus and, 
together with the splicing factor SFPQ, regulates its alternative splicing by skipping exon 10, 
resulting in 3R tau isoforms (Orozco et al., 2012; Ishigaki et al., 2017; Ishigaki and Sobue, 
2018). This is in line with the observation that upon FUS mislocalization to the cytoplasm, exon 
10 is more frequently incorporated into the mature tau-mRNA, which results in an increased 
translation of 4R tau isoforms. The increase in 4R:3R isoform ratio has previously been 
indicated to cause a variety of pathological changes within the cell, such as slightly shorter 
axons and highly enlarged growth cones with less bundled and further spread microtubules 
(Orozco et al., 2012). This toxic effect on neurite outgrowth could be rescued by silencing 4R 
tau (Ishigaki et al., 2017). This indicates how detrimental a shift in 4R:3R tau isoform ratio can 
be for the physiological function of the cell. However, it is not known to date if and to what 
extend the shift in 4R:3R tau isoform ratio, caused by the cytoplasmic mislocalization of FUS-
P525L, contributes to the axonal transport defects observed in ALS pathology.  
This study therefore aimed at investigating the direct effect of 2N4R and 2N3R tau 
isoforms, alone or in combination, on the kinesin-1-dependent microtubule gliding. For this 
purpose, recombinant human 2N3R tau-GFP and 2N4R tau-mScarlet labelled isoforms were 
expressed in and purified from insect cells (see 2.2.7). Each tau variant was at first added 
individually to the modified kinesin-1-dependent microtubule gliding assay at increasing 
concentrations (Figure 17A and B), and microtubule gliding again observed using widefield-
epifluorescence microscopy. BSA was again used as a protein crowding control at the highest 
concentration of tau variants tested (5.25 µM). While the relative microtubule gliding velocity 
goes down with increasing concentrations of either isoform (Figure 17C) compared to the 
microtubule gliding in standard motility buffer or BSA, the 4R tau-mScarlet isoform causes a 
slowdown of microtubule gliding already at much lower concentrations (starting at 0.05 µM tau) 
compared to the 3R tau-GFP isoform. At 0.8 µM 4R tau-mScarlet, the relative microtubule 
gliding speed has decreased to 0.31 ± 0.08, while the 3R tau-GFP isoforms causes a similar 
drop of relative microtubule gliding speed only at a more than 5-fold higher concentration 
(5.25 µM). 
Mechanisms of Axonal Transport in ALS  Results 
Anne Seifert  65 / 157   
 
Figure 17: The 2N4R tau isoform interferes with microtubule gliding on kinesin-1 motors at much lower 
concentrations compared to the 2N3R tau isoform. 
A) Recombinant human 2N3R tau-GFP was introduced to a kinesin-1-dependent microtubule gliding assay in 
standard motility buffer. B) Recombinant human 2N4R tau-mScarlet was introduced to a kinesin-1-dependent 
microtubule gliding assay in standard motility buffer. C) Kinesin-1-dependent microtubule gliding velocities in the 
presence of recombinant human 2N3R tau-GFP, 2N4R tau-mScarlet, at indicated concentrations, or BSA in standard 
motility buffer at a concentration of 5.25 µM. Relative speed was calculated by dividing the median microtubule 
gliding velocities after tau variant or BSA addition by the median gliding velocity of microtubules in the same channel 
in standard motility buffer before tau variant or BSA addition, respectively. Averages of three independent 
experiments ± standard deviation are shown. 
 
Since the two tested isoforms differ mainly in their number of microtubule binding 
domains, their different capacity to slowdown kinesin-1-dependent microtubule gliding might be 
explained by their distinct microtubule binding affinities. To test this hypothesis, each tau variant 
was added individually to taxol-stabilized, surface-immobilized, and Atto647-labelled 
microtubules at increasing concentrations, and the amount of tau bound to microtubules was 
observed using TIRF microscopy (Figure 18A and B). 
Binding of the 2N3R tau-GFP isoform to microtubules was apparent at 100 nM tau in 
solution, while saturation was achieved at 800 nM tau in solution (Figure 18A). In line with the 
observed slowdown of gliding microtubules in the presence of low concentrations of 
2N4R tau-mScarlet, this tau isoform bound to microtubules already at low concentrations 
(i.e. 5 nM, Figure 18B), while saturation was already achieved at 200 nM. 
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The fraction of tau protein that was bound to microtubules when a specific concentration 
of tau was present in solution, relative to the amount of the respective tau isoform bound at the 
highest concentration tested, was plotted and the data fitted using the Hill equation (Hill, 1910) 
in order to describe the binding kinetics of the respective tau isoform (Gesztelyi et al., 2012) 
(Figure 18C and D). The respective value for the highest concentration tested for each tau 
isoform (800 nM for 3R tau-GFP and 200 nM for 4R tau-mScarlet, respectively) was excluded 
from the fit due to the fact that it was used for normalization and yielded a standard error of the 
mean (SEM) of zero after averaging the experiments. Interestingly, the Hill equation determined 
a Hill coefficient (n) larger than 1 for both binding curves for 3R tau-GFP and 4R tau-mScarlet, 
namely 2.38 ± 0.67 and 1.83 ± 0.29, respectively. This indicates a cooperative binding 
mechanism for both tau isoforms (Weiss, 1997). The dissociation constant Kd (or k in Figure 
18C and D), corresponding to the concentration at which half of the tau molecules in solution 
are bound to microtubules, for 3R tau-GFP (Kd = 137.12 ± 29.7 nM) was determined to be 
approximately 20-fold higher compared to 4R tau-mScarlet (Kd = 6.79 ± 0.41 nM), indicating that 
the binding affinity of 4R tau-mScarlet to microtubules is approximately 20-fold higher than that 
of 3R tau-GFP. 
Interestingly, although the microtubule was heavily decorated with 2N3R tau-GFP 
molecules, the relative microtubule gliding speed at 750 nM 2N3R tau-GFP was only reduced to 
0.85 ± 0.07 (Figure 17C). Similarly, microtubule saturation with 2N4R tau-mScarlet at 250 nM 
corresponded to a decrease in relative kinesin-1-dependent microtubule gliding speed only 
down to 0.48 ± 0.13 (Figure 17C). For both recombinant tau isoforms, the relative microtubule 
gliding velocity decreased further at higher concentrations than those needed to saturate 
microtubules with tau. We hence suggest that tau molecules do not just form a monolayer on 
microtubules, but can cluster on the surface and impair kinesin-1 motility stronger than single 
tau molecules. 
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Figure 18: The 2N4R tau-mScarlet isoform has a stronger binding affinity towards microtubules compared to 
2N3R tau-GFP. 
A) Binding of 2N3R tau-GFP (upper panels) at indicated concentrations to Atto647-labelled microtubules (lower 
panels). Scale bar = 5 µm. B) Binding of 2N34 tau-mScarlet (upper panels) at indicated concentrations to Atto647-
labelled microtubules (lower panels). Scale bar = 5 µm. C) The fraction of bound tau describes the amount of tau 
bound to microtubules at the indicated concentration relative to the amount of tau bound at the highest tested 
concentration of 3R tau-GFP. At least 200 microtubules were analyzed for each concentration and in every 
experiment. Averages of three independent experiments ± SEM are shown. The last data point was excluded from 
Hill fit due to its SEM=0 after normalization. D) The fraction of bound tau describes the amount of tau bound to 
microtubules at the indicated concentration relative to the amount of tau bound at the highest tested concentration of 
4R tau-mScarlet. At least 200 microtubules were analyzed for each concentration and in every experiment. Averages 
of three independent experiments ± SEM are shown. The last data point was excluded from Hill fit due to its SEM=0 
after normalization. 
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3.7 Impact of increasing 4R:3R tau isoform ratios on kinesin-1-dependent 
microtubule gliding and its microtubule binding 
After having determined the effect of 2N3R tau-GFP and 2N4R tau-mScarlet on 
kinesin-1-dependent microtubule gliding individually, we next tested whether a small shift in tau 
isoform ratio towards 2N4R tau is sufficient to differentially affect kinesin-1-dependent 
microtubule gliding. Previous studies reported that upon FUS knockdown, mimicking the 
mislocalization of FUS-P525L from the nucleus to the cytoplasm, the ratio of total 4R:3R tau 
isoforms within the cell changes from approximately 0.6 to 1.3 (Ishigaki et al., 2017). To 
reconstitute this effect in vitro, both recombinant human 2N3R tau-GFP and 2N4R tau-mScarlet 
isoforms were combined at increasing ratios with a constant total tau concentration of 1200 nM 
and administered to the modified microtubule gliding assay (Figure 19A). Ratios in this study 
were calculated according to the following formula and are summarized in Table 10: 
[4𝑅 𝑡𝑎𝑢]
[3𝑅 𝑡𝑎𝑢 +  4𝑅 𝑡𝑎𝑢]
= 1200 𝑛𝑀 
Table 10: Calculation scheme for 4R:3R tau isoform ratios used in this study. 
[𝟒𝑹 𝒕𝒂𝒖]
[𝟑𝑹 𝒕𝒂𝒖 + 𝟒𝑹 𝒕𝒂𝒖]






0 0 1200 0 
0.25 300 900 0.33 
0.5 600 600 1 
0.75 900 300 3 
1 1200 0 (4) 
 
Interestingly, the relative kinesin-1-dependent microtubule gliding speed decreases from 
0.58 ± 0.1 in the presence of 4R tau-mScarlet and 3R tau-GFP at a ratio of 0.33, to a relative 
microtubule gliding speed of 0.34 ± 0.19 in the presence of 4R tau-mScarlet and 3R tau-GFP at 
a ratio of 3 (Figure 19B), compared to a buffer control or gliding in the presence of 3R tau-GFP 
alone. This indicates that an increase in the ratio of 4R:3R tau isoforms, as subtle as observed 
in vivo and without an increase in total tau levels, is sufficient to impair kinesin-1 motility on 
microtubules. Hence, an increase in 4R:3R tau isoform ratio upon depletion of FUS-P525L from 
the nucleus may contribute to the observed defects in axonal transport in FUS-ALS pathology. 
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Figure 19: An increase in 4R:3R tau isoform ratio leads to impaired kinesin-1-dependent microtubule gliding. 
A) Recombinant human 2N3R tau-GFP was mixed at different ratios with 2N4R tau-mScarlet and introduced to a 
kinesin-1-dependent microtubule gliding assay in standard motility buffer. B) Kinesin-1-dependent microtubule gliding 
velocities in the presence of recombinant human 2N3R tau-GFP and 2N4R tau-mScarlet mixed at indicated ratios. 
Relative speed was calculated by dividing the median microtubule gliding velocities after tau mixture addition by the 
median gliding velocity of microtubules in the same channel in standard motility buffer before tau mixture addition, 
respectively. Averages of three independent experiments ± standard deviation are shown. 
 
In order to determine how increasing ratios of 4R:3R tau isoforms affect the microtubule 
binding affinity of each isoform, both 4R tau-mScarlet and 3R tau-GFP were again mixed at the 
same increasing ratios as for microtubule gliding experiments and added to taxol-stabilized, 
surface-immobilized Atto647-labelled microtubules. The amount of tau bound to microtubules 
was again observed using TIRF microscopy (Figure 20A) and quantified (Figure 20B). 
Intriguingly, when 4R tau-mScarlet and 3R tau-GFP are supplied in combination to 
surface-immobilized microtubules, 4R tau-mScarlet strongly bound to microtubules and inhibited 
binding of 3R tau-GFP at a ratio as little as 0.33 (which is equal to 900 nM 3R tau-GFP and 
300 nM 4R tau-mScarlet in solution). Further, the higher the 4R:3R ratio was in solution, the 
less 3R tau-GFP was able to bind to microtubules until virtually none bound at a 4R:3R ratio of 3 
(equal to 300 nM3R tau-GFP and 900 nM 4R tau-mScarlet in solution). Interestingly, at this 
ratio, both tau isoforms were present at a concentration at which microtubules were saturated 
when only one isoform was added to the assay individually (Figure 18). In addition, the 
microtubule gliding velocity decreases at increasing 4R:3R tau ratios in a similar fashion as in 
the presence of 2N4R tau-mScarlet alone. This indicates that i) 2N4R tau-mScarlet actively 
replaces 2N3R tau-GFP on the microtubule and ii) 2N4R tau-mScarlet is more effective in 
blocking kinesin-1 motility than 2N3R tau-GFP, since the total concentration of tau is equal at all 
ratios. 
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Figure 20: The 2N4R tau-mScarlet isoform prevents binding of 2N3R tau-GFP to microtubules due to its 
stronger binding affinity. 
A) Binding of 2N3R tau-GFP (middle panels) and 2N4R tau-mScarlet (lower panels) at indicated ratios to 
Atto647-labelled microtubules (uppermost panels). Scale bar = 5 µm. B) The fraction of bound tau describes the 
amount of tau bound to microtubules at the indicated concentration relative to the amount of tau bound at the highest 
tested concentration of the respective tau isoform. At least 200 microtubules were analyzed for each ratio and tau 
isoform in every experiment. Averages of three independent experiments ± standard deviation are shown. 
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3.8 Expression levels of 4R and 3R tau isoforms in whole cell lysates 
The so far presented experimental data strongly points towards the fact that an increase in 
4R:3R tau isoform ratio within the cell contributes to the observed defects in axonal transport. 
This is likely due to a higher decoration of microtubules with 4R tau isoforms and their larger 
roadblock effect compared to 3R tau isoforms. An increased 4R:3R ratio likely results from the 
cytoplasmic mislocalization of the FUS-P525L mutant as observed in the used cell lines 
(Dormann et al., 2010; Ishigaki et al., 2017). This would indicate that the 4R:3R tau isoform ratio 
should be increased in whole cell lysates expressing the FUS-P525L-GFP variant compared to 
lysates from cells expressing the wildtype FUS-GFP variant. However, when both lysates were 
added to the herein used kinesin-1-dependent microtubule gliding assay, they did not 
differentially influence the relative microtubule gliding speed (Figure 13). Therefore, western 
blots were performed to determine the level of each tau isoform within the herein used whole 
cell lysates (Figure 21). In order to detect 3R and 4R tau isoforms individually, primary 
pan-specific antibodies detecting either 0N-, 1N-, and 2N3R tau isoforms or 0N-, 1N-, and 2N4R 
tau isoforms were used in these blots. Recombinant human 2N3R tau-GFP and 
2N4R tau-mScarlet was used as a positive control, respectively. Interestingly, none of the 4R 
tau isoforms could be detected in four biological replicates of whole cell lysates expressing the 
wildtype FUS-GFP or FUS-P525L-GFP variants, respectively (Figure 21B), as well as the 1N3R 
and 2N3R tau isoforms (Figure 21A).The 0N3R tau isoform, however, was consistently present 
in all biological replicates with a concentration between 10 and 30 nM. This indicates that the 
expression level of tau isoforms in the herein used iPSC-derived spinal motor neurons has not 
(yet) been influenced by the FUS-P525L-GFP variant, at least not within the detection limit of 
this western blot technique. However, the presence of small amounts of 0N3R tau within lysates 
might contribute to the non-significant, but consistently lower relative microtubule gliding speeds 
observed in the kinesin-1-dependent microtubule gliding assay in the presence of whole cell 
lysates supplemented with recombinant human 2N4R tau-GFP, compared to the presence of 
2N4R tau-GFP alone (Figure 13C). Alternatively, unknown factors present in whole cell lysates 
may interfere with kinesin-1-dependent microtubule gliding, which could be determined by e.g. 
pulldown experiments with microtubules and motors in the presence of whole cell lysates and 
subsequent mass spectrometry. 
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Figure 21: Western blot of tau variants expressed in whole cell lysates of spinal motor neurons. 
Representative western blot of A) recombinant human 2N3R tau-GFP and b) recombinant human 2N4R tau-mScarlet 
at indicated concentrations and four biological replicates (n) of whole cell lysates (at a concentration of 80 ng/µL) 
obtained from spinal motor neurons expressing either wildtype FUS-GFP or FUS-P525L-GFP. The blot in A) was 
incubated with primary antibodies against 0N-, 1N-, and 2N3R tau isoforms, while the blot in B) was incubated with 
primary antibodies against 0N-, 1N-, and 2N4R tau isoforms. 
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4. Discussion 
The pathology of ALS has been subject to many previous studies, and yet there is no clear 
consensus about the exact mechanisms leading to this devastating disease. Since mutations in 
SOD1 were the first discovered in ALS patients, most research results to date are based on 
models with this mutation (Rosen et al., 1993; Huai and Zhang, 2019), but intensive studies 
have also been performed on the role of mutant FUS variants (Groen et al., 2010; Shang and 
Huang, 2016; Naumann et al., 2019). Although defects in axonal transport have long been 
observed in FUS-ALS (De Vos et al., 2008; Ikenaka et al., 2012; De Vos and Hafezparast, 
2017b), little is known about underlying pathomechanisms that lead to these detrimental 
defects, and whether they are causative or occur as a consequence of other pathological 
events. The work done for this thesis therefore aimed at investigating the fundamental 
hypothesis of a direct influence of NLS-mutant, cytoplasmic mislocalized FUS on the axonal 
transport machinery involving kinesin-1. For this purpose, a kinesin-1-dependent microtubule 
gliding assay was modified to be compatible with and robustly deliver reproducible results in the 
presence of protein-rich solutions such as whole cell lysates. To evaluate the direct influence of 
FUS variants on kinesin-1 motility, recombinant human GFP-labelled FUS variants, as well as 
cell lysates from iPSC-derived spinal motor neurons expressing the same GFP-labelled FUS 
variants, were analyzed in this assay. In addition, a more indirect effect of mutant FUS variants 
on axonal transport was hypothesized and investigated: FUS is known to regulate splicing of 
mRNA coding for the microtubule-binding protein tau, which suggests that the ratio of 4R:3R tau 
is increased in cells carrying a mutation in FUS leading to its cytoplasmic mislocalization 
(Ishigaki et al., 2017). Therefore, the modified kinesin-1-dependent microtubule gliding assay 
was utilized to study whether and which 3R:4R tau ratio is sufficient to alter kinesin-1 motility on 
microtubules. 
This study therefore presents the first to address the direct role of FUS variants on 
kinesin-1 motility in a bottom-up in vitro reconstruction of axonal transport. Likewise, using the 
same reconstruction approach, it provides further evidence for the relevance of tau isoform 
variations in disease progression. The results presented herein therefore largely contribute to 
our understanding of the underlying pathomechanisms in FUS-ALS. 
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4.1 The modified kinesin-1-dependent microtubule gliding assay detects 
nanomolar amounts of recombinant human tau-GFP 
The buffer typically used in standard kineins-1-dependent microtubule gliding assays is BRB80 
(with PIPES as a buffering agent), which we aimed to substitute with PBS for optimal cell lysis at 
physiological pH (7.4). To prevent water from crystallizing and hence damage proteins during 
snap freezing, glycerol was added to every cell lysate, as well as a commercially available 
protease inhibitor cocktail. Since the phosphorylation state of proteins, in this case especially of 
tau, is important for their activity, phosphatases within lysates needed to be inhibited as well. 
However, a commercially available phosphatase inhibitor cocktail introduced to the microtubule 
gliding assay led to an immediate arrest of microtubule gliding (Figure 8C). According to the 
manufacturer, the tested phosphatase inhibitor cocktail was a mixture of the broad-spectrum 
inhibitors sodium fluoride, sodium pyrophosphate, sodium orthovanadate and 
β-glycerophosphate. Sodium fluoride and sodium pyrophosphate are general inhibitors for 
phosphoseryl and phosphothreonyl phosphatases and commonly used in the purification of 
protein kinases (Gordon, 1991; Hardie, 1993; Mercan and Bennett, 2010). The serine-threonine 
phosphatase inhibitor β-glycerophosphate acts as a bait substrate (Belfield and Goldberg, 1968; 
Chung et al., 1992; Lecanda et al., 1997), thereby protecting a protein’s phosphorylation status 
by attracting phosphatases away from endogenous proteins. Sodium orthovanadate is a general 
inhibitor for phosphotyrosyl phosphatases, alkaline phosphatases and a variety of ATPases 
(Gordon, 1991; Wang et al., 1994; Yun et al., 2001). It has been repeatedly reported to inhibit 
dynein (D’Souza et al., 2006; Kharkwal et al., 2014) and kinesin motility at a concentration as 
low as 100 mM (Scholey, 1993; Dentler et al., 1995). Orthovanadate hence is very likely to 
mediate the observed complete arrest of kinesin-1 motility. In consequence, an excess of 
β-glycerophosphate alone was used to inhibit dephosphorylation of proteins within whole cell 
lysates by serving as an alternative substrate. These high concentrations of 
β-glycerophosphate, however, interfered with microtubule-motor binding and led to detachment 
of microtubules (Figure 8D). Most likely, negatively charged phosphate groups of 
β-glycerophosphate (Kolawole et al., 2019) disturb the electrostatic interaction between the 
lattice-exposed acidic C-termini of tubulin subunits (E-hook) and the positively charged K-loop of 
kinesin-1 (Okada and Hirokawa, 2000). These E-hook/K-loop interactions are crucial to stabilize 
the weak binding state of kinesin motor domains (Okada and Hirokawa, 2000), resulting in more 
frequent detachment of microtubules from surface-bound kinesin-1 in the presence of 
β-glycerophosphate. To prevent this, methylcellulose was added to all solutions in the gliding 
assay, which increases the viscosity of the assay solution. This prevents detached microtubules 
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from escaping into solution, keeps them closer to the imaging surface and facilitates their 
efficient recapture by surface-bound motors (Wiesner et al., 2003; Saito et al., 2017; Farhadi et 
al., 2018). 
Implementation of these adjustments in the used kinesin-1-dependent microtubule gliding 
assay produced highly reproducible results (Figure 9D). In line with previous studies, 
kinesin-1-dependent microtubule gliding was completely inhibited at concentrations of 
recombinant human 2N4R tau-GFP of around 118 nM and higher (Figure 10C) (Hagiwara et al., 
1994; Peck et al., 2011; Parimalam et al., 2016). The same sensitivity still applies to the used 
kinesin-1-dependent microtubule gliding assay in the presence of whole cell lysates, underlining 
the robustness and suitability of the modified assay to study the influence of proteins in such a 
protein-rich solution on kinesin-1 motility. 
Comparison of chemical and mechanical protein isolation techniques 
Various protein isolation techniques were utilized in this study to determine the method yielding 
the most sufficient cell lysis in combination with a high concentration of total protein in the final 
lysate, while being compatible with the herein used kinesin-1-dependent microtubule gliding 
assay. Buffers used for chemical cell lysis yielded the highest amounts of total protein and 
sufficiently lysed cells so that the housekeeping protein β-actin could be detected (Table 9). 
However, those buffers interfered with microtubule gliding on kinesin-1 motors, leading to 
microtubule detachment even in the presence of very highly diluted buffer or after buffer 
exchange (Figure 8). Hence, different mechanical lysis methods, utilizing PBS as a buffer that is 
not interfering with kinesin-1-dependent microtubule gliding (Figure 8), were tested for their lysis 
efficiency and protein yield.  
In this study, the housekeeping protein β-actin could not be detected in motor neuron 
lysates produced by glass bead shearing (Table 9), suggesting that lysis was incomplete or that 
a major portion of protein got lost during lysate processing. Evidence for the latter comes from 
the fact that beads are generally provided to the cell suspension and mixed at high speeds to 
break open the cell membrane by shear force. This process generates heat, which may cause 
degradation of proteins to some degree (Shehadul Islam et al., 2017) and cause the observed 
loss of protein. This is in line with the finding that protein denaturation and aggregation has been 
observed in yeast cell lysates produced by glass bead shearing (Papanayotou et al., 2010). 
Likewise, β-actin could not be detected in lysates prepared by grinding of motor neurons in the 
presence of liquid nitrogen (Table 9). Although grinding in liquid nitrogen has been successfully 
used in previous studies, e.g. for the isolation of protein from Chlorella vulgaris (Zheng et al., 
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2011), the procedure presented several disadvantages in this study. For instance, slight thawing 
of the lysate could not be avoided during collection of the finely ground powder from the mortar, 
which might have caused some protein degradation. Also, a full recovery of the lysates from the 
mortar was not possible. A similar problem arose when preparing cell lysates using a dounce 
homogenizer. Consistent with previously reported efficient use of dounce homogenization 
(Osborne and Neuhoff, 1972; Gozes et al., 1977; Krishnaswami et al., 2016), dounce 
homogenization of single motor neurons yielded comparably high amounts of protein as well as 
well detectable levels of the housekeeping protein β-actin in this study (Table 9). However, a 
small fraction of the lysate always stuck to the walls of the homogenization tube, resulting in a 
reduced volume of recovered lysate. Therefore, mechanical lysis of motor neurons was chosen 
as a suitable method for whole cell lysate production in this study, by passing the cell 
suspension several times through a thin needle with the help of a syringe. This method resulted 
in similar protein yields and detection of β-actin in western blot as compared to dounce 
homogenization (Table 9), but nearly full lysate volume recovery since the lysate could be 
pressed out of the syringe and needle using the plunger. 
 
4.2 Wildtype and ALS-associated FUS variants do not directly interfere with 
kinesin-1 motility and do not bind to microtubules 
Defects in the axonal transport of a variety of organelles and nucleic acids have long been 
observed in ALS (Fujii and Takumi, 2005; Bilsland et al., 2010; Ikenaka et al., 2012; De Vos and 
Hafezparast, 2017b; Naumann et al., 2018; Pal et al., 2018; Smith et al., 2019), the underlying 
mechanism for impaired transport is, however, still enigmatic. In this study, a modified 
kinesin-1-dependent microtubule gliding assay was used to investigate a direct influence of 
ALS-associated FUS variants alone or in combination with their endogenous interaction 
partners present in whole cell lysates on the kinesin-1-driven transport machinery. Results 
presented herein provide clear evidence that neither recombinant human wildtype FUS-GFP nor 
FUS-P525L-GFP by itself directly binds to microtubules or inhibits kinesin-1 motility over a wide 
range of concentrations. Although relative microtubule gliding velocity in the presence of FUS 
variants slightly reduced over the course of three hours (Figure 12A), this phenomenon can be 
likely attributed to aging of the assay components. Aging occurs as a result of changes in pH, 
depletion of ATP, or oxidative damage due to depletion of oxygen scavenging components 
glucose oxidase, catalase or DTT (Rasnik et al., 2006; Aitken et al., 2008; Landry et al., 2009; 
Swoboda et al., 2012). Interestingly, although the median gliding velocity was comparable in the 
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presence of recombinant FUS variants over the course of three hours and in the presence of 
low amounts (15-25 nM) of 2N4R tau-GFP (Figure 12A and Figure 10C), aging of the assay 
resulted in a uniform decrease in the gliding velocity of all microtubules gliding in the field of 
view, while the introduction of tau-GFP caused only individual microtubules to slow down or fully 
stop (Figure 15B and D). The fraction of non-gliding microtubules sharply increased after a 
threshold concentration of 15 nM tau-GFP until virtually all microtubules have stopped gliding at 
a concentration of 50 nM 2N4R tau-GFP or above. A very similar distribution of gliding and 
non-gliding microtubules has been observed in a system employing active and inactive 
kinesin-1 motors at different ratios. When 30% of kinesin-1 motors immobilized on a glass 
surface were inactive, microtubules displayed a bistable movement with one portion of 
microtubules gliding at a peak velocity around 500 nm/s and another portion with peak velocity 
at 0 nm/s. Slightly higher or lower amounts of inactive motors shifted the distribution of 
microtubule gliding velocities towards the slower or the faster peak, respectively (Scharrel et al., 
2014). Whether a microtubule is propelled by the underlying motors therefore depends on the 
number of inactive motors that attach to the filament, where a stop of motion is achieved when 
inactive motors dominate. Similarly, whether a microtubule is propelled by underlying kinesin-1 
motors in the presence of 2N4R tau-GFP depends on the amount of tau molecules creating 
roadblocks on the microtubule, thereby impairing kinesin-1 motility. Since neither FUS variant 
tested in the present work caused a bistable kinesin-1-dependent gliding of microtubules, this 
suggests that wildtype FUS and FUS-P525L do not impair kinesin-1 motility on microtubules by 
direct interaction with either microtubules or kinesin-1 motors. 
FUS by itself hence does not interfere with the kinesin-1-driven transport machinery. 
Further, whole cell lysates of iPSC-derived spinal motor neurons expressing the same FUS 
variants did not interfere with kinesin-1-driven microtubule gliding at the tested concentrations. 
This indicates that FUS variants did not form complexes with other proteins in whole cell lysates 
that would interfere with kinesin-1 motility. Taken together, these results strongly suggest that 
neither the wildtype form nor the mislocalized cytoplasmic FUS-P525L variant directly or by 
interaction with other proteins interfere with kinesin-1-driven (anterograde) axonal transport in 
neurons. 
Yet, there are some limitations to the herein used assay setup which have to be taken into 
consideration. Although there were no aggregates of recombinant or endogenous FUS variants 
apparent in the presented experiments, even over the course of three hours, ALS-associated 
FUS aggregation has repeatedly been observed in vivo and in vitro (Shelkovnikova et al., 2014; 
Murakami et al., 2015; Patel et al., 2015; Marrone et al., 2019) and may very well be involved in 
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hindering axonal transport in neurons of ALS-patients, e.g. by sterical hindrance (Sau et al., 
2011) or sequestering of proteins (Aulas and Vande Velde, 2015; Yasuda et al., 2017). In case 
aggregates composed of cytoplasmic mislocalized FUS-P525L-GFP were initially present in 
iPSC-derived spinal motor neurons, they were most likely lost during cell lysate clearance by 
centrifugation (>100K g in pellet, Shelkovnikova et al., 2014) and hence no longer present in 
whole cell lysates. A possible impact of endogenous cytoplasmic FUS aggregates on axonal 
transport is difficult to study in a minimal system such as microtubule gliding assays, since 
compartmentalization of the neuron is lost during lysates generation. Furthermore, a loss of 
compartmentalization after cell lysis also abolishes the possibility to study pathological events 
with local impact. For instance, axonal transport of mitochondria is significantly impaired and 
their membrane potential broken down in iPSC-derived spinal motor neurons expressing 
FUS-P525L-GFP (Naumann et al., 2018), indicating a potential local depletion of ATP and 
hence impaired kinesin-1 motility. Local ATP deficiencies, however, are lost during lysis, and an 
excess of ATP is additionally supplied to cell lysates used in kinesin-1-dependent microtubule 
gliding assays to ensure efficient kinesin-1-motility. Another challenge for studying the impact of 
cytosolic inclusions in microtubule gliding assays presents the generation of FUS-containing 
aggregates. In vitro assembled FUS aggregates do not form uniformly in size and do not fully 
resemble all components present in endogenous pathological FUS aggregates (Marrone et al., 
2019). Endogenous FUS granules could be enriched by centrifugation in fractions from cell 
lysates (Shelkovnikova et al., 2014) in the past, however, this required the introduction of the 
detergent Triton X to lysates, which has been shown to influence kinesin-1-dependent 
microtubule gliding velocity and causes detachment of actin filaments from myosin motors 
(Kellermayer, 1997; Kuramitsu, 1999). Endogenous cytoplasmic FUS aggregates are also likely 
to sequester proteins and RNA interacting with cytoplasmic FUS under physiological conditions, 
which results in severe reduction in their concentration or virtual exclusion from herein used 
whole cell lysates during clearance by centrifugation or because the neuronal cytoplasm 
becomes highly diluted after lysis. Lack of such factors might hence contribute to the absence of 
a potential interference of FUS with kinesin-1-dependent microtubule gliding in this study. 
Finally, some interactions of proteins in cell lysates with kinesin-1 might have been missed due 
to the inaccessibility of motors in a gliding assay. 
Gliding assays present a useful tool to study the effect that proteins have on the transport 
machinery, in particularly if they interact with microtubules or the motor domain or motor 
proteins, and imaging of large polymeric filaments is not technically challenging. Yet, the actual 
imaging of single motors walking across cytoskeletal filaments in stepping assays presents a 
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more direct way of measuring motor characteristics and how these may change in the presence 
of proteins engaging with the motor. Depending on the motor construct that is used (i.e. 
full-length kinesin-1) in a stepping assay, the motor itself becomes much more accessible for 
interaction with proteins in solution, compared to its surface-bound state in a gliding assay. 
Proteins present within the herein used whole cell lysates may have been prevented from 
interacting with kinesin-1 due to the inaccessibility of the surface-bound motor. Hence, applying 
whole cell lysates of isogenic iPSC-derived spinal motor neurons carrying different FUS variants 
in a stepping assay may yield different results than those presented here and provide further 
insights into how mutations in FUS impact the kinesin-1-driven transport machinery directly. 
In addition, there is evidence that FUS associates with ATP-dependent actin-binding 
motor Myo5A (Yoshimura et al., 2006) and Myo6 (Takarada et al., 2009), and has been isolated 
as part of a large granule associating with KIF5B (Kanai et al., 2004). Although the herein 
presented results demonstrate that FUS by itself does not interfere with kinesin-1 (KIF5B) 
motility, it remains to be elucidated whether this holds true for actin-associated myosin motors 
as well. Similarly to the kinesin-1-dependent microtubule gliding assay used in this study, actin 
filaments can glide over myosin-coated surfaces (Rock et al., 2000; Vilfan, 2009; Hariadi et al., 
2016), and single myosin molecules can be tracked while stepping on immobilized actin 
filaments (Ricca and Rock, 2010; Bao et al., 2013). By utilizing such actin and myosin based 
gliding or stepping assays in future experiments, the direct interaction of FUS variants with 
these components of the transport machinery may be investigated. 
Taken together, the present data provide strong evidence that mislocalized, free 
cytoplasmic FUS-P525L itself does not directly interfere with kinesin-1-driven axonal transport 
on microtubules. Apart from the fact that ALS-associated FUS aggregates sequester proteins 
involved in RNA transport (Kamelgarn et al., 2016) as well as mRNA and protein of kinesin-1 
itself (Yasuda et al., 2017), there is also little evidence in the literature to date about a direct 
involvement of mislocalized cytoplasmic ALS-associated FUS in microtubule-based axonal 
transport. 
 
4.3 An increase in 4R:3R tau isoform ratio might contribute to the axonal 
transport defects observed in FUS-ALS 
Since the herein presented results show that FUS is not directly interfering with the microtubule 
based kinesin-1 mediated transport machinery, this study also investigated possible effects of 
FUS-dependent changes in the expression of tau isoforms on axonal transport. Defects in 
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axonal transport have been observed early in the progression of many neurodegenerative 
diseases, and might partly be caused by hyperphosphorylated mutant tau variants or by altered 
expression levels of tau isoforms (Ebneth et al., 1998; Stamer et al., 2002; De Vos et al., 2008; 
Goldstein, 2012; Qian and Liu, 2014; Correia et al., 2016; Fernández-Nogales and Lucas, 
2020). Overexpression of single wildtype tau isoforms (0N3R, 2N3R, 0N4R, and 2N4R) in H4 
human neuroglioma cells have previously been associated with defects in axonal transport of 
mitochondria (Stoothoff et al., 2009). Previous studies could show that the FUS, together with 
the transcription factor SFPQ, is directly involved in the splicing of tau pre mRNA, and a 
knockdown of FUS results in in a higher expression of the 4R tau isoform in mice (Ishigaki et al., 
2017; Bourefis et al., 2020). Furthermore, pathological behavioral phenotypes caused by FUS 
knockdown in these mice could be weakened by silencing of 4R tau with small hairpin RNAs 
(Ishigaki and Sobue, 2018), indicating that an increased 4R:3R ratio within the cell may indeed 
contribute to pathology. In line with this, changes in the 4R:3R in favor of 4R have been 
observed in diverse tauopathies (D’Souza and Schellenberg, 2005; Goedert and Jakes, 2005; 
Sergeant et al., 2005). However, the role of changing ratios of wildtype 4R and 3R tau isoforms, 
without increased total tau levels, in contributing to axonal transport defects is not well 
investigated to date. 
We hence hypothesized that cytoplasmic mislocalization of FUS and the resulting loss of 
function in splicing of tau might as well increase the 4R:3R isoform ratio of tau in vivo, which in 
turn might affect kinesin-1-dependdent transport in axons. In order to test this hypothesis, the 
microtubule binding affinity of purified recombinant human 2N3R tau-GFP and 
2N4R tau-mScarlet and their effect on kinesin-1-dependent microtubule gliding was analyzed in 
the modified microtubule gliding assay. 
Although the largest tau isoforms utilized in this study are the least expressed within the 
human brain (~9%, Hong, 1998), the ratio between respective 3R and 4R isoforms with varying 
N-termini (e.g. 0N3R and 0N4R) is similar and hence results obtained with 2N3R and 
2N4R tau isoforms are expected to be transferable to all other tau isoforms (He et al., 2020). 
While both tau variants used in this study impaired microtubule gliding in the modified 
kinesin-1-dependent microtubule gliding assay, a 5-fold lower concentration of 
2N4R tau-mScarlet than of 2N3R tau-GFP variant was sufficient to slow relative microtubule 
gliding speed down to 0.19 ± 0.09 and 0.31 ± 0.13, respectively (Figure 17C). In addition, an 
approximately 20-fold higher microtubule binding affinity was measured for 2N4R tau-mScarlet 
(Kd = 6.79 ± 0.41 nM) compared to 2N3R tau-GFP (Kd = 137.12 ± 29.7 nM) (Figure 18C, D). In 
both cases the binding data was best fitted with a Hill-model fit with a Hill coefficient of 
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2.38 ± 0.67 for 3R tau GFP and 1.83 ± 0.29 for 4R tau mScarlet (Figure 18C). Both coefficients 
are larger than 1, suggesting a cooperative binding mechanism for 2N3R and 2N4R tau 
isoforms (Weiss, 1997). This means that the binding of tau molecules to microtubules may not 
be independent, but that binding of one tau molecule increases the binding-probability of 
another tau molecule. While the exact mechanism by which tau binds soluble tubulin or 
microtubules is still elusive, Fung et al. have proposed a model for its cooperative binding to 
tubulin dimers (Fung et al., 2020), and other recent studies also suggest a cooperative binding 
mechanism of 2N4R tau within non diffusive, but dynamic tau condensates on microtubules 
(Siahaan et al., 2019; Tan et al., 2019). 
 Previous studies often used co-sedimentation assays to determine the binding affinity of 
3R and 4R tau isoforms to microtubules, and results varied greatly from up to 6 µM down to less 
than 100 nM (Butner and Kirschner, 1991; Goode and Feinstein, 1994; Hong, 1998; Ackmann et 
al., 2000; Goode et al., 2000). However, bound tau was in those cases assessed by SDS-PAGE 
gel analysis, which is not suitable to reliably detect tau concentrations below 1 µM (Gustke et 
al., 1994b). And yet, studies performing a much more sensitive fluorescence resonance energy 
transfer (FRET) assay or nuclear magnetic resonance (NMR) also reported largely varying 
dissociation constants for comparable tau isoforms, ranging from 2.5 µM down to 14 nM 
(Makrides et al., 2004; Sillen et al., 2007; Elbaum-Garfinkle et al., 2014; Maïo et al., 2014). Also, 
in contrast to these studies, microtubule bundles were excluded from the analysis in this study. 
The quantification of dissociation constants for tau hence largely depends on the experimental 
procedures and can be compared only to a very limited extent.  
However, while the exact Kd-values may vary, these studies consistently reported a 
stronger microtubule binding affinity for 4R compared to 3R tau variants, which is consistent 
with the herein presented results. This suggests that when the ratio of 4R:3R tau isoforms 
changes, the microtubule decoration with tau isoforms and hence the motility of kinesin-1 
walking across these microtubules may change as well. To test this hypothesis, we analyzed 
the relative microtubule-binding behavior of mixed recombinant human 4R tau-mScarlet to 
3R tau-GFP and their isoform-ratio dependent effect on kinesin-1-dependent microtubule 
gliding. Increasing 4R:3R tau isoform ratios led to decreased relative microtubule gliding 
velocities (Figure 19), suggesting that a shift towards higher 4R tau isoform levels within a 
neuron negatively affects axonal transport along microtubules. Interestingly, the fact that 
2N4R tau-mScarlet in solution seems to prevent 3R tau-GFP from binding to microtubules, even 
at low 4R:3R ratios (Figure 20), suggests that transport defects are caused by a higher 
decoration of axonal microtubules with 4R tau isoforms due to its higher roadblock efficiency. 
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Together, these results suggest that an increased 4R:3R tau isoform ratio within neurons 
expressing the FUS-P525L variant likely contributes to, or might even be sufficient to cause the 
axonal transport defects observed in FUS-ALS pathology. 
Due to the higher net positive charge of the microtubule binding domain, 4R tau also 
shields the negative surface charge of microtubules more efficiently when compared to 3R tau. 
This results in a reduced kinesin-1 landing rate and decreased kinein-1 velocities (Parimalam et 
al., 2016). In line with these findings in vitro, 0N4R tau largely co-localized with microtubules of 
NIH 3T3 cells when co-transfected with differently labeled 0N3R and 0N4R tau isoforms at a 1:1 
ratio, while 0N3R tau diffusely distributed to the cytosol (Lu and Kosik, 2001). Studying the 
effect of 4R:3R tau isoform imbalances in mouse models is difficult, as 4R tau is the 
predominantly expressed isoform in the adult rodent brain while 3R tau is hardly expressed 
(Lacovich et al., 2017; Tuerde et al., 2018). Therefore, Lacovich et al. created a trans-splicing 
model in neurons differentiated from human embryonic stem cells (hESCs), which allowed for 
selective in- and exclusion of exon 10 leading to an increase in relative endogenous levels of 3R 
or 4R tau isoforms, respectively. Using this model system, they could show that an increased 
level of 3R tau isoforms relative to 4R tau favored anterograde transport of the amyloid 
precursor protein (APP), while an increased 4R:3R tau isoform ratio promoted 
(dynein-dependent) retrograde transport by decreasing (kinesin-dependent) anterograde 
transport velocities (Lacovich et al., 2017). Although these neurons differentiated from hESCs 
predominantly express 3R tau isoforms, this data suggests that a shift in 4R:3R tau isoform ratio 
is sufficient to interfere with the transport of APP in vivo. Taken together, previous studies in line 
with the data presented herein provide clear evidence that a slight shift in 4R:3R tau isoform 
ratio, e.g. caused by the nuclear loss of function of FUS-P525L, impairs kinesin-1-dependent 
transport on microtubules. 
Interference of other tau isoforms with kinesin-1 motility 
Although the effect of tau on motor motility has been studied in detail, studies often investigated 
only one tau isoform or variant, preventing any direct cross-comparison of tau isoforms and their 
ability to interfere with kinesin-1 motility on microtubules. In addition, taxol-dependent 
microtubule stabilization or the decoration of microtubules with tau differentially affects kinesin-1 
motility. For instance, microtubules assembled in the presence of 0N3R tau glide moderately, 
but significantly faster (0.54 ± 0.01 µm/s) compared to microtubules assembled in the presence 
of 0N4R tau (0.48 ± 0.01 µm/s) (Yu et al., 2014). Similarly, another study reported a significantly 
faster gliding of microtubules assembled in the presence of 0N3R tau (0.52 µm/s) than in the 
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presence of 0N4R tau (0.43 µm/s) (Peck et al., 2011). When microtubules are, however, 
assembled in the presence of taxol and subsequently decorated with these tau isoforms, the 
gliding velocity is slower in the presence of 0N3R tau (0.29 ± 0.01 µm/s) compared to 0N4R tau 
(0.32 ± 0.01 µm/s) at tau concentrations of 100-1000 nM (Yu et al., 2014).  
The properties of molecular motors are also often studied in so called stepping assays, 
where either single motor molecules or cargo-attached motors are allowed to bind to and 
translocate along surface-immobilized microtubules, while they are visualized by TIRF 
microscopy. These assays are more suitable to investigate the characteristics of single motors 
when encountering proteins interfering with motor motility on microtubules compared to 
microtubule gliding assays, where motors act in ensemble to propel microtubules across the 
surface. In single molecule stepping assays, kinesin-1 moves at similar velocities in the 
presence of 0N3R tau (0.36 ± 0.02 µm/s) or 0N4R tau (0.33 ± 0.02 µm/s), but shows a 
decreased run length at these conditions (Vershinin et al., 2007; Dixit et al., 2008; Yu et al., 
2014). Conversely, concentrations of 2N4R tau up to 1.5 µM did not decrease the run length of 
recombinant rat kinesin-1, but drastically reduced its landing on microtubules, leading to the 
hypothesis that the crucial step in the motility of this kinesin-1 is its attachment to microtubules, 
where it translocates undisturbed by tau roadblocks once it is bound (Seitz et al., 2002). A 
similar effect of 2N4R tau has been observed in CHO cells. The velocities of a variety of cellular 
organelles and vesicles were unaffected upon microinjection of recombinant 2N4R tau into 
these cells, but attachment and detachment frequencies were altered causing impaired 
transport of these organelles and vesicles throughout the cell (Trinczek et al., 1999). 
Interestingly, low concentrations of 2N4R tau (0.25-20 nM) lead to the reversible formation of 
cohesive islands or condensates on taxol-stabilized (but not GMP-CPP-stabilized) microtubules 
(Siahaan et al., 2019; Tan et al., 2019). These condensates seem to have a kind of regulatory 
effect on motor translocation across microtubules, as they are constitute impermeable barriers 
for kinesin-1 motors but not for processive dynein-dynactin-BICD2N (DDB) complexes, while 
they are disassembled by kinesin-8. Tau islands further protect microtubules from severing 
enzymes such as katanin (Siahaan et al., 2019) or spastin (Tan et al., 2019). In vitro studies 
suggest that alternative splicing of tau does not seem to affect tau condensate formation on 
microtubules, since 2N3R and 0N3R tau readily incorporated into preformed 2N4R tau 
condensates (Tan et al., 2019). Further, it has been hypothesized that impaired motor motility 
on microtubules upon higher 4R levels in solution is not caused by an overall higher decoration 
of microtubules with tau molecules, but due to the replacement of tau molecules with three 
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microtubule binding repeats by those with four repeats, as it has been observed in vivo (Lu and 
Kosik, 2001). 
Interestingly, the presence of increasing concentrations (1-100 nM) of the longest tau 
isoform (2N4R) caused a more subtle decrease the run length of unloaded, GFP-labeled kinesin 
in stepping assays, compared to the presence of the shortest isoform (0N3R) (Vershinin et al., 
2007; Dixit et al., 2008), indicating that the projection domain of tau may actually counteract the 
roadblock effect caused by tau binding to microtubules and aid in kinesin translocation. In line 
with this, Tarhan et al. have investigated all six human tau isoforms for their capacity to act as 
roadblocks for bead-attached kinesin-1 motors. Increasing concentrations of 2N4R tau 
(0.14 - 140 nM) resulted in a significant decrease of bead velocity and hence kinesin-1 
translocation speed. While all 4R tau isoforms had a higher microtubule binding affinity and 
decreased kinesin-1 velocity along microtubules stronger compared to their respective 3R tau 
N-terminal counterparts (e.g. 0N3R compared to 0N4R), the kinesin-1 velocity increased for tau 
isoforms with more N-terminal domains (0N<1N<2N). This suggests that the negatively 
charged projection domain of tau aids in recruiting and keeping positively charged kinesin-1 
motor domains to the microtubule lattice (Tarhan et al., 2013), and in combination with a 
previously proposed sidestepping mechanism allowing kinesin to bypass roadblocks on 
microtubules (Dixit et al., 2008; Yildiz et al., 2008; Dreblow et al., 2010). Intriguingly, an 
additional N-terminal domain (i.e. in 1N3R tau) was reported to cause a considerably larger 
slowdown in microtubule gliding velocity compared to 0N3R tau (on taxol-stabilized 
microtubules decorated with 20, 200, or 400 nM of the respective recombinant tau isoform) 
(Schmidt et al., 2012).  
In light of these sometimes opposing results in previous studies, it would be interesting to 
investigate the interference of the different tau isoforms, alone or in combination with each 
other, utilized in this present study with individual kinesin-1 motors in the reversed assay 
geometry of stepping assays. In addition, the fact that the projection domain of tau may 
influence the stepping behavior of kinesin-1 on microtubules suggests that stepping assay in the 
presence of different ratios of all six 3R and 4R isoforms would add valuable knowledge as to 
how a shift in 4R:3R tau isoform ratio could impair kinesin-1 motility on microtubules within the 
cell. 
Batch-to-batch differences in purified recombinant 2N4R tau variants 
Initial experiments of this study were performed with recombinant human 2N4R tau-GFP, kindly 
provided by Dr. Marcus Braun from the Institute of Biotechnology CAS in Prague, while later 
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experiments were performed with 2N4R tau-mScarlet, purified by myself. Both batches exhibit 
significantly different inhibitory potential in the kinesin-1-dependent microtubule gliding assay. 
While kinesin-1-dependent microtubule gliding completely ceased in the presence of 118 nM of 
the 2N4R tau-GFP variant (Figure 10), about 10-fold more protein (1200 nM) of the 
2N4R tau-mScarlet variant was needed to reduce the relative microtubule gliding velocity to 
0.18 ± 0.09 (Figure 17). In order to determine to what degree different batches of tau differ in 
their inhibitory potential and to exclude variations due to the different fluorophores, two more 
2N4R tau batches, i.e. 2N4R tau-mCherry and 2N4R tau-GFP, were purified and tested in the 
modified kinesin-1-dependent microtubule gliding assay (Figure S2). Significantly larger 
amounts of 2N4R tau-mScarlet (1200 nM), -mCherry (1500 nM), or –GFP (1500 nM, second 
batch) were required to reduce microtubule gliding velocity down to 0.18 ± 0.09, 0.15 ± 0.01, or 
0.44 ± 0.01, respectively. However, the qualitative effect on kinesin-1 motility was the same for 
all tested tau isoform variants, since the addition of increasing amounts of tau consistently 
decreased kinesin-1-dependent microtubule gliding velocity. Together with above discussed 
previous studies, where the concentration of tau used ranges from nM to mM, it indicates that 
the inhibitory potential of tau varies between different purification batches (Trinczek et al., 1999; 
Seitz et al., 2002; Vershinin et al., 2007; Dixit et al., 2008; Peck et al., 2011; Schmidt et al., 
2012; Tarhan et al., 2013; Yu et al., 2014; Siahaan et al., 2019; Tan et al., 2019). 
The absolute amount of a protein needed to reproduce an effect or degree of activity often 
differs between individual batches of purified recombinant protein. During the purification of the 
protein of interest, co-purification of endogenous proteins (in this case from insect cells) 
commonly occurs, while the composition and amount of these co-purified proteins differs from 
batch to batch (Structural Genomics Consortium et al., 2008). Such proteins could include 
MAPs or motors, which are unlabeled and hence invisible for widefield-epifluorescence, but 
would interfere with kinesin-1 motility in a microtubule gliding assay. Further, intrinsically 
disordered proteins like tau (KrishnaKumar and Gupta, 2017) tend to form aggregates, a 
process often aggravated by long term storage of proteins (Chakraborty et al., 2018). 
Aggregated tau likely impairs kinesin-1 motility on microtubules differently compared to 
non-aggregated, soluble tau. In addition, the activity of tau strongly depends on its 
phosphorylation state. The microtubule binding affinity of tau is decreased upon its 
hyperphosphorylation (Ballatore et al., 2012). When purified from insect cell, tau is heavily 
phosphorylated (Tepper et al., 2014), although the exact degree of phosphorylation is not 
consistent between individual purifications. Hence, different phosphorylation states between the 
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earlier purified 2N4R tau-GFP and the later purified 2N4R tau-GFP or -mScarlet, which likely 
influence its ability to hinder kinesin-1 motility on microtubules, cannot be excluded. 
The up- and downsides of using Taxol in combination with tau 
The modified kinesin-1-dependent microtubule gliding assay presented in this study used in 
vitro polymerized microtubules that were stabilized by the addition of taxol. Previous studies 
showed that taxol can migrate through 2-nm pores within the microtubule wall, where it binds to 
the luminal face of β-tubulin (Meurer-Grob et al., 2001; Li et al., 2002; Kar et al., 2003; Ross and 
Fygenson, 2003) and counteracts the effect of GTP hydrolysis (i.e. tubulin destabilization) on 
the outward facing side of this β-tubulin molecule (Amos and Löwe, 1999; Prota et al., 2013). 
Interestingly, recent reports suggest that tau molecules occupy a similar, if not the same binding 
site in the microtubule lumen as taxol (Kar et al., 2003; Ross et al., 2004; Yu et al., 2014), with 
the N-terminus of tau projecting outside the microtubule wall (Amos, 2004a, 2004b), a process 
which primarily occurs if microtubules are assembled in the presence of tau and is thought to be 
irreversible (Makrides et al., 2004). This indicates that, because microtubules in the herein used 
assay were stabilized with taxol before tau addition, some binding sites for tau on the 
microtubules were likely already occupied by taxol molecules, which would result in less tau 
molecules interacting with the microtubule lattice. However, the incorporation of tau into the 
microtubule lumen is expected to be especially important for the stabilization of dynamic 
microtubules, and only to a lesser extent for the interaction with other MAPs such as motors. In 
addition, while tau was found to induce cooperative binding of Taxol to microtubules, the inverse 
was not observed as binding of tau to microtubules was independent of the presence or 
absence of Taxol during microtubule assembly (Ross et al., 2004). Tau has also been found to 
reversibly bind to the outer surface of microtubules (Makrides et al., 2004; Martinho et al., 
2018), along as well as across filaments (Santarella et al., 2004; Duan et al., 2017), a process 
more likely to influence microtubule-dependent transport. Hence, the stabilization of 
microtubules with taxol before tau addition, as performed in the herein presented experiments, 
is considered to have only minor impact on the herein measured microtubule gliding velocities. 
Tau isoform expression profile in iPSC-derived neuronal cultures 
Intriguingly, whole cell lysates obtained from patient-specific iPSC-derived spinal motor neurons 
expressing either the wildtype FUS-GFP or the FUS-P525L-GFP variant did not differentially 
interfere with kinesin-1-dependent microtubule gliding (Figure 13B). Due to the cytoplasmic 
mislocalization of FUS-P525L-GFP, the 4R:3R tau isoform ratio is expected to be increased in 
lysates from cells expressing this variant. Hence we would expect the relative microtubule 
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gliding velocity to decrease in lysates from neurons expressing FUS-P525L-GFP compared to 
lysates from cells expressing wildtype FUS-GFP. Therefore, the level of total 3R and 4R tau 
isoforms in the used whole cell lysates was determined by western blot using 3R or 4R isoform 
specific antibodies, respectively (Figure 21). 
However, only the shortest, 0N3R isoform could be detected in cell lysates irrespective of 
the expressed FUS variant, indicating that all other isoforms are not expressed above the 
detection limit of this technique (low pg range, Wiltfang et al., 1991). This is in line with other 
studies on iPSC-derived neurons (Iovino et al., 2015; Verheyen et al., 2015, 2018; Biswas et al., 
2016; Imamura et al., 2016; Silva et al., 2016; Hallmann et al., 2017; Sato et al., 2018) and 
reflects the relative immaturity of these reprogrammed neurons, since 0N3R tau is the only 
isoform expressed in the fetal human brain (Kosik et al., 1989; Goedert and Jakes, 1990). While 
other tau isoforms can be detected on the RNA level in iPSC-derived neurons (Ehrlich et al., 
2015), detection of the 0N4R, 1N3R, and 1N4R isoforms on the protein level is only possible 
when neurons are allowed to mature for up to 365 days (Iovino et al., 2015; Sposito et al., 
2015). In fact, recent evidence suggests that iPSC-derived neurons display transcriptional 
profiles similar to those found in human fetal brains rather than adult brains (Handel et al., 2016; 
Sobol et al., 2019; Griesi-Oliveira et al., 2020).  
Taken together, we have to assume that the whole cell lysates used in this study, obtained 
from iPSC-derived spinal motor neurons at day 21 of maturation, did not contain endogenous 
tau isoforms other than the shortest, fetal 0N3R isoform due to the relative immaturity of 
differentiated neurons. Although, previous studies reported defects in axonal transport in 
mitochondria in the iPSC-derived spinal motor neurons as early as day 21 of maturation 
(Naumann et al., 2018). This implies that the axonal transport defects observed in iPSC-derived 
spinal motor neurons are not caused by a shift in tau isoform splicing. However, further 
evidence on the transcriptional and protein level would be needed to consolidate this 
hypothesis. 
In order to obtain more mature neurons, the time that neurons are allowed to differentiate 
in culture could be increased, while the course of tau isoform expression levels within these 
neurons after defined time points should be evaluated. Other studies have demonstrated the 
culture of iPSC-derived spinal motor neurons up to almost 130 days (Devlin et al., 2015), when 
the fetal 0N3R tau isoform is however still predominantly expressed (Iovino et al., 2015; Sposito 
et al., 2015). Unfortunately, with increasing culture time, iPSC-derived spinal motor neurons 
tend to form clusters over time and detach from the herein used PLO-laminin coated surface.  
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Another recently evolved method to obtain disease- or patient-specific neurons, and to 
circumvent the rejuvenation or reset in maturation state during the production of iPSCs, is direct 
programming of neuronal subtypes from human somatic cells. A number of somatic cell types, 
including mouse and human fibroblasts, but also astrocyte and human retina-derived fibroblasts, 
can be transformed into a variety of neuronal subtypes using different combinations of 
overexpressed transcription factors, small molecules or the application of microRNAs (reviewed 
in Liou et al., 2020). 
In addition, cells cultured in a 3D culture system have recently proven to relate to the 
characteristics, including transcriptional and expression profiles, of their in vivo counterparts 
more closely compared to cells grown in conventional 2D culture systems (Kapałczyńska et al., 
2016; Duval et al., 2017). Especially the reconstruction of retinal development and regeneration 
has been extensively studied using organoids created in a 3D culture of human iPSCs (Eiraku 
et al., 2011; Zhong et al., 2014; Hallam et al., 2018; Shrestha et al., 2019). However, 3D culture 
systems have also been used to model AD and have enhanced the maturation of iPSC-derived 
cortical neurons. Interestingly, neurons grown in this 3D culture exhibit an increased RNA 
expression level of 4R tau isoforms already after 49 days in culture (Choi et al., 2014). A 
systemic analysis of tau isoform protein expression levels in a 3D culture system revealed an 
expression of 0N3R, 0N4R, 1N3R and 1N4R tau isoforms after 15 weeks in culture (105 days), 
while 2N3R and 2N4R tau isoforms were expressed after 25 weeks in culture (175 days). As in 
the 2D culture system though, the 0N3R tau isoform remained the predominantly expressed 
isoform throughout all time points (Miguel et al., 2019).  
Although the generation of mature spinal motor neurons can hence be improved through 
the above discussed culture conditions, the tau isoform expression profile within these human 
iPSC-derived neuronal subtypes presents the major limitation for studying the interference of an 
increased 4R:3R tau isoform ratio on kinesin-1-dependent axonal transport. However, the fact 
that defects in axonal transport have been observed in iPSC-derived neurons at early stages of 
maturation indicates that those defects must be due to another, non-tau related pathogenesis. 
 
4.4 FUS variants may indirectly affect microtubule-based axonal transport 
by acting on a multitude of cellular processes 
As FUS affects multiple cellular pathways, cytoplasmic mislocalized ALS-associated FUS may 
also indirectly interfere with microtubule-based axonal transport. Due to its diverse roles in DNA 
damage repair (Bertrand et al., 1999), RNA metabolism and transcriptional regulation (Yang et 
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al., 1998), and mRNA transport within the cell (Zinszner et al., 1997), mutant FUS variants can 
trigger many, not mutually exclusive, pathological events within the cell, which in turn may 
indirectly affect axonal transport. 
 
Nuclear loss of function - DNA damage repair and RNA splicing 
Wildtype FUS localizes to sites of laser-induced DNA damage prior to the recruitment of other 
key proteins involved in DNA-repair, whereas recruitment of FUS-P525L to sites of 
laser-induced DNA damage is impaired in iPSC-derived spinal motor neurons, subsequently 
leading to defects in mitochondrial transport (Naumann et al., 2018). Interestingly, the inhibition 
of PARG, which degrades the PAR chains attracting FUS to DNA damage (Lin et al., 1997), 
rescued not only FUS recruitment to laser-induced DNA damage sites, but also mitochondrial 
transport defects, suggesting that impaired DNA damage repair causes defects in axonal 
transport (Naumann et al., 2018). In addition, it was shown that DNA damage enhances 
cytoplasmic mislocalization of FUS-P525L and induces FUS aggregation as well as distal 
axonal trafficking defects (especially of mitochondria) and subsequent distal axonopathy (dying 
back of axons) (Higelin et al., 2016; Naumann et al., 2018). This supports the notion that defects 
in DNA-repair mechanisms due to cytoplasmic mislocalization of FUS inevitably result in the 
long-term accumulation of DNA damage, which coincides with the rather late mean age of onset 
in ALS. As neurons lack the ability to self-renew or replicate, they are particularly susceptible 
DNA damage accumulating over time which consequently likely causes disruptions in other 
cellular pathways, such as axonal transport (Guo et al., 2020).  
Next to role in DNA damage repair, FUS is also involved in the expression and splicing of 
a variety of motor proteins (Colombrita et al., 2012), such as KIF5B. Accordingly, cytoplasmic 
mislocalized mutant FUS variants (i.e. FUS-R521G and FUS-R521H) can no longer partake in 
proper splicing of these motors (Hoell et al., 2011). Additionally, FUS binds to mRNAs coding for 
β-actin and the actin-stabilizing protein Nd1-L (Fujii and Takumi, 2005). Altered splicing caused 
by mutant FUS variants hence likely directly affects cytoskeletal composition, which might affect 
axonal transport. 
 
Endosomal trafficking and axonal transport 
Clear evidence for how FUS is involved in both, short- and long-distance cellular transport is to 
date still sparse. Only few studies have focused on the direct influence of FUS variants on the 
axonal transport machinery. One study found that several FUS mutant variants (G230C, R495X, 
and R521G) disrupt bidirectional fast axonal transport via activation of the mitogen-activated 
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protein kinase p38 when expressed in squid axoplasm and in mouse primary motor neurons 
(Sama 2017). p38 phosphorylates kinesin-1 and thereby inhibits its translocation along 
microtubules, possibly by reducing the landing rate on microtubules (Morfini et al., 2013). 
Apart from long-distance transport along the dendritic arbor or axon, short-distance 
transport of vesicles, e.g. from the ER to the Golgi apparatus, was also found to be impaired in 
FUS-ALS. In particular, Rab-1-dependent transport of coat protein complex II-coated vesicles 
from the ER to the Golgi was found to be disrupted upon expression of several FUS-NLS 
mutant variants (but not wildtype FUS) (Soo et al., 2015). The same study also showed 
inhibition of Golgi-associated vesicular trafficking. Defects in axonal transport of ER-vesicles 
was also observed in spinal motor neurons that were differentiated from ALS-patient-derived 
iPSCs carrying the FUS-R521H or FUS-P525L variants (Guo et al., 2017b). Interestingly, mice 
expressing a frame-shift mutant FUS variant did not show major deficits in endosomal trafficking 
(Sleigh et al., 2020), indicating that impaired transport mechanisms in FUS-ALS might not affect 
endosomal trafficking in this model. 
 
Mitochondrial damage and trafficking defects 
Mutant FUS variants have extensively been linked to the impaired transport of larger organelles, 
such as mitochondria. Defective mitochondrial transport may result from the fact that FUS 
regulated the expression of mRNAs coding for several motor proteins, such as KIF5C and 
KIF1B (Schwarz, 2013; Campbell et al., 2014; Guo et al., 2020). An increase in stationary 
mitochondria was observed upon expression of human FUS-P525L, but also wildtype FUS, in 
mouse cortical neurons. The same was observed for the fly homologues cabezaP398L and 
Cabeza in Drosophila motor neurons (Baldwin et al., 2016; Chen et al., 2016a), suggesting that 
overexpression and hence increased cytoplasmic abundance of either FUS variant might 
already impair mitochondrial axonal transport. Similarly, the number of motile mitochondria was 
significantly decreased in ALS-patient-specific iPSC-derived spinal motor neurons expressing 
FUS-R521H or FUS-P525L when compared to isogenic controls (Guo et al., 2017b). 
Interestingly , mitochondrial transport defects could be rescued by HDAC6 inhibition, leading to 
increased α-tubulin acetylation and hence stabilizing microtubule protofilaments (Janke and 
Montagnac, 2017). In addition, an arrest of mitochondria (and lysosome) motility was observed 
in the distal axon of ALS-patient specific iPSC-derived spinal motor neurons expressing the 
FUS-P525L variant, accompanied by a breakdown in membrane potential and reduced 
mitochondrial length (Naumann et al., 2018). ATP production ceases upon the breakdown of 
mitochondrial membrane potential, leading to a local depletion of energy around the damaged 
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mitochondrion (Stoica et al., 2016). A recent study has linked ALS-associated FUS-P525L to 
aberrant mitophagy, since the expression of members of the mitochondrial quality control PINK1 
and Parkin, as well as ubiquitination of Miro1, is increased in cells expressing this FUS variant 
(Park et al., 2006; Sarraf et al., 2013; Chen et al., 2016a, 2016b). This indicates a higher degree 
of mitophagy in the presence of FUS-P525L, which also leads to a reduced ATP production. 
ATP depletion has been reported to lead to microtubule depolymerization (Park et al., 2013) and 
may also locally impair axonal transport due to the lack of the motor’s energy source. Further, 
ATP has recently been identified to inhibit fibrillization of pathological FUS aggregates by 
specifically binding to its RRM domain (Kang et al., 2019). This implicates that mitochondrial 
damage might not only affect axonal transport through ATP depletion, but also by worsening 
pathogenic effects of aggregated FUS. 
 
RNP and stress granules 
mRNAs assemble with RBPs into ribonucleoprotein (RNP) granules, which are transported 
through the axon by active bi-directional transport (Knowles et al., 1996; Tiruchinapalli et al., 
2003; Leung et al., 2006; Nalavadi et al., 2012; Alami et al., 2014; Medioni et al., 2014; Gopal et 
al., 2017; Wong et al., 2017; De Graeve and Besse, 2018; Turner-Bridger et al., 2018; 
Vijayakumar et al., 2019). Several studies have previously demonstrated that the transport of 
RNPs containing FUS depends on the interaction with other RNA transport-related proteins, 
such as TDP-43 and SMN (Groen et al., 2013), IMP1 (Kamelgarn et al., 2016), Sam 68 (Belly et 
al., 2005), or the adenomatous polyposis coli (APC) tumor-suppressor protein, which targets 
β2B-tubulin mRNA to the plus end of detyrosinated microtubules where APC promotes tubulin 
synthesis (Mili et al., 2008). Perturbing this interaction leads to disrupted dynamic microtubules 
within axonal growth cones (Yasuda et al., 2013; Preitner et al., 2014), and suggests that 
structural changes in the cytoskeleton might be a potential cause for axonal transport defects. 
Other studies have proposed that RNP granules hitchhike on membrane-bound organelles 
when those are transported throughout the cell (Jansen et al., 2014; Salogiannis and Reck-
Peterson, 2017). For instance, recent work has demonstrated a role for kinesin- and 
dynein-dependent endosome trafficking in mRNA transport (Gould and Lippincott-Schwartz, 
2009; Baumann et al., 2012; Pohlmann et al., 2015). The lysosome has been proposed as 
another cellular organelle acting as a platform for RNP granule transport, with coupling possibly 
mediated by Annexin A11 (Markmiller et al., 2018; Liao et al., 2019). It will be interesting to 
investigate whether mutant FUS variants show perturbed interaction with membrane-bound 
organelles and thereby hinder the transport of RNP granules. 
Mechanisms of Axonal Transport in ALS  Discussion 
Anne Seifert  92 / 157   
After liquid-to-solid phase transition (Murakami et al., 2015; Patel et al., 2015; Bowden 
and Dormann, 2016), solidified granules have lost their dynamic properties and can hence no 
longer perform their physiological functions (Bowden and Dormann, 2016). The incorporation of 
ALS-associated FUS variants into RNP or stress granules and their subsequent pathogenic 
phase transition indicates that FUS may impact axonal transport in several distinct, but not 
mutually exclusive ways. These include the sequestration of mRNAs and proteins directly 
involved in the axonal transport machinery or inhibition of translation of proteins important for 
cell survival, such as antiapoptotic factors under prolonged stress conditions (Nevins et al., 
2003). Additionally, when stress granules increase in size (Baron et al., 2013) to form 
pathological aggregates, e.g. through the continuous incorporation of RBPs and mRNA, they 
might sterically impair cellular processes, i.e. cytoskeletal assembly or axonal transport. A 
similar process has been described due to the swelling of mitochondria, which impaired 
mitochondrial and lysosomal transport in rat primary neurons (Kaasik et al., 2007). 
While it is known that the cytoplasmic localization of FUS on its own is not sufficient to 
trigger FUS aggregation or inclusion into RNP and stress granules (Bosco et al., 2010; 
Dormann et al., 2010; Ito et al., 2011; Bentmann et al., 2012), there is no clear consensus yet 
as to which domain is mainly responsible for the association of FUS with stress granules. Some 
evidence points towards its low-complexity, prion-like domain (Sun et al., 2011b; Han et al., 
2012), while others suggest the methylation of arginine residues within the RGG domain RGG 
domain(s) (Bentmann et al., 2012; Baron et al., 2013) to be essential for incorporation 
(Rappsilber et al., 2003; Dormann et al., 2012). However, its capacity to bind mRNA is clearly 
essential for FUS incorporation into granules, as mutations in FUS abolishing mRNA-binding 
greatly reduce aggregate-related toxicity (Andersson et al., 2008; Elden et al., 2010; Sun et al., 
2011b; Bentmann et al., 2012; Daigle et al., 2013). This led to the hypothesis that FUS might 
undergo conformational changes upon binding to mRNA (Wang et al., 2015; Hamad et al., 
2020), after which it might be capable to interact with an extended set of proteins including 
motor proteins or tubulin. It would hence be interesting to see whether microtubule gliding 
characteristics would change or whether FUS aggregation occurs in our kinesin-1-dependent 
microtubule gliding assay in the presence of sufficient amounts of mRNA transcripts that are 
known to interact with FUS. 
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4.5 Outlook 
The present results strongly indicate that FUS does not directly interfere with kinesin-1 or 
microtubules. However, it is possible that structurally changed FUS protein or its aggregate 
form, e.g. induced by its interaction with mRNAs, may alter its potential to interact with motors or 
cytoskeletal filaments. It will therefore be interesting to test whether FUS interferes with 
kinesin-1-dependent transport in the presence of mRNA. Further, may not only interfere with 
microtubule-associated motors, but also with actin-associated motors, such as myosin. For both 
motor types, possible interactions with FUS might be masked in a gliding assay due to lacking 
accessibility of motors. Hence, both scenarios should additionally be investigated in stepping 
assays, where motors are more accessible. 
Axonal transport in this study was reconstituted by modifying a kinesin-1-dependent 
microtubule gliding assay to be compatible with protein rich solutions such as whole cell lysates. 
Cell lysates of iPSC-derived spinal motor neurons expressing wildtype FUS-GFP or 
FUS-P525L-GFP did not differentially interfere with kinesin-1-dependent microtubule gliding. 
However, kinesin-1 motility was more strongly impaired in the presence of cell lysates 
containing endogenous 0N3R tau and supplemented with 2N4R tau-GFP compared to the 
presence of 2N4R tau-GFP alone, indicating that different tau isoform levels in cell lysates can 
potentially be detected using the modified kinesin-1-dependent microtubule gliding assay. 
However, further evidence would be needed to confirm this hypothesis. For instance, lysates of 
primary cells could be tested in this assay, e.g. using a mouse model of tauopathies (such as 
FTD or progressive supranuclear palsy, where differences in tau isoform composition are a 
major hallmark of the disease (Hu et al., 2007). 
The precise impact of increasing 2N4R:2N3R tau isoform ratios on individual motors as 
well as the contribution of the N-terminal projection domain of tau on kinesin-1 motility has to be 
investigated in further stepping assays using different ratios of shorter tau isoforms (i.e. 0N, 1N). 
Of particular interest in future experiments should be the interplay of these different isoforms 
present at different ratios with microtubules in a gliding or stepping assay, rather than the 
influence of each isoform alone. 
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4.6 Conclusion 
Defects in axonal transport are one of the major pathological events observed early in FUS-ALS 
and other neurodegenerative diseases. The exact cause and mechanism of these defects in 
neurons expressing the mutant FUS-P525L variant is largely unknown to date. This study 
provides evidence that neither wildtype FUS nor the mutant FUS-P525L variant directly 
interferes with kinesin-1-dependent axonal transport. Further, the presented results suggest that 
neither FUS variant impedes kinesin-1 motility by interacting with adaptor proteins present in 
whole cell lysates of ALS patient-specific iPSC-derived spinal motor neurons.  
We hence hypothesized that mislocalization of FUS-P525L to the cytoplasm corresponds 
to a loss of FUS-dependent splicing activity of tau mRNA. This leads to an increased ratio of 
4R:3R tau isoforms within neurons expressing this FUS mutant, affecting the kinesin-1 motility 
on microtubules. In line with recent literature, the presented results show that an increased 
4R:3R tau isoform ratio is indeed sufficient to impede microtubule-dependent kinesin-1 motility. 
Due to the 20-fold higher microtubule binding affinity of 2N4R tau compared to 2N3R tau, the 
4R tau isoform efficiently displaces the 3R tau isoform from the microtubule lattice at saturating 
tau concentrations. Since 4R tau affects kinesin-1 motility more strongly than 3R tau, an 
increase in the 4R:3R tau isoform ratio results in a 4R dose dependent reduction of the 
observed gliding velocity.  
Finally, defects in axonal transport are just one of multiple pathological processes 
occurring in neurons expressing ALS-associated FUS-P525L or other mutant FUS variants. 
These are not mutually exclusive, but rather interdependent and strongly connected. Hence, 
one malfunctioning cellular process might affect other essential processes, thereby processively 
worsening ALS pathogenesis. Whether defects in axonal transport are one of the first events 
caused by mutant FUS variant expression, leading to harmful disturbances in other cellular 
pathways, or whether it arises as a consequence of prior pathogenic developments, remains to 
be investigated in future studies. In summary, we conclude that the axonal transport defects 
seen in FUS-associated ALS arise indirectly as a consequence of FUS-P525L involvement in 
one or several of the above discussed cellular mechanisms such as DNA damage repair, RNA 
metabolism (especially splicing of tau), endosomal trafficking, mitochondrial homeostasis, and 
stress granule dynamics. 
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Supplementary Figures 
 
Figure S1: SDS-PAGE analysis of tau protein purification from insect cells. 
Samples were taken at various points throughout the purification process to monitor the purification efficiency final 
product. SN = supernatant, after cell lysates after centrifugation and filtration; FT = flow through from HisTrap column 
after lysate was passed through; F1 = fraction eluted from column (first purification); AC = after cleavage, after 
incubation with 3C 6xHis protease; Beads = Ni-NTA beads containing the cleaved off His-tag and remaining proteins 
after gravity filtration; FTConc = flow through of gravity filtration containing the protein of interest and after 




Figure S2: Different batches of insect cell expressed 4R tau cause a distinct drop in kinesin-1-dependent 
microtubule gliding speed at varying concentrations. 
A) Kinesin-1-dependent microtubule gliding velocities in the presence of different batches of 2N4R tau with varying 
labels at indicated concentrations in standard motility buffer. Relative speed was calculated by dividing the median 
microtubule gliding velocities after 2N4R tau variant addition by the median gliding velocity of microtubules in the 
same channel in standard motility buffer before 2N4R tau variant addition, respectively. Averages of three 
independent experiments ± standard deviation are shown for the first batch of 2N4R tau-GFP and 
2N4R tau-mScarlet, while relative median gliding speed ± standard deviation of one experiment are shown for 
2N4R tau-mCherry and the second batch of 2N4R tau-GFP. 
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Supplementary Tables 
Table S 1: Significance values (p-values) for kinesin-1-dependent microtubule gliding in the presence of 
wildtype FUS-GFP or FUS-P525L-GFP over time, BSA or standard motility buffer, corresponding to Figure 11 
and Figure 12 
Two-way ANOVA results: 





5 nM FUS-WT-GFP FUS-P525L-GFP BSA   
Buffer 0.9991 0.9885 0.9502 
0h FUS-WT-GFP - 0.9977 0.9079 
FUS-P525L-GFP - - 0.8285 
Buffer >0.9999 >0.9999 >0.9999 
1h FUS-WT-GFP - >0.9999 >0.9999 
FUS-P525L-GFP - - >0.9999 
Buffer >0.9999 0.9985 0.9976 
2h FUS-WT-GFP - 0.9131 0.9024 
FUS-P525L-GFP - - >0.9999 
Buffer >0.9999 0.9975 0.9933 
3h FUS-WT-GFP - 0.9968 0.9928 
FUS-P525L-GFP - - >0.9999 
 
500 nM FUS-WT-GFP FUS-P525L-GFP BSA   
Buffer 0.3289 0.0135 >0.9999 
0h FUS-WT-GFP - 0.4325 0.2927 
FUS-P525L-GFP - - 0.0111 
Buffer 0.1702 0.0543 >0.9999 
1h FUS-WT-GFP - >0.9999 >0.9999 
FUS-P525L-GFP - - 0.5244 
Buffer 0.2112 0.1338 0.8306 
2h FUS-WT-GFP - 0.9952 0.7023 
FUS-P525L-GFP - - 0.5587 
Buffer 0.1695 0.3686 0.871 
3h FUS-WT-GFP - 0.9684 0.469 
FUS-P525L-GFP - - 0.7612 
 
5000 nM FUS-WT-GFP FUS-P525L-GFP BSA   
Buffer 0.1765 0.5127 0.9899 
0h FUS-WT-GFP - 0.8327 0.0971 
FUS-P525L-GFP - - 0.3302 
Buffer 0.0162 >0.9999 >0.9999 
1h FUS-WT-GFP - 0.3011 0.016 
FUS-P525L-GFP - - 0.4378 
Buffer 0.0465 0.3882 0.9997 
2h FUS-WT-GFP - 0.6555 0.0375 
FUS-P525L-GFP - - 0.3377 
Buffer 0.0449 0.3301 0.9964 
3h FUS-WT-GFP - 0.6869 0.0691 
FUS-P525L-GFP - - 0.4408 
Mechanisms of Axonal Transport in ALS  Supplementary Tables 
Anne Seifert  135 / 157  
 
Table S 2: Significance values (p-values) for kinesin-1-dependent microtubule gliding in the presence of 
2N4R tau-GFP, corresponding to Figure 10 
Two-way ANOVA results:  Interaction p-value:  >0.0001         
 
  1 nM 5 nM 10 nM 15 nM 25 nM 50 nM 75 nM 100 nM 
0 nM >0.9999 >0.9999 >0.9999 0.8786 0.016 0.0005 0.0004 0.0004 
1 nM - >0.9999 >0.9999 0.909 0.0189 0.0005 0.0005 0.0005 
5 nM - - >0.9999 0.9537 0.0258 0.0007 0.0007 0.0007 
10 nM - - - 0.9828 0.0366 0.001 0.001 0.001 
15 nM - - - 0.9828 0.2066 0.0067 0.0063 0.0062 
25 nM - - - - - 0.6482 0.6255 0.6216 
50 nM - - - - - - >0.9999 >0.9999 
75 nM - - - - - - - >0.9999 
 
Table S 3: Significance values (p-values) for kinesin-1-dependent microtubule gliding in the presence of 
whole cell lysates from spinal motor neurons expressing wildtype FUS-GFP or FUS-P525L-GFP, BSA or 
standard motility buffer, corresponding to Figure 13B 
Two-way ANOVA results:  Interaction p-value:  0.0696   
 
  FUS-WT-GFP FUS-P525L-GFP BSA   
Buffer 0.0691 0.0544 0.3116 
50 ng/µL FUS-WT-GFP - 0.9992 0.8558 
FUS-P525L-GFP - - 0.7956 
Buffer 0.9973 0.3495 0.48 
80 ng/µL FUS-WT-GFP - 0.2831 0.4451 
FUS-P525L-GFP - - 0.998 
Buffer 0.827 0.5112 0.1648 
110 ng/µL FUS-WT-GFP - 0.9117 0.4083 
FUS-P525L-GFP - - 0.7726 
Buffer 0.9889 0.5873 0.5245 
140 ng/µL FUS-WT-GFP - 0.6499 0.5884 
FUS-P525L-GFP - - 0.9891 
 
Table S 4: Significance values (p-values) for kinesin-1-depenent microtubule gliding in the presence of whole 
cell lysates from spinal motor neurons expressing wildtype FUS-GFP or FUS-P525L-GFP, BSA or standard 
motility buffer supplemented with 2N4R tau-GFP at indicated concentrations, corresponding to Figure 13C 
Two-way ANOVA results:  Interaction p-value:  0.6536     
 
  Tau-GFP FUS-WT-GFP FUS-P525L-GFP BSA   
Buffer >0.9999 0.9876 0.9974 >0.9999 
0 nM 
Tau-GFP - 0.9544 0.9895 >0.9999 
FUS-WT-GFP - - 0.9993 0.9279 
FUS-P525L-GFP - - - 0.9786 
Buffer >0.9999 0.967 0.9748 >0.9999 
1 nM Tau-GFP - 0.9223 0.9416 0.9991 
FUS-WT-GFP - - >0.9999 0.8187 
FUS-P525L-GFP - - - 0.8505 
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 Tau-GFP FUS-WT-GFP FUS-P525L-GFP BSA  
Buffer 0.9997 0.8977 0.9003 >0.9999 
5 nM 
Tau-GFP - 0.858 0.8625 0.9989 
FUS-WT-GFP - - >0.9999 0.719 
FUS-P525L-GFP - - - 0.725 
Buffer 0.997 0.2203 0.3247 0.9987 
10 nM 
Tau-GFP - 0.0966 0.1882 >0.9999 
FUS-WT-GFP - - 0.9978 0.0775 
FUS-P525L-GFP - - - 0.1555 
Buffer 0.7365 0.1383 0.0462 0.977 
15 nM 
Tau-GFP - 0.4992 0.1674 0.8932 
FUS-WT-GFP - - 0.9636 0.0992 
FUS-P525L-GFP - - - 0.0182 
Buffer 0.0002 <0.0001 0.0029 0.0002 
25 nM 
Tau-GFP - 0.9991 0.7958 >0.9999 
FUS-WT-GFP - - 0.6478 0.9995 
FUS-P525L-GFP - - - 0.776 
Buffer <0.0001 <0.0001 <0.0001 <0.0001 
50 nM 
Tau-GFP - >0.9999 >0.9999 >0.9999 
FUS-WT-GFP - - >0.9999 >0.9999 
FUS-P525L-GFP - - - >0.9999 
Buffer <0.0001 <0.0001 <0.0001 <0.0001 
75 nM 
Tau-GFP - >0.9999 >0.9999 >0.9999 
FUS-WT-GFP - - >0.9999 >0.9999 
FUS-P525L-GFP - - - >0.9999 
Buffer <0.0001 <0.0001 <0.0001 <0.0001 
100 nM 
Tau-GFP - >0.9999 >0.9999 >0.9999 
FUS-WT-GFP - - >0.9999 >0.9999 
FUS-P525L-GFP - - - >0.9999 
 
Table S 5: Significance values (p-values) for kinesin-1-dependent microtubule gliding in the presence of 
2N3R tau-GFP and 2N4R tau-mScarlet, corresponding to Figure 17 
Two-way ANOVA results: Interaction p-value: 0.9739         
 Concentration p-value: <0,0001      
 Tau variant p-value: 0.0009      
 
3R-GFP 750 nM 1500 nM 2250 nM 3000 nM 3750 nM 4500 nM 5250 nM 
500 nM 0.9999 0.7801 0.3063 0.1222 0.0082 0.0004 0.0002 
750 nM - 0.9491 0.5552 0.2729 0.0245 0.0014 0.0007 
1500 nM - - 0.9922 0.8952 0.265 0.0268 0.0139 
2250 nM - - - 0.9996 0.7307 0.158 0.0922 
3000 nM - - -  0.9449 0.3739 0.2446 
3750 nM - - - - - 0.9571 0.8772 
4500 nM - - - - - - >0,9999 
5250 nM - - - - - - - 
 
4R-mScarlet 150 nM 250 nM 400 nM 600 nM 800 nM 1000 nM 1200 nM 
50 nM 0.6572 0.0675 0.044 0.0212 0.0008 0.0001 <0,0001 
150 nM - 0.8682 0.7776 0.5955 0.0718 0.0128 0.0042 
250 nM - - >0,9999 0.9997 0.6744 0.2605 0.1172 
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 150 nM 250 nM 400 nM 600 nM 800 nM 1000 nM 1200 nM 
400 nM - - - >0,9999 0.783 0.3521 0.1698 
600 nM - - - 
 
0.9151 0.5308 0.2911 
800 nM - - - - - 0.996 0.9446 
1000 nM - - - - - - 0.9999 
1200 nM - - - - - - - 
 
Table S 6: Significance values (p-values) for binding of 2N3R tau-GFP and 2N4R tau-mScarlet to 
surface-immobilized microtubules, corresponding to Figure 18 
Two-way ANOVA results: Interaction p-value: 0.0001   
  Concentration p-value: <0,0001   
  Tau variant p-value: <0,0001   
 
3R-GFP 50 nM 100 nM 200 nM 400 nM 800 nM 
25 nM 0.9391 0.0013 <0,0001 <0,0001 <0,0001 
50 nM - 0.0118 <0,0001 <0,0001 <0,0001 
100 nM - - 0.0055 <0,0001 <0,0001 
200 nM - - - 0.0975 0.0635 
400 nM - - -  >0,9999 
800 nM - - - - - 
 
4R-mScarlet 10 nM 250 nM 400 nM 600 nM 800 nM 
5 nM 0.0067 <0,0001 <0,0001 <0,0001 <0,0001 
10 nM - 0.1709 0.0206 0.0098 0.0105 
25 nM - - 0.9088 0.7645 0.7807 
50 nM - - - 0.9995 0.9997 
100 nM - - -  >0,9999 
200 nM - - - - - 
 
Table S 7: Significance values (p-values) for kinesin-1-depenent microtubule gliding in the presence of 
2N3R tau-GFP and 2N4R tau-mScarlet mixed at indicated ratios, corresponding to Figure 19 
One-way ANOVA results:  Interaction p-value:  0.0087   
 
4R:3R Ratio 0.33 1 3 4 
0 0.2517 0.0906 0.0175 0.0076 
0.33 - 0.9523 0.4437 0.2163 
1 - - 0.8211 0.5184 
3 - - - 0.9786 
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Table S 8: Significance values (p-values) for binding of 2N3R tau-GFP and 2N4R tau-mScarlet mixed at 
indicated ratios to surface-immobilized microtubules, corresponding to Figure 20 
Two-way ANOVA results: Interaction p-value: <0,0001 
  Ratio p-value: 0.3174 
  Tau variant p-value: <0,0001 
 
3R- GFP         
4R:3R Ratio 0.33 1 3 4 
0 <0,0001 <0,0001 <0,0001 <0,0001 
0.33 - 0.0521 0.0035 0.0008 
1 - - 0.7294 0.3397 
3 - - - 0.9585 
4 - - - - 
 
4R-mScarlet         
4R:3R Ratio 0.33 1 3 4 
0 <0,0001 <0,0001 <0,0001 <0,0001 
0.33 - 0.0433 0.0008 <0,0001 
1 - - 0.4112 0.0062 
3 - - - 0.2277 
4 - - - - 
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Summary 
Background 
Neurodegenerative diseases have become one of the most common causes of death worldwide 
over the last couple of decades, with increasing tendency. Amyotrophic lateral sclerosis (ALS) is 
the most common neurodegenerative disease affecting specifically spinal (lower) and cortical 
(upper) motor neurons in the spinal cord and brainstem, respectively. It is usually a late onset 
disorder (average age of onset in Germany is 61 years) and leads to death within 2-5 years 
after symptoms onset due to respiratory failure. To date, there is no cure for ALS and only two 
drugs have been approved for its treatment, which prolong the lifespan for up to six months or 
slow down disease progression in a subpopulation of patients. About 90 % of ALS cases are 
sporadic, while about 10 % are familial and hence caused by mutations in specific genes, 
among them fused in sarcoma (FUS), a DNA- and RNA-binding protein. Mutations in FUS 
account for roughly 5 % of familial cases and occur predominantly in its nuclear localization 
sequence (NLS), such as the FUS-P525L mutation. Neurons expressing this variant display a 
strong cytoplasmic mislocalization of FUS and hence a loss of its nuclear function. Among other 
pathological events, defects in axonal transport along microtubules have been observed early in 
disease progression in several models of FUS-ALS, indicating its role as a major hallmark of the 
disease. However, the mechanism of how transport is impaired within these neurons remains 
unknown to date.  
Hypothesis 
This study aimed at investigating two possible mechanisms how the FUS-P525L mutant variant 
affects microtubule-based axonal transport. First, it was analyzed whether FUS directly interacts 
with microtubules or motors and if the mislocalized, mutant variant alters this interaction. 
Secondly, cytoplasmic mislocalized FUS-P525L can no longer fulfil its regular role in the splicing 
of pre-mRNAs, among them the mRNA coding for the microtubule-associated protein tau. This 
reportedly leads to an increased ratio of translated tau isoforms containing four microtubule 
binding repeats (4R) to those containing three repeats (3R). 4R tau isoforms are known to have 
a stronger binding affinity towards microtubules and may hence impair transport more severely 
by acting as a roadblock for motor proteins. Towards this end, this study investigated whether 
an increase in 4R:3R tau isoform ratio is sufficient to impair microtubule based transport. 
Methods 
Axonal transport was reconstituted in vitro using a kinesin-1-dependent microtubule gliding 
assays, in which microtubules are propelled by surface-immobilized kinesin-1 motors. The 
assay was modified and optimized to operate sensitively and robust in the presence of complex 
solutions such as whole cell lysates and the microtubule gliding velocity analyzed as a measure 
for motility of the underlying motors. To determine the direct interaction of FUS variants with 
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kinesin-1 or microtubules, recombinant human wildtype FUS-GFP and FUS-P525L-GFP was 
added to the assay. In addition, ALS patient-specific induced pluripotent stem cells (iPSCs) 
expressing the same FUS variants were differentiated towards spinal motor neurons and their 
cell lysates applied to this assay in order to determine whether FUS variants need endogenous 
adaptors or interaction partners to interfere with kinesin-1 motility on microtubules. Further, to 
investigate the interference of tau isoforms with kinesin-1 motility, recombinant human 2N3R 
tau-GFP and 2N4R tau-mScarlet was purified from insect cells and added to the modified 
kinesin-1-dependent microtubule gliding assay, either individually or combined at different 
ratios. In addition, the binding of these tau variants to microtubules was assessed. 
Results 
The kinesin-1-dependent microtubule gliding assays was modified to operate sensitively and 
robustly in the presence of β-glycerophosphate (to inhibit endogenous phosphatases in whole 
cell lysates), and methylcellulose (to prevent microtubule detachment from kinesin-1 motors due 
to presence of β-glycerophosphate). Under these conditions, neither recombinant human 
FUS-GFP nor endogenous FUS-GFP variants in lysates of spinal motor neurons bound to 
microtubules or interfered with kinesin-1 motility. In contrast, both tau isoforms used in the 
present study bound to microtubules and impaired kinesin-1 motility, while 2N4R tau-mScarlet 
was a much more potent inhibitor of microtubule gliding and displayed a 20-fold stronger binding 
affinity to microtubules compared to 2N3R tau-GFP. Interestingly, increasing ratios of 4R:3R tau 
isoforms impaired kinesin-1-dependent microtubule gliding. In addition, the presence of 2N4R 
tau-mScarlet strongly prevented 2N3R tau-GFP from binding to microtubules. 
Conclusion 
This study provides evidence that neither wildtype FUS nor the FUS-P525L variant directly 
interfere with axonal transport by interacting with kinesin-1 motors or microtubules. Further, the 
present data suggests that neither FUS variant impedes kinesin-1 motility on microtubules by 
interacting with endogenous adaptor proteins present in cell lysates of iPSC-derived spinal 
motor neurons. Therefore, it is proposed that axonal transport defects are not directly caused by 
interaction of cytoplasmic mislocalized FUS with the motors or microtubules, but rather arise as 
a consequence of other pathological events triggered by mutant FUS variants. In particular, this 
study demonstrates that an increased ratio of 4R:3R tau isoforms is sufficient to impair kinesin-1 
motility on microtubules due to increased decoration of microtubules with 4R tau isoforms, 
preventing 3R tau isoforms from binding to microtubules. This strongly suggests that an 
increased ratio of 4R:3R tau isoforms, since FUS no longer regulates splicing of tau pre-mRNA 
upon its cytoplasmic mislocalization, may be sufficient to cause or contribute to the axonal 
transport defects observed early in FUS-ALS pathology. 
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Zusammenfassung 
Hintergrund 
Neurodegenerative Erkrankungen sind in den letzten Jahrzehnten mit zunehmender Tendenz 
zu einer der häufigsten Todesursachen weltweit geworden. Amyotrophe Lateralsklerose (ALS) 
ist die häufigste neurodegenerative Erkrankung, die spezifisch spinale (untere) und kortikale 
(obere) Motoneuronen im Rückenmark bzw. im Hirnstamm betrifft. Es handelt sich in der Regel 
um eine spät einsetzende Krankheit (das mittlere Erkrankungsalter in Deutschland beträgt 61 
Jahre) und führt innerhalb von 2-5 Jahren nach Auftreten der Symptome zum Tod aufgrund von 
Atemversagen. Bisher gibt es keine Heilung für ALS und es wurden nur zwei Medikamente für 
die Behandlung zugelassen, die die Lebensdauer um bis zu sechs Monate verlängern oder das 
Fortschreiten der Krankheit bei einer Subpopulation von Patienten verlangsamen. Ungefähr 
90% der ALS-Fälle sind sporadisch, während ungefähr 10% familiär sind und daher durch 
Mutationen in bestimmten Genen verursacht werden, darunter fused in sarcoma (FUS), einem 
DNA- und RNA-bindenden Protein. Mutationen in FUS machen etwa 5% der familiären Fälle 
aus und treten überwiegend in der Kernlokalisierungssequenz (NLS) auf, wie beispielsweise die 
FUS-P525L Mutation. Neuronen, die diese Mutante exprimieren, zeigen eine starke 
zytoplasmatische Fehllokalisierung von FUS und damit einen Verlust seiner Funktionen im 
Zellkern. Neben anderen pathologischen Ereignissen wurden in mehreren FUS-ALS 
Modellsystemen Defekte im Mikrotubuli-basierenden axonalen Transport früh im 
Krankheitsverlauf beobachtet, was auf seine Rolle als eines der Hauptmerkmale dieser 
Krankheit hindeutet. Der Mechanismus, wie der Transport innerhalb dieser Neuronen 
beeinträchtigt wird, ist jedoch bis heute unbekannt. 
Hypothese 
Ziel dieser Studie ist es, zwei mögliche Mechanismen zu untersuchen, wie das mutierte 
FUS-P525L Protein den axonalen Transport entlang von Mikrotubuli beeinflusst. Zunächst 
wurde analysiert, ob FUS direkt mit Mikrotubuli oder Motorproteinen interagiert und ob 
zytoplasmatische fehllokalisierte FUS-P525L Protein diese Interaktion verändert. Ferner kann 
zytoplasmatische fehllokalisiertes FUS-P525L seine reguläre Rolle beim Spleißen von 
Prä-mRNAs nicht mehr erfüllen, darunter die mRNA, die für das mit Mikrotubuli-assoziierte 
Protein Tau kodiert. Dies führt zu einem erhöhten Verhältnis von translatierten Tau-Isoformen, 
die vier Mikrotubuli-Bindestellen (4R) enthalten, zu solchen mit drei Bindestellen (3R). Es ist 
bekannt, dass 4R-Tau-Isoformen eine stärkere Bindungsaffinität zu Mikrotubuli im Vergleich zu 
3R-Tau-Isoformen aufweisen und daher den Transport stärker beeinträchtigen können, indem 
sie als Hindernis für Motorproteine agieren. In dieser Studie wurde daher untersucht, ob eine 
Erhöhung des Verhältnisses von 4R:3R-Tau-Isoform ausreicht, um den Mikrotubuli-basierenden 
Transport zu beeinträchtigen. 
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Methoden 
Der axonale Transport wurde in vitro unter Verwendung eines Kinesin-1-gestuerten Mikrotubuli 
Motilitätsassay rekonstruiert, bei welchem Mikrotubuli von darunterliegenden 
oberflächenimmobilisierte Kinesin-1 Motorproteinen transportiert werden, also über die 
Oberfläche gleiten. Der Assay wurde modifiziert und optimiert, um in Gegenwart komplexer 
Lösungen wie Ganzzelllysaten sensitiv und robust zu funktionieren, und die 
Gleitgeschwindigkeit der Mikrotubuli wurde als Maß für die Motilität der darunterliegenden 
Motoren analysiert. Um die direkte Wechselwirkung von FUS-Varianten mit Kinesin-1 
Motorproteinen oder Mikrotubuli zu bestimmen, wurde dem Assay rekombinantes menschliches 
Wildtyp-FUS-GFP und FUS-P525L-GFP hinzugegeben. Zusätzlich wurden ALS-
patientenspezifische, induzierte pluripotente Stammzellen (iPSCs), welche dieselben FUS-
Varianten exprimieren, zu spinalen Motoneuronen differenziert und ihre Zelllysate in diesem 
Assay angewendet, um zu bestimmen, ob FUS-Varianten endogene Adapter oder 
Interaktionspartner für die Interaction mit Kinesin-1 oder Mikrotubuli benötigen. Um den Einfluss 
von Tau-Isoformen auf die Kinesin-1 Motilität zu untersuchen, wurde rekombinantes 
menschliches 2N3R Tau-GFP und 2N4R Tau-mScarlet aus Insektenzellen aufgereinigt und 
dem modifizierten Kinesin-1-gestuerten Mikrotubuli Motilitätsassay entweder einzeln oder in 
unterschiedlichen Verhältnissen kombiniert hinzugegeben. Zusätzlich wurde die Bindung dieser 
Tau-Varianten an Mikrotubuli analysiert. 
Ergebnisse 
Die Kinesin-1-gesteuerte Mikrotubuli Motilitätsassay wurden so modifiziert, dass er in 
Gegenwart von β-Glycerophosphat (zur Hemmung endogener Phosphatasen in 
Ganzzelllysaten) und Methylcellulose (zur Verhinderung der Ablösung von Mikrotubuli von 
Kinesin-1 Motoren aufgrund von β-Glycerophosphat) empfindlich und robust funktioniert. Unter 
diesen Bedingungen zeigten weder rekombinantes menschliches FUS-GFP noch endogene 
FUS-GFP-Varianten in Lysaten von spinalen Motoneuronen eine Wechselwirkung mit 
Mikrotubuli und beeinträchtigten auch nicht die Kinesin-1 Motilität. Im Gegensatz dazu banden 
beide in der vorliegenden Studie verwendeten Tau-Isoformen an Mikrotubuli und 
beeinträchtigten die Kinesin-1-Motilität, wobei 2N4R Tau-mScarlet das Gleitens von Mikrotubuli 
viel stärkerer beeinträchtigte und eine 20-fach stärkere Bindungsaffinität zu Mikrotubuli im 
Vergleich zu 2N3R Tau-GFP zeigte. Ferner beeinträchtigten steigende Verhältnisse von 4R:3R 
Tau-Isoformen über Kinesin-1 gleitende Mikrotubuli, während die Präsenz von 2N4R 
Tau-mScarlet die Bindung von 2N3R Tau-GFP an Mikrotubuli stark verminderte. 
Schlussfolgerung 
Diese Studie liefert Hinweise darauf, dass weder Wildtyp-FUS noch die FUS P525L-Variante 
den axonalen Transport direkt beeinflussen, da sie nicht mit Kinesin-1 Motorproteinen oder 
Mikrotubuli interagieren. Ferner legen die vorliegenden Daten nahe, dass keine der FUS-
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Varianten die Kinesin-1 Motilität auf Mikrotubuli durch Wechselwirkung mit endogenen 
Adapterproteinen behindert, die in Zelllysaten von iPSC-differenzierte spinalen Motoneuronen 
vorhanden sind. Dies legt nahe, dass axonale Transportdefekte nicht durch direkte 
Wechselwirkung von zytoplasmatisch fehllokalisiertem FUS Protein mit Motorproteinen oder 
Mikrotubuli verursacht werden, sondern als Folge anderer pathologischer Ereignisse auftreten, 
die durch mutierte FUS-Varianten entstehen. Insbesondere zeigt diese Studie, dass ein 
erhöhtes Verhältnis von 4R:3R Tau-Isoformen ausreicht, um die Kinesin-1 Motilität auf 
Mikrotubuli zu behindern. Dies geschieht vermutlich aufgrund der erhöhten Bindung von 4R 
Tau-Isoformen an Mikrotubuli, weil dadurch die Bindung von 3R Tau-Isoformen an Mikrotubuli 
verhindert wird. Dies deutet stark darauf hin, dass ein erhöhtes Verhältnis von 4R:3R 
Tau-Isoformen, verursacht durch die fehlende regulatorische Beteiligung von FUS am Spleißen 
von Tau-Prä-mRNA aufgrund der zytoplasmatischen Fehllokalisation von FUS, wahrscheinlich 
zu den axonalen Transportdefekten beiträgt, die früh in der FUS-ALS-Pathologie beobachtet 
wurden.
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